The parking lot was full for a Tuesday morning, which Diane took as a good sign. Practices that ran busy tended to run well. She parked in a visitor space near the entrance, checked the time (10:52), and gathered her tote bag and tablet from the passenger seat. A brief drizzle had come through on the drive over. She stepped around a puddle at the curb.

Inside, the waiting room was warm, half-full, mostly mothers with toddlers, one older boy paging through a book on the floor. A cardboard cutout of a giraffe stood by the reception window with a taped sign reading FLU CLINIC SATURDAYS. The front-desk staff knew she was coming. A young woman named Kelsey looked up, smiled, and said, “Ms. Halloran, right? Dr. Marston said to come on back whenever you got here.”

Diane thanked her and followed Kelsey through the side door into the clinical corridor. The practice occupied a single-story building that had been thoughtfully renovated, she noted, with sound-dampening panels on the ceilings and warm wood accents on the exam-room doors. She heard a child’s brief cry from one of the rooms and then a mother’s soothing voice.

Kelsey brought her to a small back office next to what looked like a supply room. “This is ours for however long you need it. Dr. Marston will be with you in a minute; he’s just finishing up with a family. Can I get you coffee?”

“That would be lovely,” Diane said. “Just black, thank you.”

The office was tidy. A round table, four chairs, a whiteboard with staff initials and shift patterns, a small window looking out onto a strip of grass and the neighboring parking lot. Diane took a seat, set down her tote, and pulled out her tablet. She opened the cover, and the lockscreen came up with the photograph she had chosen last month: her two boys in matching red jackets at the pumpkin patch, Ben grinning without his front teeth, Charlie holding up a gourd almost too heavy for him. She looked at it for a beat and then swiped in her passcode.

The IQIP dashboard loaded, and the practice’s data populated across the top of the screen. Coverage assessment complete: 94.1%. Twelve-month change: +2.3 points. Missed opportunities identified: 47 across the review sample. She scrolled through the highlighted charts and read the notes she had prepared last night from her hotel room. The 94.1% put this practice comfortably in the upper quartile for the region. Her target for the twelve-month follow-up was 97%, well within reach.

Dr. Marston came in with two mugs of coffee and set one down in front of her. He was in his early fifties, gray at the temples, a stethoscope slung around his neck over a soft blue cardigan. He shook her hand warmly and sat down across from her.

“Diane, thanks so much for coming out today. We’ve been looking forward to this. I blocked the whole two hours, so we shouldn’t have any interruptions worth speaking of.”

“Thank you for making the time, Dr. Marston. And your numbers look terrific.”

“Peter, please. And thank you. We’ve been working hard on it.” He glanced at the tablet screen. “That two-point-three, I have to say, I’m a little proud of. Last cycle we were flat, and I really wanted to see us move.”

“You should be. Practices at your size usually don’t see that kind of gain without a lot of workflow change.”

“Well,” he said, “we did some things. I want to walk you through them.”

They spent the first forty minutes on his side of the story. He had built a set of prompts into the EMR that flagged any patient coming in for a well-child visit whose immunizations were more than two weeks behind schedule. The prompt fired at the top of the encounter note and again at the discharge screen. Sick visits used to be dead zones for coverage, he told her; his MAs now asked about immunization status at every encounter, and it had picked up a surprising number of catches. The standing orders were rewritten so any nurse could pull and prepare a vaccine without waiting for physician sign-off. That last one had shaved minutes off each encounter and, more importantly, removed a friction point where families sometimes changed their minds.

Diane listened, took notes, asked clarifying questions. Everything he described was exactly what IQIP encouraged. She would be citing this practice in her regional summary as an example of successful strategy adoption.

“Now,” she said, moving into the second phase of the review, “let me walk you through the missed opportunities I flagged from the sample.”

She turned the tablet so he could see, and they went through the charts one by one. A four-month-old whose parents had asked to delay Hep B and never rescheduled. A fifteen-month-old whose MMR had been deferred because of a low-grade fever, with no follow-up call to bring the family back once the fever resolved. A three-year-old who had come in for an ear infection and left without her overdue DTaP catch-up. A ten-year-old who had aged out of the earlier schedule slot without receiving the second varicella dose. An eleven-year-old whose HPV series had been started and then dropped after the first dose because, the note said, “family wants to discuss further.”

Peter nodded through each one, occasionally making a small sound of recognition. “Yeah. Yeah, we saw that pattern too when we went back through internally. The deferrals are the killer. Once they walk out without the dose, the odds of catch-up drop by half.”

“That’s the national data too,” Diane said. “Which is why the scheduling strategy is so important. If you can get them booked for the next visit before they leave the building, you’re not relying on them to call back in six weeks. You’re not relying on your recall system to find them. The appointment is already in the calendar.”

“We’ve been doing that with the well-child schedule for about six months,” Peter said, “but I don’t think we’ve been consistent with the catch-ups. That’s a good catch. Marisol handles most of the front-desk scheduling; I’ll have her build it into the checkout protocol.”

“That’s exactly the kind of change that moves the needle.”

He smiled. “We want to get to 97 next year.”

“You will.”

They worked through a few more charts. Diane pointed out three cases where the EMR prompt had fired but the encounter had ended without the vaccine being given, and Peter said he would review those with the individual providers to see what was happening in the room. She noted his response in her observation field. This was a physician who took ownership of his data, which she would flag in the qualitative section of her report.

Around 12:15, the sounds of the practice shifted. She heard the phone at the front desk ring less often, and the general bustle in the corridor thinned. Peter mentioned that most of the staff took their lunch in shifts starting at noon, and the last morning slot was usually a fifteen- or thirty-minute cushion so that the doctors could catch up on notes.

There was a light knock on the doorframe. A woman in her thirties in dark blue scrubs, a stethoscope around her neck, leaned into the room.

“Sorry, Dr. Marston. Real quick. It’s about the Ellis family.”

“Come on in, Jenna. This is Diane Halloran, she’s with the state, we’re doing our IQIP review. Diane, Jenna is one of our MAs, she’s been here longer than I have.”

Jenna smiled, then turned back to Peter. “So I got Sarah Ellis on the phone this morning about scheduling Nolan’s fifteen-month. He’s due for the next set. And she said she doesn’t want to do it. She said after the last round he wouldn’t stop crying for like two days and she’s just, she doesn’t want to put him through it again. I didn’t push. I told her I’d talk to you and call her back this afternoon.”

Peter nodded slowly, thinking. “Okay. The inconsolable crying thing, that’s actually pretty common, and it’s almost always benign. It’s just the immune response and sometimes the site tenderness. It resolves on its own. But for mom, obviously, it was scary.”

“She was pretty upset about it.”

“Right. So here’s what I’d say to her. Tell her that what she saw is a known and expected reaction, it’s the body doing exactly what we want it to do, and it doesn’t indicate anything is wrong. Then remind her that the fifteen-month is a really important visit because that’s where we get the MMR and the varicella and the Hib booster, and these are the ones that carry the child through the preschool years. If she wants, we can space them out. She doesn’t have to do all of them the same day. But we do want to get him back in.”

Jenna nodded, taking it in. “So offer to split them up.”

“Offer to split them up. And if she’s still hesitant, tell her I’d be happy to hop on a quick call with her, just five minutes, before the appointment. Sometimes hearing it from the doctor helps.”

“Okay. That’s really helpful. Thank you.”

“Anytime, Jenna. And nice work not pushing on the phone. That was the right instinct.”

Jenna smiled and left. Diane heard her footsteps go back down the corridor toward the front.

“That’s such a good example,” Diane said, turning slightly in her chair. “The families that come back with concerns after a reaction, those are the highest-risk drop-offs, and how you handle that first call is everything. Your staff clearly knows what to do.”

“They’re good,” Peter said. “Jenna especially. She’s got a way with parents. She’s been calling back all our hesitancy cases herself for about a year now.”

“Do you have a written script, or is it something you’ve trained her on more informally?”

“More informal, honestly. We’ve talked through the common concerns, and she knows my general approach. I keep thinking I should write it up so the newer MAs have something to work from.”

“That would be a great addition. It’s actually one of the optional strategies in the IQIP framework. If you want, I can send you some template language from other practices in the region that have built out scripts.”

“That would be great. Thank you.”

Diane made a note in the follow-up field. She would email him the scripts and the coverage-comparison data from the peer practices before the end of the week. This was the kind of engaged provider who would actually implement what she sent, which was not always the case.

They worked another twenty minutes, wrapping up the chart review and moving to the summary section. Peter walked her through the practice’s plans for the next quarter, including a Saturday flu clinic he was hoping to expand, and a partnership with the local school district on adolescent catch-up. Diane made encouraging observations and jotted a few final notes. When they had covered everything, she turned back to the tablet and pulled up the site-visit summary form.

She entered the updated coverage data, ticked the boxes for strategies implemented since the last visit, and typed her qualitative notes into the observation field. Strong physician engagement. Effective use of EMR prompts. Front-desk scheduling protocols well established for well-child visits, opportunity for expansion to catch-up visits. Excellent hesitancy management by clinical support staff, potential model for regional dissemination. She reviewed the form, signed the acknowledgment, and submitted it. The screen refreshed and the practice’s file updated in the state system. Twelve-month projection: 96.8%. Well within the target range.

Peter walked her back through the corridor to the front. The waiting room had filled up again with the early-afternoon slots. Kelsey waved from behind the reception window. At the door, Peter shook her hand.

“Really, thank you, Diane. This was useful. We’ll get to 97.”

“I have no doubt. Talk soon.”

She stepped out into the parking lot. The drizzle had cleared, and the sun was breaking through in patches. She walked to her car, set the tablet on the passenger seat, and started the engine. The dashboard clock read 1:14. Her next visit was on the other side of the county, a smaller practice, less prepared, more of a lift. She checked her mirrors and pulled out of the lot.

Inside, at the front desk, Jenna was on the phone with Sarah Ellis, working out a new date for Nolan. The appointment went into the system for a Tuesday morning three weeks out. The reminder call was queued for twenty-four hours before.

The IQIP program depicted in this story is real. Its full name is Immunization Quality Improvement for Providers, and it is administered by the CDC through state health departments. It is described in the CDC's Pink Book (Epidemiology and Prevention of Vaccine-Preventable Diseases).

A note from the author. This essay is written from the terrain paradigm. Disease is the body’s response to dietary, toxic, electromagnetic, and psychological insult. Microorganisms and blood clots appear at sites of tissue breakdown rather than cause it. Within conventional cardiology’s plaque-theory framework, the twelve practices that follow are standard clinical care. From the terrain side, they are deceptions. Two registers operate here. When the essay engages material framed in establishment terms (ejection fraction, atherosclerosis, autoimmune arteritis, the “immune” system, genetic susceptibility, vitamins as discrete nutrients), the establishment vocabulary appears in quotation, attribution, and reference titles. The terrain paradigm operates in the author’s own analytical voice. Readers who have not made the shift from germ theory and mechanistic biology to terrain may find the conclusions inverted from what they expect.

What Was Done to Kilmer McCully

In 1968, Kilmer McCully, an assistant professor of pathology at Harvard Medical School, examined tissue from an eight-year-old boy who had died of a stroke. The child had homocystinuria, a metabolic condition producing massive elevations of the amino acid homocysteine. His coronary arteries looked like those of an elderly man with advanced atherosclerosis. His cholesterol level was normal.⁴

McCully had seen tissue like this before, from a two-month-old infant with the same condition. Two children with arteries destroyed by an amino acid the medical literature had barely discussed. His 1969 paper in the American Journal of Pathology proposed a mechanism. Elevated homocysteine damages the endothelium directly, generates free radicals in the arterial wall, impairs the production of nitric oxide, and promotes clotting. The biochemical cofactors that clear homocysteine (folate, B6, B12) are systematically stripped from the industrial food supply. Restore the cofactors, clear the homocysteine, protect the artery. The proposal was simple, testable, and cheap.

Harvard’s response was not scientific rebuttal. Harvard denied him tenure. Massachusetts General Hospital, where he held a joint appointment, moved his laboratory to the basement. His research funding evaporated. He was told his work was “not of sufficient interest” to the institution. For two years no medical institution would hire him. Colleagues who had praised his work stopped returning his calls. He eventually secured a position at the Veterans Administration hospital in Providence, Rhode Island, and continued his research quietly, publishing steadily, waiting for the profession to catch up.⁴ He is now in his nineties. The mechanism he identified is beyond dispute. The test he proposed is still not part of routine cardiology practice.

What was done to McCully in the early 1970s was not a mistake. It was a structural response. The mechanism he found could not be commercialized. B vitamins are cheap and unpatentable. Statins were about to be launched and would generate over a trillion dollars in sales. A profession whose training, income, and institutional standing depended on the cholesterol hypothesis had to choose between the man and the market. It chose the market. Every subsequent choice the specialty has made about what to test, what to prescribe, and what to teach has followed the same structural logic.

An interventional cardiologist earns between $500,000 and $1,000,000 annually, most of it from procedures performed in the cath lab.¹ Hospitals depend on cardiac procedure revenue. Device manufacturers spend billions marketing their products to the specialists who implant them. The ACC/AHA guidelines that govern clinical decisions are written by committees dominated by members with financial ties to the drug and device companies whose products the guidelines recommend. When the 2004 National Cholesterol Education Program guidelines lowered LDL targets in a way that would put millions of additional Americans on statins, most panel members had undisclosed pharmaceutical ties. The Washington Post reported the conflicts. Critics demanded disclosure. The guidelines were not changed.²

The specialty’s foundational hypothesis was itself a selection artifact. Ancel Keys had data available for twenty-two countries when he published his 1953 graph correlating fat consumption with heart disease mortality. He selected six that fit his hypothesis. When the full twenty-two were subsequently analyzed by Yerushalmy and Hilleboe in 1957, the correlation vanished.³ The diet-heart hypothesis that emerged from Keys’ selection became the framework for the entire preventive apparatus of American cardiology, its dietary guidelines, its diagnostic categories, and its drug portfolio.

What follows are twelve specific things the specialty has decided not to say. Each is documented in the specialty’s own trials, its own registries, or its own admissions. What the twelve share is a common cause: the profession’s incentive structure selects for what generates procedures and prescriptions, and against what threatens them. McCully’s story is the pattern. The twelve items are its effects.

Two More Buried Figures

McCully was not the only researcher whose work threatened cardiology’s foundations. Two others deserve mention because their work is drawn on throughout what follows.

Uffe Ravnskov (1934–2023), Danish physician and independent researcher, published The Cholesterol Myths in 1991 in Sweden and in 2000 in English. The book documented, with citations to the primary literature, the fraudulent foundation of the diet-heart hypothesis. During a live Swedish television broadcast in 1992, a copy of the book was burned on air.⁵ Ravnskov co-founded The International Network of Cholesterol Skeptics. Their 2016 systematic review in BMJ Open, finding that high LDL was inversely associated with mortality in people over sixty, was the most-read article on the journal for six consecutive months. Their 2018 review in Expert Review of Clinical Pharmacology became the second-most-downloaded paper from Taylor and Francis.⁶ Statin prescribing continued to rise.

Thomas Cowan (born 1957), American physician, spent forty years reframing the organ itself. His Human Heart, Cosmic Heart (2016) makes the case that the heart’s primary function is to organize vortex patterns in blood flow, rather than to generate the pressure that pushes blood through the vessels. Blood moves via the properties of structured water lining the endothelium, described by Gerald Pollack’s laboratory work at the University of Washington.⁷ Cowan also preserved knowledge of strophanthus in English after German cardiology abandoned it. His framework will surface at Items 11 and 12.

Malcolm Kendrick, the Scottish general practitioner whose two books on the cholesterol hypothesis and the thrombogenic alternative anchor much of the evidence in what follows, provides the master documentation across the twelve items.

1. Cholesterol does not cause heart disease.

The teaching: elevated LDL causes atherosclerosis. Lowering it prevents heart attacks and strokes. Statins are the primary tool. Prescribe widely.

The specialty’s own longest-running study contains the confession. The Framingham Heart Study, launched in 1948 and specifically designed to establish the cholesterol-heart-disease link, published its thirty-year data with a finding buried in the report. For each 1 mg/dl drop in cholesterol, there was an 11 percent increase in coronary and total mortality.⁹ People whose cholesterol fell over the follow-up period died at higher rates than those whose cholesterol rose. William Castelli, former director of Framingham, admitted publicly that in Framingham, the more saturated fat and cholesterol a person ate, the more calories a person ate, the lower their serum cholesterol.⁹ The Multiple Risk Factor Intervention Trial, following 361,662 men, found that those with cholesterol below 170 mg/dl had double the death rate from cerebral hemorrhage compared to those with higher levels. Below 160, the death rate quadrupled.¹⁰

The most damning fact requires no biostatistics to state. Most people who have heart attacks do not have elevated LDL. Most people who have elevated LDL do not have heart attacks.¹¹ A causal agent absent from most cases and present without effect in most other cases is a marker of something else, or of nothing at all.

Merck knew. Statins block HMG-CoA reductase, an enzyme in the mevalonate pathway that produces both cholesterol and coenzyme Q10. The two share a biosynthetic route. Q10 is the primary electron carrier in the mitochondrial respiratory chain. The heart, the organ with the highest energy demand in the body, contains the highest concentration of Q10 in the body.¹² Statins deplete plasma Q10 by 16 to 54 percent.¹³ Before launching lovastatin, Merck filed two patents in 1990 for combinations of their statin with Q10 supplementation. US Patent 4,929,437 and US Patent 4,933,165. The second patent named Nobel laureate Michael S. Brown as inventor. Its stated rationale: “since CoQ10 is of benefit in congestive heart failure patients, the combination with HMG-CoA reductase inhibitors should be of value in such patients who also have added risk of high cholesterol levels.”¹⁴ Neither combination was ever marketed. Kendrick asked the operative question: could statins be totally innocent if they required a built-in antidote?¹⁵

For the full development of the cholesterol argument, see The Wrong Enemy and Cholesterol and Statins: An Essay on the Most Successful Unfalsifiable Claim in Medicine.

2. Stents do not prevent heart attacks in stable disease.

Roughly a million stents are placed in the United States annually, at about $30,000 per procedure. The rationale offered to patients is that opening a narrowed artery prevents the heart attack the narrowing would otherwise cause.

The COURAGE trial, published in the New England Journal of Medicine in 2007, randomized 2,287 patients with stable coronary disease to stenting plus optimal medical therapy or to optimal medical therapy alone. Follow-up averaged 4.6 years. No difference in death or myocardial infarction between the two groups.¹⁶ The ORBITA trial, published in The Lancet in 2017, went further. It used a sham-controlled design in which some patients received a real stent and others received a simulated procedure without a stent placed. Neither the patients nor the assessing physicians knew who had received which. The primary endpoint was exercise time. There was no difference. Sham stenting produced the same result as real stenting.¹⁷ The ISCHEMIA trial, published in the New England Journal of Medicine in 2019, tested an invasive strategy (angiography followed by revascularization) against conservative medical management in 5,179 patients with moderate to severe ischemia. No mortality benefit. No reduction in myocardial infarction.¹⁸

Three trials in the specialty’s own flagship journals. Nothing changed in practice. Stent placement did not decline. The revenue continued.

3. Bypass surgery does not extend life for most patients who receive it.

Approximately 400,000 coronary artery bypass grafting procedures are performed in the United States annually, at roughly $100,000 each. Surgical mortality is 1 to 2 percent from the procedure itself.

The Coronary Artery Surgery Study, the VA Cooperative Study, and the European Coronary Surgery Study collectively established in the 1970s and 1980s that bypass surgery extends life only in the narrow subgroup of patients with left main coronary disease or three-vessel disease with impaired left ventricular function. For everyone else, which is most patients who undergo the procedure, no mortality advantage over medical management.¹⁹ The MASS-II trial, published in Circulation in 2010, compared bypass surgery to medical therapy in stable multi-vessel disease over ten years of follow-up. No difference in overall mortality.²⁰ Vein grafts harvested from the leg develop atherosclerosis faster than the native coronary arteries they were meant to replace. Many patients need repeat procedures.

4. The artery they open is rarely the artery that later kills you.

Coronary angiography identifies the biggest visible narrowings. The specialty then treats the biggest narrowings on the assumption that the biggest are the most dangerous.

Autopsy studies contradict the assumption. Giorgio Baroldi, the Italian pathologist whose autopsies of heart attack victims Cowan cites, found that 80 percent of people dying of a heart attack showed no arterial blockage sufficient to explain the event.²¹ Many had extensive stable plaques compensated by collateral circulation and had lived symptom-free for years. Others died from vessels the angiogram would have called minor. Vulnerable plaques, the ones most likely to rupture and produce the acute event, tend to be small, non-obstructive, and invisible on angiography. Large stable plaques calcify and reinforce themselves. Coronary calcium scores, marketed as advanced screening, measure the healed plaques rather than the dangerous ones and correlate with lower heart attack risk, not higher.²³

Angiography is also less reliable than the specialty presents it as. Different cardiologists reading the same angiogram reach different conclusions on the significance of a given lesion 30 to 40 percent of the time.²² A two-dimensional shadow of a three-dimensional structure viewed from a single angle can look like a 50 percent stenosis or a 90 percent stenosis depending on which projection is chosen. The specialty’s most confident intervention rests on the least reliable diagnostic image in cardiology.

5. Blood pressure targets keep dropping to sell more drugs.

The threshold for hypertension has moved down repeatedly across the specialty’s history. 160/95 became 140/90. 140/90 became 130/80. The 2017 ACC/AHA guidelines lowered it again, capturing roughly thirty million additional Americans into a new drug-eligible category overnight.

The trial that drove the last drop was SPRINT, published in the New England Journal of Medicine in 2015. SPRINT compared intensive blood pressure control (systolic target below 120) to standard control (target below 140) in 9,361 patients. The trial excluded diabetics, who had been studied separately in the ACCORD trial with a negative result the guidelines then ignored. SPRINT used automated unattended blood pressure measurement, which reads approximately 10 mmHg lower than standard office measurement, so patients meeting the “120” threshold in the trial were actually running closer to 130 by conventional office readings. The trial was stopped early on the basis of interim analysis, a technique known to inflate apparent effect size.²⁴ Cochrane reviews of tight blood pressure control in the elderly have not found mortality benefit and have documented increased falls, kidney injury, and syncope.²⁵

Each guideline revision brings in millions of patients who were told the previous year that their numbers were fine.

6. Saturated fat was rehabilitated by the specialty’s own meta-analyses.

For fifty years the specialty told the population that saturated fat causes heart disease. The advice reshaped the food supply. Households pulled butter and lard from their cupboards; institutional cafeterias substituted margarine and vegetable oil.

The specialty’s own meta-analyses have overturned the advice. Siri-Tarino in 2010, pooling twenty-one prospective studies covering 347,747 subjects, found no association between saturated fat intake and cardiovascular disease.²⁶ Chowdhury in 2014, pooling seventy-two studies covering over six hundred thousand subjects, found the same.²⁷ De Souza in 2015, pooling seventy-three studies, found no association between saturated fat and total mortality, cardiovascular mortality, coronary disease, or ischemic stroke.²⁸ Three large meta-analyses in the mainstream cardiovascular literature. The specialty’s dietary advice has not been updated.

The intervention trials tell a sharper story. The Sydney Diet Heart Study, run from 1966 to 1973, replaced saturated fat with vegetable oil in the treatment group. The full data was buried until Christopher Ramsden, working at the National Institutes of Health, recovered it and reanalyzed it in 2013. The men who replaced saturated fat with vegetable oil had a 62 percent higher death rate.²⁹ The Minnesota Coronary Survey, hidden for four decades and recovered by Ramsden’s team in 2016, showed that for every 30 mg/dl reduction in cholesterol in the treatment group, mortality increased by 22 percent.³⁰ Teicholz’s The Big Fat Surprise documents the institutional history of how the advice came to be given despite the evidence that contradicted it.³¹

7. Salt restriction raises mortality in most people.

The teaching is that salt raises blood pressure, blood pressure causes heart disease, therefore restrict salt. The specialty targets 2,300 mg of sodium per day for the general population and 1,500 mg for anyone with hypertension or over the age of fifty.

James DiNicolantonio, cardiovascular researcher and author of The Salt Fix, has assembled the data the guidelines do not cite. About 80 percent of people with normal blood pressure are salt-insensitive, meaning their blood pressure does not rise with increased salt intake. Among those with prehypertension, roughly 75 percent are insensitive. Even among those diagnosed with hypertension, about 55 percent are insensitive.³² The optimal sodium intake range for healthy adults sits between 3 and 6 grams per day, well above the guideline target. The relationship between sodium intake and cardiovascular mortality follows a J-curve. The lowest sodium intake groups, which is to say those meeting or beating the guideline target, have the highest cardiovascular and all-cause mortality. The PURE study, following 101,945 people across seventeen countries, confirmed the pattern.³³

The Korean paradox. Koreans consume among the highest sodium intakes in the world, over 4,000 mg per day. They have one of the world’s lowest rates of hypertension and cardiovascular disease.³² Low-salt diets increase heart rate, activate the renin-angiotensin-aldosterone system the antihypertensive drugs are designed to block, contribute to insulin resistance, and elevate the risk of hyponatremia in the elderly.³² The advice to restrict salt is not supported by the evidence used to give it.

8. Ancel Keys built the diet-heart hypothesis by discarding data.

The 1953 graph. Six countries on a straight line. Fat consumption on one axis, heart disease mortality on the other. Elegant. Persuasive. The image on which the entire diet-heart hypothesis was constructed.

The countries not shown. Data was available for twenty-two nations at the time Keys drew his graph. He selected the six that fit his hypothesis. When Jacob Yerushalmy and Herman Hilleboe reanalyzed the full twenty-two-country dataset in 1957, publishing in the New York State Journal of Medicine, the correlation vanished. Countries with similar fat intakes had heart disease rates that varied by factors of three and four. Keys’ clean line was an artifact of his selection.³ Kendrick performed a version of the same exercise using the seven European countries with the lowest saturated fat intake and the seven with the highest. The high-fat countries had lower heart disease rates. Every one of them.¹¹

Even within Keys’ own selected data, the internal inconsistencies were visible. In Finland, the region of Karelia had five times the coronary mortality of Turku despite nearly identical cholesterol levels. On the Greek islands, Corfu had five times the cardiac deaths of Crete despite lower cholesterol.¹¹

The Sugar Research Foundation, faced with emerging evidence linking sucrose to coronary disease in the 1960s, paid Harvard researchers the equivalent of $50,000 in today’s money to write a review attacking the sugar research and promoting the fat hypothesis instead. The researchers assured the sugar industry that they were “well aware of your particular interest” and would “cover this as well as we can.” The review appeared in the New England Journal of Medicine in 1967 without disclosure of the funding source. The documents establishing the payment and the intent surfaced decades later in the archives of Cristin Kearns and were published in JAMA Internal Medicine in 2016.³⁴

The specialty’s founding hypothesis is a selection artifact underwritten by a documented industry payment. Its diagnostic categories, dietary guidelines, and drug portfolio all descend from this base.

9. Homocysteine, and the test the specialty still refuses to run.

Cardiologists do not routinely test homocysteine. It is not in the ACC/AHA lipid panel. Most insurance plans do not cover it. Most patients have never heard of it. Fifty years after McCully identified the mechanism, the specialty’s silence on the topic is the loudest ongoing indictment in this list.

The observational data assembled in the interval has been consistent. The Framingham data showed that people with the highest homocysteine levels had twice the heart disease risk of those with the lowest.³⁵ The European Concerted Action Project showed that elevated homocysteine increased heart disease risk by 200 percent.³⁶ The Nurses’ Health Study, following over 80,000 women, found that those with the highest folate and B6 intake had 45 percent less heart disease than those with the lowest, an effect independent of other risk factors.³⁷

The randomized trials of B-vitamin supplementation for cardiovascular events have been mixed. HOPE-2 in 2006 gave folic acid, B6, and B12 to 5,522 patients with vascular disease and reduced stroke by 25 percent as a secondary endpoint, though the composite primary endpoint did not reach significance.³⁸ NORVIT and VISP were negative for the composite endpoint.³⁹ The subsequent debate has largely been about whether the trials used the right forms (folic acid, which requires enzymatic conversion, rather than methylfolate, which does not) and the right populations (patients already on statins and aspirin whose damage patterns may mask the intervention).⁴⁰ The observational marker data has not been meaningfully disturbed. Cardiology’s response to the marker has been to ignore it in daily practice.

The compounds involved (folate, methylcobalamin, pyridoxal-5-phosphate) are the biochemical cofactors the methylation cycle requires to clear homocysteine. They are present in whole foods (organ meats, eggs, leafy greens, legumes) and stripped from processed foods. White flour has 90 percent of its B6 removed in processing. A diet of industrial food combined with clinical silence on homocysteine testing produces the endothelial injury the specialty then treats with drugs that address neither the cofactor depletion nor the mechanism.

For the fully worked case on the homocysteine mechanism, see The Wrong Enemy.

10. The teeth and the heart are the same problem.

The teaching is silence. Cardiologists do not ask about dental history. Periodontal disease is a problem for the dentist, not the internist. Root canals are considered dental infrastructure with no bearing on cardiac risk. The specialty separated the mouth from the heart around 1950, when the American Dental Association reversed the focal-infection position it had held since the 1920s.

Weston Price, the founding director of the American Dental Association’s research section and its chairman from 1914 to 1928, spent twenty-five years documenting the systemic effects of root-canal-treated teeth. He worked with a sixty-person research team and over five thousand animals. He extracted root-filled teeth from patients with specific systemic diseases and implanted fragments under the skin of rabbits. Rabbits inoculated from patients with heart disease developed heart disease. Rabbits inoculated from patients with kidney disease developed kidney disease. In one endocarditis case, cultures from a fifteen-year-old’s infected molar were injected into thirty rabbits. Twenty-eight died of endocarditis. Ground root-canaled teeth were then sterilized to remove all bacteria and injected in minute quantities. The rabbits still developed heart disease and died. The toxins produced by the anaerobic organisms colonizing the dead tooth were more potent than the organisms themselves.⁴¹ Price’s own son had died of a heart attack shortly after Price performed a root canal on him. That was the research’s origin.

The modern data confirms the pattern. Willershausen and colleagues, publishing in the Journal of Endodontics in 2009, compared 125 patients hospitalized with acute myocardial infarction to matched controls and found significantly higher rates of chronic endodontic infection in the infarction group.⁴² Larger observational studies have found that endotoxemia from periodontal disease and root canals correlates with cardiovascular events more tightly than cholesterol does.⁴³ A textbook of periodontal medicine states that the evidence is “strong enough to establish oral infections as an independent risk factor for CVD.”⁴⁴

The cardiologist does not ask about the dentist. The dentist does not ask about the cardiologist. Two specialties treating the same disease from opposite ends of the same organism, neither acknowledging the other.

For the extended treatment of the dental side of this problem, see 12 Things Your Dentist Was Trained Not to Tell You.

11. Ejection fraction measures a function the heart does not primarily perform.

Ejection fraction is the master metric of modern cardiology. The percentage of blood in the left ventricle expelled with each beat. Normal is 55 to 70 percent. Below 40 percent is called “reduced” and triggers escalating pharmaceutical intervention. Below 35 percent is the threshold for implantable defibrillator placement, a device costing $50,000 to $100,000 with ongoing surveillance costs. Below 20 percent puts a patient on the transplant list. The number governs decisions about defibrillators, transplants, drugs, prognosis, and the conversation the cardiologist has with the family.

The number measures the volume percentage expelled per beat under the founding assumption that the heart is a pressure-propulsion pump and that the ejection percentage is a meaningful index of that function. As a pressure-propulsion pump, the heart is only about 30 percent efficient. Leon Manteuffel-Szoege, working in Warsaw in the 1940s, demonstrated that blood continues to circulate for up to two hours after the heart stops, and concluded that blood has its “own motor energy” independent of cardiac contraction.⁴⁵ Blood begins flowing in the developing embryo before the heart has formed. Rivers of blood move through primitive vessels while what will become the heart is still an unstructured cluster of cells.⁴⁶ These are not observations the pump model can accommodate.

The specialty’s own diagnostic category called heart failure with preserved ejection fraction (HFpEF) makes the case for the metric’s inadequacy on the specialty’s own terms. HFpEF now constitutes more than half of all heart failure cases. The heart contracts normally. The ejection fraction is preserved, sitting in the 55 to 70 percent range. And the patient is still dying. Every major trial of the cardiovascular drug classes the specialty had built its practice on, applied to HFpEF, has failed to reach its primary endpoint. CHARM-Preserved with candesartan (3,023 patients). PEP-CHF with perindopril (850 patients). I-PRESERVE with irbesartan (4,128 patients, death rates essentially identical between drug and placebo at 52.6 versus 52.3 per 1,000 person-years). TOPCAT with spironolactone (3,445 patients).⁴⁷ The 2023 JACC Heart Failure Scientific Statement conceded that “the pathophysiologic mechanisms driving HF progression in HFpEF remain poorly understood.”⁴⁸ Two SGLT2 inhibitors imported from diabetes practice have shown modest reductions in heart-failure hospitalizations in HFpEF through mechanisms that are still debated, without clear all-cause mortality benefit. What has not appeared inside the pump-model framework is a drug that fixes the physiology the ejection fraction claims to measure.

Peter Langsjoen’s 2019 study demonstrates what happens when the actual cause is addressed. 142 heart failure patients with mean 6.8 years of statin exposure. 94 percent had HFpEF. Treatment protocol: stop the statin, start Q10 at 300 mg per day. NYHA Class I improved from 8 percent to 79 percent. In the subgroup with reduced ejection fraction, mean EF improved from 35 percent to 47 percent. One-year mortality: zero. Three-year mortality: 3 percent.⁴⁹ The metric moves when the treatment addresses the actual injury. The Q-SYMBIO trial confirmed the direction with 420 patients across 17 centers, randomized placebo-controlled: Q10 halved cardiovascular mortality over two years. Number needed to treat to prevent one death: ten.⁵⁰

The metric governs decisions the specialty cannot justify from the physiology. A cheap unpatentable molecule outperforms every major HFpEF drug trial in the specialty’s literature and has not entered guideline care.

For the fully worked case, see Congestive Heart Failure: The Modern Beriberi.

12. The heart is not a pump.

The teaching is old and universal. The heart is a muscular pump that pushes blood through roughly 60,000 miles of vessels. Every downstream intervention on this list, from the drugs that support contractility to the mechanical devices that assist it to the transplants that replace the organ altogether, sits inside this frame.

The mathematics do not close. The heart weighs about 300 grams. The vascular network it supplies extends across sixty thousand miles of vessels. Most of that network is capillaries, so narrow that red blood cells must deform and pass through single file. The pressure required to push blood through this network against the documented resistance exceeds by orders of magnitude what a 300-gram organ could produce. Athletes increase cardiac output by 600 percent during intense exercise. The heart muscle mass does not multiply sixfold in the process. The energy available does not multiply sixfold. Blood continues moving through capillaries even in tissue surgically isolated from cardiac pressure.

The alternative comes from Gerald Pollack’s laboratory at the University of Washington. Pollack demonstrated that water adjacent to hydrophilic surfaces (which include the interior walls of blood vessels) forms a structured layer, distinct from bulk water in liquid or solid phase, that he named the fourth phase of water. This layer carries a negative charge, excludes solutes, and grows when the surface is illuminated by infrared light. In tubes, it generates flow without any pumping. The mechanism can be replicated on a bench.⁵¹ Applied to the vasculature, the model gives blood its own motor. The negatively charged exclusion zone lining the vessel walls repels the negatively charged red blood cells, propelling them along the vessel.

The heart’s actual function, on this model, is to organize the flow into specific vortex patterns. Frank Chester discovered that a specific seven-sided geometric figure, which he named the chestahedron, sits at exactly 36 degrees when nested inside a cube. This is precisely the angle of the heart in the chest. When the chestahedron is spun in water, it generates vortex patterns that match those seen in echocardiograms of the ventricles.⁷ Francisco Torrent-Guasp, working over several decades in Spain, demonstrated that the ventricular muscle fibers form a helical spiral, wrapping around themselves in a figure-eight pattern.⁵² That arrangement is far more complex than a pump wall would need to be, and is exactly what vortex generation would require.

Blood begins flowing in the developing embryo before the heart forms. Rivers of blood move through primitive vessels via the properties of structured water in those vessels, weeks before there is a heart to pump them. When the heart forms, it forms at a bend in an already-flowing stream, the way a hydraulic ram is inserted into an existing river.⁴⁶

What the specialty calls heart failure is not, on this model, primarily pump failure. It is systemic energy deficit, autonomic dysregulation, and the failure of structured water dynamics in the vasculature. The interventions cardiology performs (drugs to force the pump to work harder, mechanical devices to assist pumping, transplants to replace the pump) are all built on a model that misidentifies the organ’s primary function.

The buried medicine confirms the model by working through it. Strophanthus, a cardiac glycoside derived from the seeds of an East African vine, was used in German cardiology for over fifty years for angina, heart failure, and prevention of heart attacks. Coal miners in 1970s Germany died at approximately thirty per year of heart attacks in a workforce of 1,800. After the introduction of strophanthus extract, deaths dropped to two per year. Professor Kern documented the 93 percent reduction.⁵³ A Berlin hospital’s twelve-year series reported that 99 percent of chest pain patients became complaint-free within two weeks on oral strophanthus. A survey of practicing German physicians found that 98 percent reported high effectiveness. The remaining 2 percent described it as “within limits positive.” Not one physician reported negative assessment.⁵³ The mechanism operates through Gilbert Ling’s cellular framework, in which the sodium-potassium pump the specialty was taught to believe in mathematically cannot exist. Ling calculated that the pump would require thirty times more ATP than cells actually produce.⁸ Cells maintain the sodium-potassium distribution through the structure of intracellular water, which forms a gel that geometrically excludes sodium while accommodating potassium. Ouabain, the active compound in strophanthus, supports the formation of that gel.

Strophanthus disappeared from mainstream medicine in the 1970s. Digoxin, the other cardiac glycoside in use, remained. Digoxin is fat-soluble, accumulates in tissue, has a narrow therapeutic window, causes roughly eight thousand US hospital visits annually for toxicity, and produced no mortality benefit in the DIG trial.⁵⁴ The safer medicine, requiring less monitoring, disappeared. The dangerous one, requiring continuous physician supervision and blood tests, survived.

For the extended treatment of the strophanthus story and the cellular biology beneath it, see The Gift from Paradise: Strophanthus and the Heart Medicine That Disappeared, and my summary of Human Heart, Cosmic Heart.

The Cardiologist’s Waiting Room

The next appointment is on the calendar. You have not canceled it. It is Tuesday at 3:15.

You will sit down. The nurse will take your blood pressure. A phlebotomist will draw blood for a lipid panel. Twelve electrodes will go on your chest, wrists, and ankles for the ECG. The cardiologist will study the numbers, find something above threshold, present a treatment plan. You will schedule the next appointment, pick up the prescription, and come back in six months.

Nothing in the sequence will ask about the six years of grief since your husband died, about the antidepressants you were put on after that, about the electrical hum in the house since the smart meter was installed, about the sixteen root canals in your extended family, about the decades of industrial food that stripped the cofactors from your methylation cycle before the homocysteine that will not be tested for climbed to whatever it is now. None of it will be asked because the visit is not structured to ask it.

Cardiology in its current form is a repair industry positioned at the end of a long causal chain. The chain begins in the kitchen, the workplace, the bedroom, the electromagnetic environment, the dentist’s chair, the medicine cabinet, and the accumulated psychological weight the patient carries into the six-month appointment. A cardiology that addressed those upstream causes would be a smaller cardiology, less remunerative, with fewer specialists. The market did not select for that cardiology. The insurance codes do not pay for the diet conversation, the stress conversation, the dental conversation, the medication-review conversation.

The knowledge exists. McCully documented the mechanism in 1969. Ravnskov dismantled the diet-heart hypothesis across three decades of publication. Cowan reframed the organ itself. Kendrick assembled the evidence into two books that any interested reader can obtain. The work was done, and published, and translated into English, and left there. It has been the specialty’s choice not to integrate it.

What remains is the redirected gaze. Toward the food on the table. Toward the water in the glass. Toward the sunlight, the ground, the sleep, the community. Toward the dentist who will remove the root canal that has been leaking anaerobic toxins into the systemic circulation for twenty years. Toward the electromagnetic environment that no cardiologist has ever asked about. Toward strophanthus, still available from a small number of practitioners, still working through the mechanism the specialty walked away from, still ignored.

You will go to the appointment on Tuesday. You will ask the questions the appointment is not structured to handle. What the cardiologist says, or does not say, is the diagnostic finding you take home.

What This Means for the Next Appointment

Before any statin prescription, ask for the absolute risk reduction and the number needed to treat, not the relative risk reduction the promotional materials use. The two numbers can differ by a factor of thirty.

Before any stent recommendation for stable disease, ask about the COURAGE trial and the ORBITA trial by name. The cardiologist knows what they are.

Before any bypass for stable disease, ask about MASS-II.

Before accepting an ejection fraction as a prognosis, ask about the Langsjoen 2019 study and whether Q10 depletion by statins might have contributed to the number.

Ask what homocysteine testing shows. If it has not been performed, ask why not.

Ask whether the specialist has read McCully’s The Heart Revolution, Kendrick’s The Great Cholesterol Con, Ravnskov’s The Cholesterol Myths, or Cowan’s Human Heart, Cosmic Heart. The answer, or the manner of the answer, will tell you what to do next.

Ask about the dentist. Ask what percentage of your teeth are root-canaled or crowned. Ask whether the cardiologist has ever asked a patient about their dentist. If the answer is no, ask why not.

A cardiologist who has read the sources will not be threatened by the questions. One who has not will treat them as obstruction, as internet misinformation, or as denialism. Either response is useful information. The appointment has shifted from a procedure being done to a procedure being negotiated.

For patients already deep in the cascade, on the statin for the third decade, with the stent placed or the bypass performed, told the ejection fraction leaves them with a limited window: the terrain is still upstream. Reversible cardiomyopathy is a recognized category in the specialty’s own literature. Alcoholic cardiomyopathy resolves in 42 percent of cases with abstinence. Tachycardia-induced cardiomyopathy normalizes with rate control. What made the damage produced the damage. Removing what made the damage removes some fraction of the damage.

How to Explain It to a Six-Year-Old

Your heart is like the gardener at the center of a big garden. The gardener does not water every plant one by one. That would be impossible, because the garden is huge and the gardener is small. What the gardener does is stir the water in the pond into a special swirling pattern. The swirling pattern makes the water move through all the little channels in the garden by itself. Every plant gets watered because the swirl keeps going.

The doctors who take care of hearts do not know about the swirl. They were taught in school that the gardener pushes the water through the channels by squeezing very hard. So when the plants start to droop, the doctors give the gardener drugs to make him squeeze harder, or they put in mechanical arms to help him squeeze, or they cut open the channels and put in metal tubes to help the water get through the tight spots. None of it works very well. The plants keep drooping. The gardener gets tired.

What is actually happening is that the water in the garden has stopped swirling properly, because too many bad things have gotten into the garden and messed up the swirl. Bad food. Bad water. Bad worry that never stops. Bad electric humming from the machines everywhere. Bad teeth that are leaking poison into the pond. When you fix those upstream things, the swirl comes back. The plants stop drooping. The water starts flowing through the little channels by itself again.

Once, a long time ago, doctors in Germany used a special medicine that helped the swirl. It came from a plant that grows in Africa. Most heart doctors today have never heard of it. The heart is a gardener. The pump is the story the doctors were taught. The swirl is what actually keeps you alive.

References

1. Interventional cardiologist compensation data, MGMA Physician Compensation Survey, and Medscape Cardiologist Compensation Report 2023.

2. Washington Post, “Statins Committee Members Had Ties to Drug Firms,” October 15, 2004, documenting undisclosed pharmaceutical ties among National Cholesterol Education Program panel members. See also Malcolm Kendrick, The Great Cholesterol Con: The Truth About What Really Causes Heart Disease and How to Avoid It (London: John Blake Publishing, 2008).

3. Yerushalmy, J. and Hilleboe, H.E. “Fat in the Diet and Mortality from Heart Disease: A Methodologic Note.” New York State Journal of Medicine 57 (1957): 2343–2354.

4. Kilmer S. McCully, The Heart Revolution: The Extraordinary Discovery That Finally Laid the Cholesterol Myth to Rest (New York: HarperPerennial, 1999). McCully’s original paper: McCully KS, “Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis,” American Journal of Pathology 56 (1969): 111–128.

5. Uffe Ravnskov, The Cholesterol Myths: Exposing the Fallacy That Saturated Fat and Cholesterol Cause Heart Disease (Washington, DC: NewTrends Publishing, 2000). The book burning incident on Swedish television is documented in Ravnskov’s public writings and in various profiles of THINCS.

6. Ravnskov U et al., “Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review,” BMJ Open 6 (2016): e010401. Ravnskov U et al., “LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature,” Expert Review of Clinical Pharmacology 11 (2018): 959–970.

7. Thomas Cowan, Human Heart, Cosmic Heart: A Doctor’s Quest to Understand, Treat, and Prevent Cardiovascular Disease (White River Junction, VT: Chelsea Green Publishing, 2016).

8. Gilbert Ling, Life at the Cell and Below-Cell Level (New York: Pacific Press, 2001), and Gilbert Ling, A Revolution in the Physiology of the Living Cell (Malabar, FL: Krieger Publishing, 1992). Ling’s calculations of the ATP requirement for the sodium-potassium pump and his stripped-membrane experiments are summarized in Cowan, Human Heart, Cosmic Heart, and in the strophanthus literature at newbiologyclinic.com.

9. Framingham Heart Study, 30-year follow-up data, discussed extensively in Ravnskov, The Cholesterol Myths, and Kendrick, The Great Cholesterol Con. William Castelli’s admission on saturated fat and serum cholesterol appears in Castelli WP, “Concerning the possibility of a nut...,” Archives of Internal Medicine 152 (1992): 1371–1372.

10. Multiple Risk Factor Intervention Trial (MRFIT) Research Group, various publications 1982–1996, discussed in Ravnskov, The Cholesterol Myths.

11. Malcolm Kendrick, The Clot Thickens: The Enduring Mystery of Heart Disease (Columbus Publishing, 2021).

12. Peter Langsjoen and Alena Langsjoen, “The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10,” BioFactors 18 (2003): 101–111. See also Karl Folkers et al., “Lovastatin decreases coenzyme Q levels in humans,” Proceedings of the National Academy of Sciences 87 (1990): 8931–8934.

13. Marcoff L, Thompson PD, “The role of coenzyme Q10 in statin-associated myopathy: a systematic review,” Journal of the American College of Cardiology 49 (2007): 2231–2237. Qu H et al., “Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis,” European Journal of Medical Research 23 (2018): 57.

14. United States Patent 4,929,437, “Coenzyme Q10 with HMG-CoA reductase inhibitors,” issued May 29, 1990. United States Patent 4,933,165, “Coenzyme Q10 with HMG-CoA reductase inhibitors,” issued June 12, 1990 (Michael S. Brown, inventor). Both assigned to Merck & Co.

15. Malcolm Kendrick, The Great Cholesterol Con, chapter on statin side effects.

16. Boden WE et al. (COURAGE Trial), “Optimal medical therapy with or without PCI for stable coronary disease,” New England Journal of Medicine 356 (2007): 1503–1516.

17. Al-Lamee R et al. (ORBITA), “Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial,” The Lancet 391 (2018): 31–40.

18. Maron DJ et al. (ISCHEMIA), “Initial invasive or conservative strategy for stable coronary disease,” New England Journal of Medicine 382 (2020): 1395–1407.

19. Coronary Artery Surgery Study (CASS) Principal Investigators, “Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery,” Circulation 68 (1983): 939–950, and related follow-up publications.

20. Hueb W et al., “Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study II (MASS II),” Circulation 122 (2010): 949–957.

21. Giorgio Baroldi, “Coronary heart disease: significance of the morphologic lesions,” American Heart Journal 85 (1973): 1–5, and subsequent autopsy series. Discussed in Cowan, Human Heart, Cosmic Heart, and Stephen Hussey, Understanding the Heart (White River Junction, VT: Chelsea Green Publishing, 2022).

22. Zir LM et al., “Interobserver variability in coronary angiography,” Circulation 53 (1976): 627–632, and subsequent replications.

23. Blaha MJ et al., “Coronary artery calcium scoring: is it time for a change in methodology?” JACC Cardiovascular Imaging 10 (2017): 923–937. Discussion of the paradox that calcification indicates stability rather than danger appears throughout Kendrick, The Clot Thickens.

24. SPRINT Research Group, “A randomized trial of intensive versus standard blood-pressure control,” New England Journal of Medicine 373 (2015): 2103–2116. Critique of the unattended BP measurement protocol appears in Kjeldsen SE et al., “Unattended blood pressure measurements in the Systolic Blood Pressure Intervention Trial: implications for entry and achieved blood pressure values compared with other trials,” Hypertension 67 (2016): 808–812.

25. Diao D et al., “Pharmacotherapy for mild hypertension,” Cochrane Database of Systematic Reviews 8 (2012): CD006742.

26. Siri-Tarino PW et al., “Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease,” American Journal of Clinical Nutrition 91 (2010): 535–546.

27. Chowdhury R et al., “Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis,” Annals of Internal Medicine 160 (2014): 398–406.

28. de Souza RJ et al., “Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies,” BMJ 351 (2015): h3978.

29. Ramsden CE et al., “Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis,” BMJ 346 (2013): e8707.

30. Ramsden CE et al., “Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73),” BMJ 353 (2016): i1246.

31. Nina Teicholz, The Big Fat Surprise: Why Butter, Meat and Cheese Belong in a Healthy Diet (New York: Simon & Schuster, 2014).

32. James DiNicolantonio, The Salt Fix: Why the Experts Got It All Wrong and How Eating More Might Save Your Life (New York: Harmony Books, 2017).

33. Mente A et al. (PURE), “Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies,” The Lancet 388 (2016): 465–475.

34. Kearns CE, Schmidt LA, Glantz SA, “Sugar industry and coronary heart disease research: a historical analysis of internal industry documents,” JAMA Internal Medicine 176 (2016): 1680–1685.

35. Selhub J et al., “Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis,” New England Journal of Medicine 332 (1995): 286–291 (Framingham data).

36. Graham IM et al., “Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project,” JAMA 277 (1997): 1775–1781.

37. Rimm EB et al., “Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women,” JAMA 279 (1998): 359–364.

38. Lonn E et al. (HOPE-2), “Homocysteine lowering with folic acid and B vitamins in vascular disease,” New England Journal of Medicine 354 (2006): 1567–1577. Stroke as a secondary endpoint: hazard ratio 0.75 (95% CI 0.59–0.97, p=0.03). The primary composite endpoint (cardiovascular death, MI, stroke) did not reach statistical significance.

39. Bønaa KH et al. (NORVIT), “Homocysteine lowering and cardiovascular events after acute myocardial infarction,” New England Journal of Medicine 354 (2006): 1578–1588. Toole JF et al. (VISP), “Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial,” JAMA 291 (2004): 565–575. Both trials were null for their composite cardiovascular endpoints.

40. Debreceni B, Debreceni L, “The role of homocysteine-lowering B-vitamins in the primary prevention of cardiovascular disease,” Cardiovascular Therapeutics 32 (2014): 130–138. Discussion of methylation-cycle bioavailability differences between folic acid and methylfolate appears in Scaglione F, Panzavolta G, “Folate, folic acid and 5-methyltetrahydrofolate are not the same thing,” Xenobiotica 44 (2014): 480–488.

41. George E. Meinig, Root Canal Cover-Up (Bion Publishing, 1998), documenting Weston Price’s twenty-five-year research program, the rabbit-implantation studies, the endocarditis case in which 28 of 30 rabbits died, and the sterilized-powder experiments demonstrating that the toxin remained potent after bacterial removal.

42. Willershausen I et al., “Association between chronic dental infection and acute myocardial infarction,” Journal of Endodontics 35 (2009): 626–630.

43. Stephen Hussey, Understanding the Heart: Surprising Insights into the Evolutionary Origins of Heart Disease and Why It Matters (White River Junction, VT: Chelsea Green Publishing, 2022), chapter on dental-cardiac connections.

44. Louis F. Rose et al., eds., Periodontal Medicine (Hamilton, ON: BC Decker, 2000), cited in Hussey, Understanding the Heart.

45. Manteuffel-Szoege L, “Remarks on the circulation of the blood following stopping of the heart,” Journal of Cardiovascular Surgery 7 (1966): 201–208. Discussed in Hussey, Understanding the Heart, chapter 6.

46. Embryological observations on pre-cardiac blood flow are documented in Branko Furst, The Heart and Circulation: An Integrative Model (London: Springer, 2013), and discussed in Cowan, Human Heart, Cosmic Heart.

47. Yusuf S et al. (CHARM-Preserved), The Lancet 362 (2003): 777–781. Cleland JGF et al. (PEP-CHF), European Heart Journal 27 (2006): 2338–2345. Massie BM et al. (I-PRESERVE), New England Journal of Medicine 359 (2008): 2456–2467. Pitt B et al. (TOPCAT), New England Journal of Medicine 370 (2014): 1383–1392.

48. Desai AS et al., “2023 JACC Heart Failure Scientific Statement on heart failure with preserved ejection fraction,” JACC Heart Failure (2023).

49. Langsjoen PH et al., “Statin-associated cardiomyopathy responds to statin withdrawal and administration of coenzyme Q10,” The Permanente Journal 23 (2019): 18.257.

50. Mortensen SA et al. (Q-SYMBIO), “The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial,” JACC Heart Failure 2 (2014): 641–649.

51. Gerald H. Pollack, The Fourth Phase of Water: Beyond Solid, Liquid, and Vapor (Seattle: Ebner and Sons Publishers, 2013).

52. Torrent-Guasp F et al., “The structure and function of the helical heart and its buttress wrapping. I. The normal macroscopic structure of the heart,” Seminars in Thoracic and Cardiovascular Surgery 13 (2001): 301–319, and Torrent-Guasp F et al., “Towards new understanding of the heart structure and function,” European Journal of Cardio-Thoracic Surgery 27 (2005): 191–201.

53. German clinical literature on strophanthus compiled by Dr. Knut Sroka and Dr. Rolf-Jürgen Petry, archived at strophantus.de and in the Internet Archive. Coal miners data from Professor Kern, 1970s Germany. Berlin hospital twelve-year series and the survey of German physicians documented in “The Gift from Paradise: Strophanthus and the Heart Medicine That Disappeared,” Lies Are Unbekoming, February 4, 2026.

54. Digitalis Investigation Group, “The effect of digoxin on mortality and morbidity in patients with heart failure,” New England Journal of Medicine 336 (1997): 525–533. Digoxin toxicity hospital visit data from Patel N et al., “Digoxin Toxicity,” in StatPearls (2024).

All the blood in the body passes through the thyroid gland every seventeen minutes, and during each passage the gland’s iodine kills weak germs and weakens strong ones — provided iodine is present. Eighty-five sterilisation cycles in twenty-four hours, running automatically, costing nothing, requiring only that the chemical agent be there to do the work. Folk Medicine: A Doctor’s Guide to Good Health, published in 1958 by D. C. Jarvis, documents this mechanism alongside a more uncomfortable observation: chlorinated drinking water and table salt strip iodine from the body through the halogen displacement law, because lighter halogens displace heavier ones from biological tissue. Chlorine displaces iodine. Fluorine displaces all three. The seventeen-minute cycle continues running, but empty.

Jarvis was a fifth-generation Vermonter who trained in organised medicine at Burlington, served as an ear-nose-throat physician in Barre for over fifty years, and conducted a twenty-year correspondence study with fifty nationally known doctors — many of them faculty members at medical schools — across thirty-two states. The letters went out Tuesdays and Fridays, basing their findings on cumulative observations from his clinical practice. He came to the work as a trained specialist who recognised, on arriving in Barre, that he would need to learn the indigenous medicine of the back-road farms if he hoped to gain the confidence of the people he served. The book is the testable residue of that fifty-year practice — protocols followed in dairy herds and human patients, urine reactions recorded over two years by twenty-four “human guinea pigs,” milk-production tables across multiple seasons.

By 1958 the pharmaceutical model was well established and the older nutritional traditions were being displaced from medical training. Sulphanilamide had been tried on the Jersey cow with chronic mastitis “for two years” and had failed; vinegar resolved it. Penicillin was being used to save seriously sick cows in herds not receiving iodine. Chlorination of municipal water supplies was treated as settled public health, the halogen-displacement consequence unmentioned. Honey, which Sackett had documented at Colorado Agriculture College as killing typhoid germs in forty-eight hours and dysentery germs in ten, was being replaced on American tables by manufactured corn syrup. Jarvis was writing into a moment when what farm communities had known for generations was being stripped from clinical practice and replaced with patented substitutes that suppressed symptoms while leaving the underlying terrain unaddressed.

The framework sits within the older terrain tradition that Béchamp and Bernard articulated and that Shelton extended into the suppression-to-chronic-disease pathway: the soil determines what grows, the symptom is the body’s intelligent response, the suppression of the symptom drives the acute toward the chronic. The full summary unpacks the bacterial pH table supplied to Jarvis by a medical-school bacteriology department — every pathogenic organism on the list grows on alkaline media, every one — alongside the 23 boarder cows whose pregnancies started within four months on apple-cider vinegar, the eight-year-old boy whose five-month head cold cleared within five minutes of his first chew of honeycomb, and Cavanaugh’s demonstration at Cornell that kelp reduces fracture healing time by twenty per cent. The Andean Peruvians at 16,000 feet make the month-long round trip to the Pacific to fill little bags with kelp, which they carry carefully. They use it, they say, to guard the heart.

Read more

In 1924, Arm & Hammer distributed a twenty-eight-page booklet to physicians describing sodium bicarbonate as clinical medicine — for influenza, kidney disease, gastric distress, uric acid disturbances, respiratory illness, and the general support of the body’s cleansing processes. Arm & Hammer, as the manufacturer, could not distribute that booklet today. The substance is unchanged. What changed is the regulatory environment, which now restricts what manufacturers of unpatentable compounds can say about them.

Two of those compounds are the subject of the two books out today. Both were in every kitchen. Both were routine medicine for generations. Both were quietly written out of the professional conversation as the drug model took over. Neither has stopped working. Neither is expensive. Neither is new. What they are is recovered.

Baking Soda: The Terrain Book on the Compound Medicine Forgot

Buy on Lulu → · 289 pages · USD $19.99

This is a brand new book, available now for the first time.

Baking Soda locates sodium bicarbonate inside the terrain framework that industrial medicine buried. It maps what the compound does at the level of the blood, the kidneys, the lungs, the digestion, the mouth, the skin, and the acidic tissue that industrial modernity produces. It is honest about what bicarbonate cannot do, and about what must accompany it — hydration, minerals, breath, the removal of what is driving the acidity in the first place — for the framework to actually work.

Across eighteen chapters and three Q&A appendices, the book covers the physiology, the historical burial of the terrain framework, and the specific applications: respiratory, kidney, digestive, athletic, dental, transdermal baths, and cancer — where bicarbonate is documented in research on altering the tumour microenvironment.

The compound is cheap. The compound is in every grocery store. The compound is one of the safest substances in general medical and household use. And it has been progressively excluded from the professional medical conversation while remaining freely available to any reader willing to acquire it and understand what it does.

For the family that wants a single reference on a compound they already own. For the reader who has heard terrain mentioned and wants to see it in practice on a substance they can hold.

A word on the second edition

The next book, Castor Oil, first appeared as a digital edition earlier this year. Readers of that first edition should know that the print edition is substantially different — not a reprint, but a second edition, revised and expanded.

The revision is substantial — restructured from the ground up. The clinical record of Dr. William McGarey’s A.R.E. Clinic — the largest single body of documented castor oil practice in modern medicine — is now integrated throughout rather than referenced. Barbara O’Neill’s contemporary teaching from her retreat in the New South Wales mountains sits alongside it. Ulric Williams’s surgical observations from 1930s New Zealand, Edgar Cayce’s Palma Christi tradition, D.C. Jarvis’s Vermont folk practice, and the terrain framework as taught by Tom Cowan are all woven in.

Ten appendices give you the pack construction, the McGarey survey, companion kitchen remedies, sourcing and quality, protocols for the first month, frequently asked questions, and the Vermont tradition. A full index sends you to what you need. If you have the first edition on your screen, this is the version you keep on the shelf.

The Castor Oil Book: The Kitchen Medicine That Nearly Disappeared

Buy on Lulu → · 220 pages · USD $19.99 · Second Edition, Revised and Expanded

Castor oil is the medicine mainstream healthcare quietly stopped talking about. Not because it stopped working — it didn’t. Because a two-dollar bottle from the pharmacy doesn’t sit well in a system built on prescriptions and procedures. So it faded into the background, and with it, four thousand years of documented practice.

This book recovers that practice.

Twenty-two chapters cover kidney stones, appendicitis, liver congestion, fibroids, adhesions, breast conditions, chest conditions, the male terrain, and pediatric applications. The clinical observations behind each are documented. The protocols are given in full. The limitations are stated honestly. The reader is trusted to read the record and decide what to do with it.

For the household that wants one honest reference on a compound already in the cupboard. For the person who has been told there is nothing to be done and wants to see what four thousand years of practice actually documents.

The shelf

Ten books now. More coming.

The first five took on specialisms trained not to see the thing they treat — motherhood, vaccination, dentistry, veterinary medicine, psychiatry. The next three took on suppressed remedies and the germ-theory question underneath — DMSO, chlorine dioxide, and No Contagion (co-authored with Jamie Andrews). These two take on something quieter and closer to home: the compounds already in the kitchen, and the framework that makes them make sense.

That framework has a name. Terrain. It is what medicine looked like before the drug model, and what medicine will need to look like again if it is going to address the chronic disease that the drug model has produced. Each of these books is a piece of that recovery.

The books are printed to order and shipped worldwide from Lulu. The full shelf is at lulu.com/spotlight/unbekoming.

A note of thanks

None of this shelf would exist without the people carrying it. Those of you who bought one book to try it, then came back for a second. Those buying two or three at a time. Those buying the full set, sometimes more than one copy of the same title to give to a friend or a parent. I see every order. Each one is a real person deciding that this work is worth space on their shelf and dollars from their week. Thank you. I do not take that lightly.

— Unbekoming

Feargus O’Connor Greenwood’s 180 Degrees: Unlearn The Lies You’ve Been Taught To Believe ran to 700 pages of citations, footnotes, and cross-referenced sources — 15,000 hours of research designed to move readers gradually from unquestioning belief in official narratives to critical scepticism. Its follow-up, Spiritual War: Tales of the Unexpected — Part 1, opens with the author lying in bed being “spooned” by an invisible presence in a locked, empty house, his nervous system firing as if hooked to a low-voltage socket. This is not a sequel. Greenwood calls it “a radical departure,” and he means it. Where 180 Degrees was engineered to slide readers from A to Z, Spiritual War “starts at Z and then tosses them off the cliff. This is Sparta.” The earlier book was aimed at nudging “the herd” into questioning the official narrative; this one targets the “sceptical independent thinkers” who already got out, and asks them to consider what lies beyond materialism itself. Where 180 Degrees addressed what Greenwood terms “fifth generation warfare — the war for your mind,” Spiritual War addresses “tenth generation warfare — the war for your soul.”

Full disclosure. I read 180 Degrees at a moment when I badly needed it. After Kennedy’s The Real Anthony Fauci had cracked the AIDS narrative open for me, and Liam Scheff’s Official Stories and Joe Plummer’s Tragedy & Hope 101 had shown me the wider architecture of manufactured reality, 180 Degrees arrived and sat above all of them. It taught me more than any book I have ever read. When I interviewed Greenwood in October 2023, he told me his next book would be on “a more spiritual tip” — the least and most spiritual book the reader would ever encounter, combined into one. Spiritual War is that book, and it delivers on the promise.

Greenwood chose humour as his “main vector of attack” — an unusual choice for material this heavy, but a deliberate one. Dialogue is set in script format. Personal anecdotes carry the argument. Part I contains no formal bibliography, only inline references and QR codes; Greenwood didn’t want an academic feel because “many of the ‘tales’ are not citable.” The reader is dropped into a series of scenes: a psychic lodger sketching a French spirit guide named Elena; an 81-year-old friend named Abner who has been astral-travelling since he was five; a woman who describes herself as a “walk-in” who possessed her own body after a suicide attempt; a 75-year-old channelling a Hopi Indian who clears a chronic throat blockage in thirty seconds. The method sounds indefensible on paper. It works on the page because Greenwood is a genuinely funny writer and because the anecdotes cluster into patterns rather than sitting as isolated oddities.

The book’s spine is Greenwood’s own conversion. A London maths graduate and self-described committed rationalist, he documents his own left-brain favouritism and the atomically slim odds of ever going “inter-dimensional.” The turning point is the bedroom encounter, followed by what he calls his “T-system” — a full-body tingle response that begins triggering at unpredictable moments. In the Victoria & Albert Museum, it fires at the coffin effigy of Eleanor of Aquitaine. Through his lodger Tales, whose sketches and channelled messages he treats as data rather than décor, he identifies two persistent spirit guides. Greenwood is careful throughout to state what he cannot prove and to let the reader adjudicate. The framing is closer to field notes than to revelation.

The theoretical backbone comes from Jerry Marzinsky, the psychologist whose four decades of work with schizophrenic patients led him to conclude that “the voices” are not internal at all. When patients asked the voices who they were, the answer was always “we are you.” Marzinsky’s clinical position — that the voices lie systematically about their origin in order to keep the host identified with them — sits alongside Robert Falconer’s argument in The Others Within Us that minds are porous, and the assumption of the mind as a sealed private fortress is catastrophically wrong. Greenwood layers in the Catholic three-stage model of oppression, obsession, possession, and the observation that looped negative memories generate the emotional charge non-human entities are said to feed on. The material is presented as testable rather than doctrinal: revisit a bad memory; if the associated emotion no longer fires, the shadow work on that item is complete.

Chapter 9 is where the book earns its keep as a practical manual. Greenwood sets out eight defence protocols in sequence: shadow work, awareness, cleaning the temple, discernment, verbal dismissal, command and control, psychic weapons for quiet wars, and leveraging the herd. The section on shadow work draws on Bert Hellinger’s Family Constellations therapy and includes a lengthy first-person account from Ben Hawkes — the man who narrated the 180 Degrees audiobook — describing how the resolution of a past-life debt cleared both a chronic marital conflict and a set of business obstacles that had been moribund for years. “Clean the temple” addresses fluoride, GMO food, EMFs, blue-light overload, and physical decluttering. “Psychic weapons” covers intuition, mental strength, non-attachment, fearlessness, and the transmutation of anger into determination. Whatever the reader makes of the ontology, the protocols read as sane hygiene practice for anyone under sustained psychological pressure.

Greenwood’s case for why this book exists now runs through the final chapter. Ancient prophecies across multiple traditions describe a coming bifurcation — a great split in humanity — with what the esoteric literature calls “8th Sphere soul capture” as the losing outcome. Rudolph Steiner, in an October 1917 lecture, described a future in which people would be inoculated against their disposition towards spiritual ideas and materialistic physicians would be entrusted with expelling the souls from mankind. The current push toward what David A. Hughes calls Omniwar — “a stealth war waged against cognition and rationality, across every domain of life” — is, in Greenwood’s reading, the surface layer of something older. Transhumanism and bio-digital convergence are presented as the operational endpoint, with the book citing academic papers advocating what their authors term “anti-love biotechnology” — the search for a chemical cure for love. Greenwood’s preferred term for the whole is not Omniwar but Spiritual War, because that frame focuses attention on where the actual battle lies and what it is aimed at.

180 Degrees was a book you handed to people who still believed the mainstream account. Spiritual War is a book you hand to people who have already burned that account and are looking for what comes next. It will lose some readers early — the opening bedroom scene will end it for a certain kind of sceptic — and Greenwood knows it. He is not writing to convert anyone. He is laying out testimony, patterns, and protocols, and letting the reader do the work. Part II is coming, and he signals it will “go for the Demiurge’s jugular” — a sharper, darker book on the war for the soul proper. This one is the on-ramp: personal, funny, unnerving, and structurally serious under the levity. For anyone who found 180 Degrees to be a master key, Spiritual War is what the key was for.

SPIRITUAL WAR: Tales Of The Unexpected: Part I: Greenwood, Feargus O'Connor: Amazon.com: Books

Author’s note: This essay continues my work on remedies that cannot be patented and have been displaced by ones that can. Jarvis’s iodine protocol sits at the clearest end of that pattern: documented in two published books, prescribed to named patients, almost entirely absent from mainstream practice today. It costs a few dollars a year. The territory it opens onto, the modern management of anxious and dysregulated children, is contested; I have kept my focus on what Jarvis observed and how it was displaced. My thanks to the paid subscribers who make this work possible.

“Dr Jarvis, what am I going to do? One of these girls is a racehorse and the other is a farm horse.”

The mother had five-year-old twin daughters. One was nervous, highly-strung, irritable, always ready to fight. The other had a calm, even disposition, peaceful and quiet. The racehorse twin kept her sister and her mother in a permanent state of upset. Spanking made it worse. She blew up. The mother had no idea how to live with the child.

Jarvis’s answer was two drops of Lugol’s solution of iodine plus a teaspoon of apple cider vinegar in a glass of water. Given any time the child’s temper shifted into high gear. Two weeks later the mother reported that her racehorse daughter had quieted within two hours of the first dose. With continued use, the child could be managed. By the time she graduated high school the tantrums of her early years were behind her. She married. She kept her home. If she ever again felt her constitution slip into high gear, she knew what to do about it.¹

That five-year-old, today, would be evaluated for attention-deficit hyperactivity disorder or oppositional defiant disorder, prescribed a Schedule II controlled substance (methylphenidate or amphetamine), and monitored for years. The CDC now reports that roughly one in nine American children between the ages of three and seventeen has been diagnosed with ADHD, and a majority of them take a prescription stimulant.²

Two treatments. Two therapeutic worlds. Between them sits a constitutional framework that used to be recognized and a set of industrial and pharmaceutical decisions that made it invisible.

Audio Deep Dive (for Paid Subscribers)

The Second Case

Jarvis did not stop with the twin. In the same chapter he describes a second child, unrelated to the first. Her mother had been a professor at a women’s college before her marriage; her father was a university graduate. The elder daughter was even-tempered and easy to live with. The second was the racehorse type. The mother came to Jarvis with the same complaint. Jarvis prescribed the same remedy. Within two hours the child was different. She grew into a successful college student who developed her mind and her artistic ability and made friends easily.¹

Two cases is not a trial. Jarvis did not claim it was. What he claimed was a reproducible pattern: a constitutional type that responded, on a specific timeline, to a specific intervention. He also ran a two-year observational study of twelve small children under the age of five, testing whether children became ill on an alkaline urinary background and recovered when the urine returned to acid. That was the study the twins came from. The dosing responses were repeatable enough that Jarvis wrote, of the calming effect on nervous children, “I have never seen it fail to calm down a nervous child.”³

A Constitutional Category

The racehorse type is not a metaphor Jarvis reached for once. It is a working clinical category running through both books. Some children come into the world with their sympathetic nervous system dominant. The human motor idles in high gear. Sleep is difficult, attention scattered, emotional reactivity high. The body is organized for combat when combat is not required.

Jarvis attributed the pattern in part to the parents’ diet before conception, particularly the mother’s, and to the diet the child was raised on. He described the two divisions of the autonomic nervous system as the two gears of a motor. Sympathetic dominance produces the racehorse constitution. Parasympathetic dominance produces the farm horse. The mapping onto the autonomic system is standard physiology. What Jarvis added was the observation that the gear could be shifted.

He tested it on animals first. Pugnacious bulls calmed down within a month or two on a daily dose of apple cider vinegar poured over the ration. The same intervention shifted cross dogs, irritable horses, and mastitis-prone dairy cows toward docility. In humans, two teaspoons of vinegar and two of honey in a glass of water, taken at each meal, produced the same shift.⁴ When that was not enough, when the constitutional pull toward high gear was strong, Jarvis added iodine.

The pattern itself is not what modern medicine disputes. What is disputed is where it comes from and what to do about it. Current practice treats the pattern as neurodevelopmental, largely fixed, requiring pharmaceutical management often for the whole of childhood and increasingly into adult life. Jarvis treated it as a state, produced and sustained by daily nutrition, correctable through the same channel.

What Iodine Does

Jarvis attributed three functions to iodine, none mystical, all anchored in observable outcomes.

The first was energy. Depleted energy and endurance, he wrote, are commonly a sign of low iodine intake. He asked, of any patient presenting with fatigue, whether the soil of the state they lived in was iodine-poor and whether any dietary source of iodine was in place. The thyroid gland concentrates iodine and produces the hormones that set the basal rate of energy production in every cell. Insufficient iodine means insufficient thyroid hormone, which means insufficient cellular energy.³

The second was the calming of nervous tension. “When nervous tension runs high,” Jarvis wrote, “there is irritability and difficulty in sleeping well at night, and the body is continually on a combat basis, organised for fight and flight.” His observation was that iodine, in small doses, shifted the body out of that continuous combat organization and into rest. Thyroid function affects the metabolism of adrenaline and the tone of the autonomic nervous system. What Jarvis had was the clinical observation and the reproducible dose.³

The third was clear thinking. “The mind simply works better,” he wrote, “when the body is supplied the iodine it needs.”³ Sally Fallon, four decades later, cataloged corroborating findings: iodine depletion has been linked to cognitive impairment, mood disturbance, and delayed mental development.⁵ Paul Bergner cataloged the same set of findings. Anxiety, depression, hyperactivity, and insomnia cluster with depletions in iodine, magnesium, zinc, and B-group nutrients, especially in populations eating industrial food.⁶

The picture Jarvis drew is coherent. A child running in permanent high gear, unable to settle at night, irritable and hard to discipline by day, is a child whose energy-regulating machinery is being asked to run without a critical mineral input. Add the mineral back and the machinery can regulate.

The two-hour timeline Jarvis reports across cases is not what pharmacology would predict from correcting a nutritional shortfall. Restoring the thyroid’s iodine stores takes weeks. The rapid calming effect points to a different mechanism, and the protocol itself suggests what it is.

Apple cider vinegar has documented effects on postprandial glucose. Acetic acid slows gastric emptying and blunts the glucose spike that follows a carbohydrate-heavy meal, in some studies by twenty to thirty percent.¹¹ Honey provides a lower and slower glycemic curve than refined sugar. Sipped through a meal, the mixture flattens the spike-and-crash pattern that follows standard modern eating.

That pattern is where the racehorse child gets hit. When blood sugar crashes an hour or two after a high-glycemic meal, the body compensates with a surge of adrenaline. In an adult this feels like the mid-afternoon jitters. In a sympathetic-dominant child it presents as irritability and the classic pre-dinner meltdown. Flatten the glucose curve and the adrenaline surge does not fire.

Iodine works on a slower clock. Rebuilding thyroid stores and shifting autonomic tone takes weeks, which is why Lugol’s has been used therapeutically for over a century in doses larger than what current guidelines call sufficient. Jarvis’s protocol is a compound intervention: vinegar and honey give the fast calming, iodine gives the sustained shift. He was not choosing between them. He was giving both, at every meal, and he saw the fast effect first.

The Halogen Displacement

Iodine’s chemistry makes it structurally vulnerable. It sits at the bottom of the halogen group, the column containing fluorine, chlorine, bromine, and iodine, with the highest atomic weight of the four. Within the halogen group, lighter elements displace heavier ones from the biological sites they compete for. Fluorine displaces chlorine, bromine, and iodine. Chlorine displaces bromine and iodine. Bromine displaces iodine. Iodine displaces none of them.³

Jarvis names this in Folk Medicine and draws the practical conclusion: chlorinated drinking water strips iodine from the thyroid. So does excess sodium chloride. He does not name fluoride because in 1961 municipal fluoridation was a new program. Fluorine sits at the top of the displacement hierarchy, a stronger iodine-stripper than chlorine, and now enters daily consumption through both municipal water and toothpaste. He does not name bromine as a dietary contaminant because the industrial substitution that would put bromine into the daily bread of every American child had not yet happened. But he lays out the chemistry that predicts both.

This is the mechanical backbone of the suppression story. Iodine is not stolen from the body by malice. It is displaced by lighter halogens introduced into daily consumption. Fluoridate the water, chlorinate it, switch the flour additive from an iodine compound to a bromine compound, and the child eating and drinking will lose iodine at every meal. The thyroid gland, which the entire blood volume passes through every seventeen minutes, gets scrubbed of the mineral it depends on.

Wolff-Chaikoff

In 1948, two researchers at Berkeley, Jan Wolff and Israel Chaikoff, published a study showing that rats given large doses of iodide showed a temporary suppression of thyroid hormone production. The effect was transient. The rats adapted within days and thyroid function resumed normally. What the paper described was the thyroid’s own homeostatic regulation.⁷

The paper was cited for something else. Over the following decades, medical practice absorbed the study as evidence that therapeutic iodine dosing was dangerous. The transient nature of the effect in rats, its subsequent full reversal, its irrelevance to the doses used in clinical practice, none of this made it into standard teaching. What made it into standard teaching was: iodine in doses larger than trace amounts is thyroid-suppressive and should be avoided. Guy Abraham, the endocrinologist who spent decades documenting iodine’s clinical history, described the interpretation as a misreading that acquired the status of received truth and was cited thereafter without re-examination.⁸

Before Wolff-Chaikoff, iodine at therapeutic doses had been a standard medical intervention for nearly a century. Jarvis in 1961 was still working in that tradition. Every pharmacist knew how to make Lugol’s, every drugstore carried it in stock, and the doses he prescribed for adults were larger than what current guidelines call the upper safe limit. Nothing had changed about iodine. What had changed was the willingness of physicians to prescribe it. A paper became the reason a therapy that had worked for a century was progressively withdrawn from mainstream practice.

The Bromate Swap

The second structural change happened in commercial baking. Bread had been the major dietary source of iodine for American children through most of the twentieth century, first because iodized salt was used in commercial baking and then, from the 1940s onward, because potassium iodate was routinely added to bread as a dough conditioner. A single slice contained roughly 150 micrograms of iodine, the amount now designated as the full daily RDA.⁹

Beginning in the 1980s, commercial bakers replaced potassium iodate with potassium bromate. The stated reason was that bromate produced a better dough: higher rise, better texture, longer shelf life. What was accomplished at the same time was two changes running in opposite directions. The largest single dietary source of iodine for American children was removed. A halogen that displaces iodine in the thyroid was introduced in its place. Every slice of commercial bread now contains not the mineral the child needs but the mineral that flushes what remains.

Median urinary iodine concentrations in the United States, tracked by NHANES, dropped by roughly half between the early 1970s and the mid-1990s and have not fully recovered.¹⁰ The population is more iodine-depleted than it has been at any point since the pre-iodization era.

The substitution is documented. It appears in food-industry technical literature. The population depletion that followed appears in NHANES. Neither triggered any regulatory reversal.

What Filled the Space

Between 1961 and now, Lugol’s solution left the counter of the neighborhood pharmacy. Iodine as a therapeutic tool for fatigue and the anxious constitution left routine medical practice. In its place a new therapeutic category grew: pharmaceutical management of the same constitutional pattern Jarvis was correcting with two drops in a glass of water.

Methylphenidate was patented in 1954. Its use expanded slowly through the 1960s and 1970s, mostly for what was then called minimal brain dysfunction. The category was renamed attention-deficit disorder in 1980 and attention-deficit hyperactivity disorder in 1987. Prescriptions climbed. Amphetamine formulations were reintroduced for the same category through the 1990s. By the late 2010s, roughly 3.5 million American children were taking a prescription stimulant daily. The figure has continued to grow.² Market analyses put global ADHD medication sales at approximately twenty billion dollars annually.¹²

The diagnostic naming has fragmented what Jarvis treated as one thing. Both of his cases, the tantrum twin and the professor’s daughter, would today move through evaluations that split the racehorse constitution across several separate labels: ADHD for the inattention and restlessness, oppositional defiant disorder for the fighting and the tantrums, disruptive mood dysregulation disorder for the outbursts, generalized anxiety for the underlying tone. Each label carries its own medication protocol. Each of those medications has its own patent, its own manufacturer, its own marketing budget, its own physician-education pipeline. The racehorse constitution is not in the DSM.

Iodine cannot be patented. Neither can apple cider vinegar or honey. The protocol Jarvis prescribed to the mother of the twin costs a few dollars a year. There is no commercial infrastructure with an interest in that protocol being recovered, and there is a large commercial infrastructure with an interest in the constitutional pattern it treats being permanently renamed and permanently medicated. Neither observation is a conspiracy claim. Both are visible in the disclosed financial statements of the companies involved.

The suppression argument does not require malice. It requires only an accurate description of what happens when therapies with revenue attached to them can afford research, marketing, regulatory attention, and physician education, and therapies without revenue attached to them cannot afford any of those things. The second category becomes invisible to the first, then absent from medical training, then forgotten by all but the small number of practitioners who read outside the current literature. Every mother who takes her difficult child to a pediatrician today is met by a physician trained inside a knowledge system from which the racehorse constitution and its two-drop remedy have been erased.

Two Children

Jarvis’s twin, five years old, was given two drops of Lugol’s solution and a teaspoon of vinegar in a glass of water. Within two hours she was calmer. Over the years, as needed, she took the remedy again. By the time she left high school her early temperament was a memory. She married. She kept her home. She was, by every measure Jarvis reported, well.

A five-year-old with the same constitution today, brought to the evaluation her mother would be told to seek, moves down a different path. She is observed for six weeks and diagnosed. She is started on a Schedule II controlled substance, methylphenidate at a low dose, increased in steps. Her sleep changes. Her appetite changes. If the first drug is not tolerated, she is switched to a second. If additional symptoms are identified, an SSRI or an atypical antipsychotic is added. By adolescence she is likely on more than one medication. The prescriptions typically continue into adulthood.

Both children began with the same constitution. What differs is the framework that met them and the therapy that framework had available. In Jarvis’s framework, the constitution was a state: real, observable, correctable through mineral repletion and dietary adjustment, not requiring lifetime pharmaceutical management. In the current framework, the same constitution is a disorder: a neurodevelopmental condition of unclear origin, requiring accurate diagnosis and appropriate pharmaceutical treatment, typically for years.

Jarvis’s approach worked. The evidence is thin by modern trial standards. Two named cases, a twelve-child observation study, decades of clinical practice reports. Not zero. And the therapy costs almost nothing to try. Lugol’s is still sold. Apple cider vinegar and honey are still sold in every supermarket. Any parent watching a child at the edge of a diagnostic pathway that leads to fifteen years of amphetamine prescriptions can, before consenting to that pathway, try the intervention Jarvis prescribed for the same constitutional presentation in 1961. Two drops of Lugol’s, two teaspoons of vinegar, two teaspoons of honey, a glass of water. Sipped through a meal. Repeated as needed.

The twin quieted within two hours. The professor’s daughter did too. It is possible that the same intervention, offered before the diagnostic pathway begins, would produce the same result today. It is also possible that a generation of children could grow up as Jarvis’s patients did: not permanently labeled, not carrying prescriptions into adult life, but recognizably themselves, in their own particular temperaments, brought out of permanent high gear by a mineral their bodies were built to use.

The bottle every pharmacist once kept in stock is still available. It costs a few dollars. What is not available in the current framework is the recognition that the racehorse twin’s mother was two weeks away from having a different child.

Note on Dosing

Lugol’s 5% solution delivers roughly 6.25 mg of elemental iodine per drop. Jarvis’s protocol was two drops for adults, one drop for children, in a glass of water made acid with a teaspoon of apple cider vinegar, sipped through a meal. In the United States, 5% Lugol’s is regulatory-restricted to 1 oz bottles and can be harder to find; 2% Lugol’s is more widely available on Amazon and elsewhere. The equivalence is straightforward: five drops of 2% delivers the same iodine as two drops of 5%. Compounding pharmacies remain a reliable source for both.

This is Lugol’s solution, not povidone iodine. Lugol’s is elemental iodine plus potassium iodide in water, formulated for internal use. Povidone iodine is iodine bound to a polymer for external wound care and should not be substituted.

Anyone with an existing thyroid condition, particularly Hashimoto’s, should read Guy Abraham’s and David Brownstein’s work before starting therapeutic doses. Introducing iodine into an inflamed thyroid can produce a transient worsening before improvement. Selenium is the essential companion mineral, roughly 200 micrograms per day, obtainable from three Brazil nuts.

How I’d Explain It to a Six-Year-Old

Some children come into the world wound up like a racehorse. Others come into the world calm like a farm horse. Both kinds are normal.

A long time ago, a country doctor noticed that the wound-up children became calmer, within about two hours, when they drank a glass of water with a spoonful of vinegar, a spoonful of honey, and two tiny drops of a medicine called iodine. He tried it many times. It kept working.

Iodine is a mineral that comes from the sea. It helps a small gland in your neck do its job. Without enough iodine, some children stay wound up all the time.

Bread used to have iodine in it. Then bakers stopped putting it in and started using a different chemical, called bromine, that actually pushes iodine out of the body. So children now get less of what they need and more of what steals it.

When a wound-up child sees the doctor today, they are usually given a very strong medicine that changes how the brain works, often for many years.

The old drink is still around. Vinegar and honey are in every kitchen. Iodine is at the drugstore. A day of the drink costs less than a piece of candy. That is what this essay is about.

References

1. Jarvis DC. Arthritis and Folk Medicine. Pan Books; 1962. Chapter 12: The Usefulness of Lugol’s Solution of Iodine.

2. Centers for Disease Control and Prevention. Data and Statistics on ADHD. National Survey of Children’s Health, 2022. Approximately 11.4% of US children aged 3–17 have been diagnosed with ADHD; a majority of those currently diagnosed take a prescription medication for the condition.

3. Jarvis DC. Folk Medicine: A Doctor’s Guide to Good Health. Pan Books; 1961. Chapters on iodine, the halogen displacement law, and the racehorse type.

4. Jarvis DC. Arthritis and Folk Medicine. Pan Books; 1962. Chapter on apple cider vinegar and the calming of pugnacious bulls, cross dogs, and mastitis-prone dairy cows.

5. Fallon S, Enig MG. Nourishing Traditions. NewTrends Publishing; 2001. Section on iodine.

6. Bergner P. The Healing Power of Minerals, Special Nutrients, and Trace Elements. Prima Publishing; 1997. Chapter 13 (Iodine) and Table 25.1 (nutrients associated with functional depletion states).

7. Wolff J, Chaikoff IL. Plasma inorganic iodide as a homeostatic regulator of thyroid function. Journal of Biological Chemistry 1948; 174: 555–564.

8. Abraham GE. The safe and effective implementation of orthoiodosupplementation in medical practice. The Original Internist 2004; 11: 17–36.

9. Pearce EN, Pino S, He X, Bazrafshan HR, Lee SL, Braverman LE. Sources of dietary iodine: bread, cows’ milk, and infant formula in the Boston area. Journal of Clinical Endocrinology and Metabolism 2004; 89: 3421–3424.

10. Caldwell KL, Makhmudov A, Ely E, Jones RL, Wang RY. Iodine status of the U.S. population, National Health and Nutrition Examination Survey, 2005–2006 and 2007–2008. Thyroid 2011; 21: 419–427.

11. Johnston CS, Kim CM, Buller AJ. Vinegar improves insulin sensitivity to a high-carbohydrate meal in subjects with insulin resistance or type 2 diabetes. Diabetes Care 2004; 27(1): 281–282. See also Östman E, Granfeldt Y, Persson L, Björck I. Vinegar supplementation lowers glucose and insulin responses and increases satiety after a bread meal in healthy subjects. European Journal of Clinical Nutrition 2005; 59(9): 983–988.

12. Grand View Research. ADHD Therapeutics Market Size, Share & Trends Analysis Report. Global ADHD medication market estimated at approximately $20 billion USD as of 2023, with continued projected growth.

Author’s Note

Parts of what follows are documented and verifiable. Other parts are interpretive reconstructions built on that documentation. And some parts, by the framework's own structure, cannot be adjudicated on evidence at all. I am not making a claim about which is which for every element of the argument. I am attempting something narrower: to produce a working definition of a term that has begun showing up with real frequency in podcasts, interviews, and long-form writing on hidden power, and that most readers who encounter it have no clear idea what to do with.

The framework is not mine. It belongs to Joseph Farrell, developed across roughly seven books and a long-running conversation with Catherine Austin Fitts on the Solari Report. My job here is to explain what he means so that the next time you hear the phrase used, you understand what is being pointed at. Whether the thing being pointed at exists, and in what form, is a separate question the essay does not adjudicate.

If you have never read Farrell, this is your entry point. If you have read some of him, this may organize what you already know. If you reject the framework, this may at least let you reject the version he actually holds rather than a caricature.

The essay brackets Farrell’s claims about exotic technology (the Bell, directed energy, weather engineering) so the definitional work stays clean. Those claims are important to his larger body of work and may get their own treatment separately.

A term that is used without being understood is a term that does work in the culture without accountability. This essay is an attempt to make one such term accountable to its actual meaning.

The check was cleared in Buenos Aires. It was drawn on Manufacturers Hanover and on Chase Manhattan. The signature was Martin Bormann’s. The year was somewhere in the early 1960s.

Bormann is supposed to have died in a Berlin bunker on May 2, 1945. Remains recovered in Berlin were identified as his through dental records in 1972; mitochondrial DNA testing conducted in 1998 was, by German authorities, treated as final confirmation. On the standard account, the man was dust for two decades before the check was written.

Paul Manning, a CBS journalist who had worked closely with Edward R. Murrow, spent years investigating an alternative account. He published his findings in a book called Martin Bormann: Nazi in Exile. In it, he documented the check.¹

You may believe Manning was wrong. You may believe the check was cleared under a false signature or that Manning was deceived. Some other explanation is available if you want one. What the documentary evidence will not let you do, if you take it seriously, is treat the postwar period as settled history where the visible surface is the whole story.

The check is a small piece of evidence for a very large claim. The claim is that a substantial part of what actually happened after 1945 has never made it into the standard account. Joseph Farrell has spent roughly the last twenty years assembling the case for that claim, book by book, cross-reference by cross-reference. The framework he built to organize what he found borrows its central term from another writer: the UFO historian Richard Dolan, who in the second volume of UFOs and the National Security State used a phrase that has since escaped into the wider culture without most of the people using it knowing what it means.²

Dolan called it a breakaway civilization.

This essay explains what he meant, what Farrell built on top of it, and why the concept, once you have it, does not easily leave.

What Dolan noticed

Dolan’s insight came near the end of a long historical study of the U.S. government’s postwar handling of the UFO phenomenon. He was working the archival record and reading the classified budget history. He noticed something the material forced on him whether or not he wanted it.

Continuous secret spending compounds.

Fund a black project for a year and you have a project. Fund it for a decade and you have a program. Fund it for two generations at scale, and you no longer have a program. You have institutions. Then facilities. Then personnel who spend their careers inside those facilities and never leave. Then their children, some of whom follow them in. Then a body of accumulated knowledge that exists nowhere else, held by people who cannot describe what they know.

At some point in this accumulation, the group ceases to be an offshoot of the society funding it. The technology it works with changes what its members consider possible. The information it has access to changes what its members consider real. The rules it operates under diverge from the rules its parent society thinks are in force. It becomes its own thing.

Dolan’s word for it was civilization. He chose the word carefully. He meant it literally.

Farrell’s question

Joseph Farrell read Dolan and took the concept as a hypothesis to test. His question was not whether the idea was aesthetically appealing. It was operational. If Dolan was right, what would such a thing have needed in order to come into existence? Where would those needs have been met? What footprints would it have left in the visible record?

The answer he arrived at, across a series of books published between 2004 and 2015, is what people are pointing to now when they use the term. The Nazi series (Reich of the Black Sun, SS Brotherhood of the Bell, Nazi International, The Third Way) traces the historical origins. The breakaway trilogy (Saucers, Swastikas and Psyops, Covert Wars and Breakaway Civilizations, Covert Wars and the Clash of Civilizations) develops the framework and applies it.³

The core of the framework is this. A breakaway civilization, if it exists, requires a hidden system of finance sustained across decades and insulated from any political process that could shut it down. The origin of that system, in the western half of the postwar world, was the strategic situation the United States faced as the war closed. And the operational architecture that emerged from that situation is still running.

What such a thing has to eat

The financing requirement is more restrictive than it sounds. Ordinary appropriations turn over with elections. Even a classified budget under congressional oversight is exposed to periodic scrutiny. Congress writes checks and Congress can un-write them.

What a genuinely breakaway operation needs is money that is not subject to any of that. A pool sustained across decades, kept off the public books, insulated from the visible economy. The pool has to be large enough to build and maintain a hidden infrastructure. It has to be structured so that no elected official can find the string that unravels it. And it has to keep growing, because the operations it funds keep growing.

Farrell’s contention is that such a pool exists and has existed since 1945. His reconstruction of how it was built runs in three movements.

The three movements of the money

First movement: the seed capital, 1945 through the late 1950s

At the end of the war the United States confronted three problems simultaneously, each of which required secret means and none of which could be addressed publicly. The Communist bloc, against which American intelligence had almost no human network. The surviving Nazi apparatus, which had spent the last two years of the war planning a strategic evacuation of personnel, capital, and technology from Europe. And, in Farrell’s reading, a persistent phenomenon of unidentified craft over sensitive military installations severe enough to be one of the driving concerns behind the reorganization of the entire national security apparatus under the National Security Act of 1947.

Each problem demanded money that Congress could not know about. The Americans built the plumbing.

Nazi capital, laundered through the Bank for International Settlements and Swiss banks, flowed into major western banks after the war and gave them off-balance-sheet reserves large enough to underwrite the postwar credit expansion.⁴ Japanese plunder from occupied Asia, discovered by American forces at the end of the war, was authorized by Truman as a slush fund for the National Security Council.⁵ The Exchange Stabilization Fund at the New York Fed, sitting outside the normal budgetary bureaucracy, became one of the primary vehicles for postwar covert operations, including the rigging of the 1948 Italian elections. The National Security Act of 1947 and the CIA Act of 1949 gave the American government the statutory ability to appropriate money for one purpose and shift it into unaccountable classified accounts. This is the origin of what is now called the black budget.

By the late 1950s the seed capital was in place. It was hidden. It was large. It answered to no one who could be voted out.

Second movement: industrialization, 1960s through 1980s

The seed money grew, and the machinery around it hardened. The postwar restructuring of the international narcotics trade in the 1960s and 1970s, documented by the Danish journalist Henrik Krüger, displaced the French Connection and inserted postwar fascist networks as on-the-ground operators for what became a joint enterprise with American intelligence in Latin America.⁶ Drug revenue fed the black budget. The black budget was laundered through mortgage securities and government securities fraud.

Then came the decisive institutional shift. Under the incoming Reagan administration, an executive order qualified private corporations to perform secret and highly classified functions paid for by the U.S. government.⁵ This turned the trillion-dollar black budget into a mechanism by which private corporations, not government agencies, could own and control the most advanced technology in the world on a non-transparent, non-accountable basis. The classified work moved outside the direct chain of command of the elected government. The corporations doing the work were themselves privately held, or subsidiaries of privately held entities, and answered to boards no voter had heard of.

By the end of the 1980s the breakaway civilization, if that is what it was, had a permanent industrial base. It was funded by a mixture of appropriated black budget, criminal revenue, and hidden financial reserves inherited from the war. It operated through private corporations under sovereign immunity. It employed hundreds of thousands of cleared personnel. And its output was, by design, indistinguishable from the outside from ordinary defense contracting.

Third movement: consolidation, 1990s to present

In the spring of 1995 a mortgage banker walked into Catherine Austin Fitts’ office in Washington carrying a database. His family had been in the mortgage banking business for three generations. His core competency was tracking every FHA-insured mortgage issued in the United States. He had a message. The number in the newly published federal financial statements, 400 billion dollars of outstanding FHA insurance, was wrong. The real figure, he said, was several multiples higher.⁷

Fitts, who had been Assistant Secretary of Housing under the first Bush administration, initially dismissed the claim. She refused to take his database, on the reasonable calculation that whoever accepted it would probably not live to publish it.

She was wrong to dismiss it. Her later litigation with the federal government forced her back to the numbers. Independent research by Professor Mark Skidmore at Michigan State, published in 2017, established that the U.S. Treasury, the Department of Justice, the Department of Housing and Urban Development, JP Morgan Chase, and the New York Fed had been engaged in coordinated undocumentable adjustments to the federal accounts running to 21 trillion dollars between fiscal 1998 and fiscal 2015.⁸ The number has been revised upward since.

This is where Fitts and Farrell converge. Farrell had proposed the architecture. Fitts documented its footprint in the accounts. Twenty-one trillion dollars leaving the visible budget between 1998 and 2015 is the size of the entire U.S. economy for a year. It went somewhere. Whatever the breakaway civilization is, that is roughly what it has been paid.

In October 2018, the Federal Accounting Standards Advisory Board issued Statement 56, effective for federal fiscal year 2019 onward. Statement 56 permits federal entities to modify or omit financial information from their published reports on grounds of national security.⁹ In Fitts’ reading, this is the moment the hidden system stopped running alongside the visible one and began subsuming it. The books were legally darkened. The consolidation was complete.

Two constituencies

Farrell distinguishes two players in the western half of this arrangement, and refusing to collapse them into one is central to what he has been arguing.

The first he calls the Post-War Nazi International. His starting distinction is that the German government surrendered in 1945; the Nazi Party did not. During the last years of the war, senior party leadership had established a network of corporate fronts, moved capital through Switzerland and the Bank for International Settlements, and prepared operational continuity plans that included evacuation to Latin America and elsewhere. American counter-intelligence identified and shut down roughly 750 of these fronts. Farrell’s argument is that the operation was much larger than what was shut down, that it survived, and that it continued its wartime research programs as an extraterritorial entity using corporations and nations as cut-outs.

The evidence is specific. The postwar fusion project run in Argentina under Juan Perón by the German scientist Ronald Richter, the same Richter who had worked on the same physics inside the Third Reich. The 1945 deal, recorded in Reinhard Gehlen’s memoirs, in which the head of Nazi military intelligence for the East handed over his entire espionage network to Allen Dulles on terms that preserved German interests where they clashed with American interests, and kept Gehlen himself in operational command.¹⁰ The Gehlen organization became the Bundesnachrichtendienst, modern Germany’s federal intelligence service, which meant the CIA’s Soviet analysis on the day the agency was chartered was being produced by former Nazi intelligence officers. And the Bormann check, cleared in Buenos Aires over his own signature, sixteen years after his officially recorded death.

The second constituency is the American deep state. Not the phrase as it is used in mainstream political commentary, but the specific postwar nexus Farrell traces: Wall Street law firms, prime banks, intelligence agencies, defense contractors, and the corporations that had done business with IG Farben and its counterparts before the war. Sullivan & Cromwell, the Dulles brothers, Standard Oil, and the Rockefeller interests on the American side; Hermann Josef Abs at Deutsche Bank and Prince Bernhard of the Netherlands, a wartime IG Farben manager and SS officer, on the European side. These names recur in the historical record with a frequency Farrell treats as diagnostic.

Operation Paperclip supplied the technical staff. Von Braun, Rudolph, Dornberger, and hundreds of others took positions across American universities, foundations, and defense contractors, their wartime records sanitized. Farrell notes that American counter-intelligence assessments in the late 1940s established that these scientists were maintaining contact with each other through Latin America. That is, they operated as a coherent network within the host country. Farrell’s term for what this implied is a Nazi extraterritorial state already functioning inside the American system by the late 1940s.

The two constituencies cooperated where cooperation served them. They competed where it did not. Together they constituted the western wing of what would become the breakaway.

Why the word “civilization”

Dolan chose the word carefully, and Farrell has been insistent that it be taken literally rather than as metaphor. Once you enumerate the properties a civilization has, the argument about whether one exists becomes tractable.

A civilization has infrastructure, hard and soft. The soft infrastructure is the hidden financial system already described. The hard infrastructure is a network of underground facilities. Fitts, working with a researcher and drawing on the published work of Richard Sauder, arrived at an estimate of over 140 such facilities in the United States alone. Add the tunnel systems Farrell attributes to the postwar Nazi presence in Latin America, the Soviet and Russian underground network, the Antarctic installations, and whatever exists under China, and the picture is of a global system of hidden physical plant under continuous construction for eighty years.

A civilization has borders. In this case the borders are security perimeters and cleared-access requirements that separate the classified world from the ordinary one.

A civilization has a legal system. Fitts’ term for it is sovereign immunity: the layered legal shields placing national security operations, intelligence agencies, central banking arrangements, and their contractor networks beyond the reach of ordinary courts. Members of the breakaway civilization are above the law with respect to the visible society and operate under their own internal system of adjudication with respect to each other.

A civilization has personnel: the cleared workforce that lives and works inside the security perimeter and whose work cannot be described outside it.

And a civilization, Dolan argued, eventually has its own way of thinking. Access to technology no one else has changes what its holders consider possible and necessary. Decisions get made inside the perimeter that make no sense outside it, because they are being made on the basis of information the outside does not have. This is the specific sense in which the group ceases to be an offshoot and becomes something distinct.

Farrell’s larger body of work extends into claims about what the classified research has actually produced: exotic propulsion systems, directed-energy weapons, technologies for manipulating weather and seismic events, and physics derived from Nazi wartime research on a device called the Bell. Those claims are outside the scope of this essay. Readers who want to pursue them can begin with Reich of the Black Sun and SS Brotherhood of the Bell.³ For present purposes the point is narrower: money on the documented scale, sustained across decades within the institutional architecture already described, produces something. Whatever that something turns out to be, it exists.

The mafia war

Farrell is careful not to describe this as a single unified entity. If the model is correct, every major power that has run significant black research over the postwar period has developed some version of it. Russia has one. China has one. Farrell suspects France and India do as well. The Nazi International was itself extraterritorial rather than tied to any single state.

What sits at the top, in his current framing, is a set of factions in intermittent cooperation and increasingly open conflict. He calls it the mafia war. The postwar arrangement between the surviving Nazi structure and the American financial oligarchy is coming apart. Markers are being called in. Bank bailouts function as signals between factions. Recent disruptions of the visible international order, including the move toward multipolarity and the visible decay of American institutional capacity, Farrell reads as surface manifestations of a struggle among hidden formations for control of what remains.

The mafia war framing is not metaphorical. In Farrell’s account, the factions have real weapons developed with the hidden money, and they use them. Insider positions taken against a country’s sovereign debt in the week before a natural disaster wipes out its territory. Bank bailouts demanded with the specific stipulation that there be no oversight, which in Farrell’s reading looks like the behavior of someone acting under duress. When these factions fight each other, they do not use conventional weapons. They use what the classified research has produced. The collateral damage falls on the visible civilization, on the people who did not know the hidden one existed.

Fitts has extended the framework with a historical parallel. In the feudal system, a serf or minor noble owed allegiance to a local lord, but might also owe allegiance to another lord higher up. When two lords demanded his obedience against each other, the concept of ligeancy determined which loyalty was ultimate. In Fitts’ reading, we have not quite reached the stage where the modern equivalent has crystallized. But the visible signs are there: sovereign immunity claims multiplying, and a widening gap between what officials say and what officials do as different classes of decision-maker respond to different sets of orders. When ligeancy becomes explicit, the mafia war stops being a phrase and becomes a fact on the ground.

What the concept lets you see

There is a moment in Fitts’ account of the 2004 Indian Ocean tsunami that is worth stopping on.

She had been managing a portfolio for a private client. She had put a portion of it into a world bond fund, and 15 percent of the fund’s holdings were in Indonesian sovereign debt. In the week after her client bought in, the fund dropped 15 percent overnight on massive insider selling. There was no interest rate move. There was no news. Nothing in the visible information environment explained what she was seeing.

A week later the tsunami arrived. It killed at least 227,000 people across fourteen countries.

Someone had known. Not by luck. Not by market intuition. They had known specifically enough, and confidently enough, to move a significant amount of capital against a specific country’s debt with a specific timing that only made sense if they knew, in advance, what was about to happen to that country’s coastline.

You can dismiss this observation as anecdotal. You can construct alternative explanations. What you cannot do, once you have looked at it seriously, is put it back where you found it. Because if what Fitts saw was what it looks like, then some things follow.

If some party can induce a tsunami, that party has a weapon no elected government has publicly disclosed. If that weapon exists, the money to develop it has been spent. If the money has been spent, it left a trail. And the trail, when you look for it, is where Fitts and Farrell have been telling you to look.

Once the concept of a breakaway civilization is in your working vocabulary, certain features of the visible world become legible that were not before.

Missing federal money in the tens of trillions is not an accounting error and is not evidence that the government is broke. It is the visible footprint of a hidden system of finance funding something.

Political leadership that appears to be following orders no ordinary voter would recognize as coming from any electoral mandate is not a mystery. It is the visible footprint of a hidden actor whose decisions are made inside the security perimeter and communicated outward.

The persistent inability of qualified financial analysts to make sense of the visible economy, the “nothing about this makes sense from any angle” reaction Farrell has described repeatedly in his conversations with Fitts, is not their failure of analysis. It is what happens when you try to reconcile a set of accounts that has, by design, been separated from another set of accounts you do not know exists.

What you have to decide

None of this requires accepting the specific technology claims Farrell makes elsewhere. The structural argument stands independently. If a hidden system of finance of the documented scale has been operating for eighty years, it has bought something. Something has been built. Someone runs what has been built. Those people, across decades, become distinct from the people funding them in their information, their assumptions, their loyalties, their sense of what is possible.

That distinctness, accumulated across generations, is what the term breakaway civilization names.

The reason the term does not easily leave once you have it is that the alternative is worse. The alternative is to keep reading the news as if the visible surface is the whole story. To treat the missing trillions as a curiosity that will presumably be reconciled at some future audit. To treat the odd trades before disasters as coincidences. To treat leadership decisions that make no visible sense as the ordinary confusion of politics. To treat the widening gap between what the world officially is and what the world actually seems to be doing as, essentially, nothing.

Once you have the concept, that reading is no longer available. Every anomaly you notice is either evidence that the concept applies or evidence that it does not, and the ordinary tools for adjudicating which is which are, by the concept’s own logic, the ones that have been captured.

One further thing the reader should know before deciding. The framework has structural features that make it partially self-sealing. Once you have it, evidence for it accumulates and evidence against it can be reinterpreted as successful concealment. Absence of documentation becomes evidence of effective secrecy. Rejection by credentialed historians becomes evidence of the institutional capture the framework predicts. This is a feature of the framework you should hold in mind whether you accept it or reject it. It does not by itself refute the framework — real hidden systems would produce exactly this epistemic shape — but it does mean the framework cannot be adjudicated purely on evidence, and any reader who tells you otherwise, in either direction, is selling you something.

This is not a problem the essay can solve for you. Farrell built the framework. Fitts documented the footprint. What is on the table, now that you have looked at it, is on you.

How to explain it to a 6 year old

Imagine your parents give you a small allowance every week for eighty years. Most of it you spend on things everyone can see. But some of it you put in a secret jar in the garage that no one ever looks in.

After a very long time there is enough in the jar to buy a bicycle. Then a shed. Then a small workshop, because you have started to build things. Then you hire a friend. Then a bigger workshop, then another friend, then a fence, then rules about who is allowed inside the fence.

Your parents still think you are the kid who buys candy. They do not know about the workshop or the fence. When they ask what you did with the money, you say “not much.” They believe you, because the jar has been in the garage the whole time and they have never looked.

After eighty years the workshop is bigger than your parents’ house. The kids inside the fence do not follow your parents’ rules anymore. They have their own school, their own kitchen, and things your parents do not know exist. They are still your parents’ kids, technically. But if your parents called them in for dinner, they would ignore it, because they have their own dinner, in their own kitchen, in the workshop your parents do not know is there.

That is what a breakaway civilization is. The parents are the ordinary country. The kids behind the fence are the people who spent the secret money. The fence is why we cannot see what they built.

References

1. Paul Manning, Martin Bormann: Nazi in Exile, Lyle Stuart, 1981.

2. Richard M. Dolan, UFOs and the National Security State: The Cover-Up Exposed, 1973–1991 (Volume II), Keyhole Publishing, 2009.

3. Joseph P. Farrell, the “Nazi series”: Reich of the Black Sun (2004), SS Brotherhood of the Bell (2006), Nazi International (2008), The Third Way (2015); and Saucers, Swastikas and Psyops (2011), Covert Wars and Breakaway Civilizations (2012), Covert Wars and the Clash of Civilizations (2013). Adventures Unlimited Press.

4. Christopher Simpson, Blowback: America’s Recruitment of Nazis and Its Effects on the Cold War, Weidenfeld & Nicolson, 1988.

5. Joseph P. Farrell and Catherine Austin Fitts, Solari Report interview, “Covert Wars and Breakaway Civilizations,” September 6, 2012; and Solari Report, “Who Is Mr. Global?” with Joseph P. Farrell, November 11, 2021.

6. Henrik Krüger, The Great Heroin Coup: Drugs, Intelligence and International Fascism, South End Press, 1980.

7. Catherine Austin Fitts, Solari Report publications and presentations on federal finance, missing money, and the hidden system of finance. Primary source of the FHA mortgage insurance fraud documentation and the 2004 Indonesian sovereign debt insider trading observation. See in particular the Missing Money archive at solari.com.

8. Mark Skidmore et al., research on undocumentable adjustments in U.S. federal financial reporting, Michigan State University, 2017; and subsequent Solari Report documentation.

9. Federal Accounting Standards Advisory Board, Statement of Federal Financial Accounting Standards 56, “Classified National Security Activities,” issued October 2018.

10. Reinhard Gehlen, The Service: The Memoirs of General Reinhard Gehlen, World Publishing, 1972.

Author’s Note

For a thousand years, leprosy meant exile: the bell tied to the wrist, the door barred against the sick, the priest reading the office of the dead over a living body. The disfigurement was real. What caused it was another question, and it was never asked seriously until 1873, when a Norwegian physician named Gerhard Armauer Hansen looked into a microscope and decided he had the answer. The essay below examines what he actually found, what he never demonstrated, what actually made people sick in the places called leprous, and what made the disease disappear from Europe centuries before any medicine existed for it. The paradigm is the target. The suffering was always real.

On November 3, 1879, at the Bergen leprosy hospital in western Norway, a physician named Gerhard Armauer Hansen ordered a thirty-three-year-old patient into his office. Her name was Kari Nielsdatter Spidsøen. She had lived with a mild form of leprosy for seventeen years. Hansen held a cataract knife tipped with material he had scraped from an active lepromatous nodule on another patient. In front of colleagues, without warning her, without her consent, he attempted to inoculate the material under her conjunctiva. She fought him off. She reported the assault to the hospital pastor. The pastor reported it to civil authorities. Hansen was tried and convicted the following year.

Six years earlier, in 1873, Hansen had observed a rod-shaped bacillus in the tissue of another Bergen patient and named it as the cause of the disease. The Bergen assault was his attempt to prove the causation he had already claimed. It produced no transmission. Spidsøen did not develop the more severe form of the disease. And 152 years after Hansen’s initial observation, no laboratory anywhere in the world has ever grown Mycobacterium leprae in a culture dish. Every claim that followed, that leprosy is an infectious disease caused by M. leprae, that it spreads by droplet or contact, that antibiotics cure it, that a vaccine will finish it off, rests on the assumption Hansen tried and failed to demonstrate in Kari’s eye.

“Axenic media” is the technical term: a defined nutrient preparation, free of other organisms, in which a bacterium can be reproducibly divided and passaged. Every standard medical bacterium meets this test. M. leprae does not. The most recent comprehensive review, published in Frontiers in Microbiology in May 2025, opens with the confession: the bacterium “remains uncultivable in axenic media, a constraint that continues to hamper leprosy research.”¹ The reviewers examined 78 studies. Every historical claim of successful cultivation on egg-based or synthetic media proved irreproducible, or the organism grown turned out to be a different mycobacterium entirely. The only reproducible method for sustained laboratory growth is inside a live animal: the mouse footpad, or the armadillo. The bacterium the entire modern account rests on cannot be persuaded to divide in a dish.

Robert Koch, whose postulates still define the standard for demonstrating microbial causation, required that the microorganism be isolated from a diseased host and grown in pure culture. The second postulate has never been fulfilled for M. leprae. Not by Hansen, who first observed the bacillus under a microscope in Bergen in 1873. Not by any of the researchers, in any of the 78 studies just reviewed, over the century and a half that followed. The bacterium was named, described, published, cited, and inscribed as the causative agent of leprosy on the strength of an observation and an assumption. The proof was never produced, and the medical account has since built around the missing proof rather than obtaining it.

What sits on top of the missing proof is a cascade of admissions. The CDC’s own transmission page states, plainly: “It is not known exactly how Hansen’s disease spreads between people.”² The same CDC page reports that “more than 95% of all people have natural immunity to the disease.”³ A November 2011 review of leprosy vaccine research, published in Human Vaccines and cited approvingly by the industry, states that “M. leprae infection does not always cause disease, and it is estimated that anywhere between 30–75% of infections are spontaneously cleared without causing significant symptoms.”⁴ The same review describes leprosy as “one of the most renowned, but least understood diseases of man.”⁵ The medical establishment cannot say how the bacterium reaches its host, cannot say why the host resists it in the overwhelming majority of cases, and cannot claim to understand the disease it has spent 152 years attributing to a single cause.

Audio Deep Dive (for Paid Subscribers)

The Disease Before the Bacterium

The word “leprosy” was never a diagnosis in the modern sense. For most of its history, it labeled almost any visible skin disorder that disfigured the sufferer badly enough to warrant exclusion. Herbert Shelton, writing in the natural hygiene tradition, observed that “for ages the term leprosy was applied to a wide variety of skin diseases.”⁶ The medieval European leprosaria housed patients whose actual conditions, by any modern differential, would have included eczema, syphilis, chronic fungal skin conditions, arsenic poisoning, mercurial dermatitis, and tuberculoid skin lesions of every etiology. What united them was appearance, not etiology. The category was social before it was medical.

The biblical category is more revealing than usually noticed. Tsara’ath, translated as leprosy in the King James Bible, encompassed three categories the priest was instructed to examine: skin conditions, mildew on woolen and linen cloth, and damp rot and mold on the walls of houses. Leviticus 14:45 instructs the priest to demolish the affected stones of the house and carry them outside the town. No bacterium infects wool and stone. Whatever tsara’ath was, it was a category of visible surface degradation across biological and non-biological materials, and the remedy for household tsara’ath was mold remediation as still practiced. The uniting principle was not one causative agent. It was a class of visible outcome: surface breaking down under environmental stress. Skin, cloth, and wall respond to their environments in analogous ways, and the ancient category captured all three under one label.

The medieval response was exile. Cities passed leprosy statutes; the sick were declared civilly dead, stripped of property rights, made to carry a rattle or bell so that healthy citizens could avoid them. Priests read the Missa pro mortuis over living patients as they entered the leprosarium. This was the terrain in which the diagnosis operated for a thousand years: not laboratory confirmation, but visible disfigurement, judged by clergy and civil authorities against a standard set by scripture and custom.

Then leprosy left Europe. It began to fade from most of the continent in the fifteenth century, four centuries before Hansen would observe the bacillus in his microscope. It was rare across most of Western Europe by the seventeenth century. By the eighteenth it was essentially gone, well before the germ theory existed. Even the Leprosy Mission’s own historical account admits that “the reason for this decline is not well understood,” and speculates about improvements in living conditions.⁷ Whatever removed leprosy from Europe operated without any specific medical intervention against it. The decline was already essentially complete when Hansen arrived to explain it.

Norway was the striking exception. On the wet, crowded, malnourished western coast, in the closed fjord communities of Vestland, the disease re-emerged in the eighteenth century and peaked in the mid-nineteenth. By the 1850s, some Bergen districts recorded prevalence of 25 per 1,000 population.⁸ These are the conditions Hansen worked in. His fame rests on the coincidence that the last European stronghold of leprosy happened to be the country where he lived.

The Bacterium That Cannot Be Grown

Hansen was appointed medical officer for leprosy in Norway in 1875, two years after his initial observation of the bacillus. He knew, and his contemporaries knew, that the observation alone did not establish causation. Koch, corresponding with Hansen from Breslau, had already begun formalizing what would become the postulates. Hansen understood that he needed to transmit the disease. He tried, and failed, in twelve consecutive animal experiments.⁹ The bacillus he had observed refused to cause the disease he claimed for it. The 1879 assault on Spidsøen was his thirteenth attempt and his last.

The court case that followed is remembered for its ethical narrative. What is not usually reported alongside it is what the failed experiment demonstrated. Hansen conceded, in court, that he had neither obtained her consent nor informed her of his purpose. The judgment, published in 1880 and reproduced in the historical record by Vogelsang, found him guilty of injuring the patient without cause.¹⁰ ¹¹ He lost his post at the leprosy hospital, though in a political compromise he retained his position as chief medical officer for leprosy in Norway. Spidsøen already carried the mild tuberculoid form of the disease. Hansen was attempting to induce the more severe lepromatous form by direct inoculation of active lepromatous material under her conjunctiva. No nodule developed. No lepromatous transformation occurred. The most direct human transmission attempt in the historical record, conducted by the discoverer of the bacillus, on a patient already believed susceptible, produced no transmission.

The bacillus he could not grow, he could not transmit either. And in the 146 years since, the situation has not improved. The 2025 Frontiers review, cited above, documents that the only sustained growth of M. leprae in a laboratory remains growth inside a live animal host. Mouse footpad inoculation was developed by Charles Shepard in 1960. The armadillo model, exploited because armadillos have a lower core body temperature than most mammals, was developed by Waldemar Kirchheimer in the early 1970s. Both require whole living animals. Neither is a fulfillment of Koch’s second postulate. Neither has produced a definitive causation experiment that would satisfy the third.

The armadillo model has been turned into something stranger. When wild armadillos in Louisiana and Texas were found to carry M. leprae, the CDC reversed the direction of inference: not that armadillos had been inoculated from human sources during the mid-twentieth-century research programs at the National Hansen’s Disease Center at Carville, but that armadillos are a natural reservoir from which humans acquire the disease.¹² A bacterium that cannot be grown in the laboratory is now described, on the CDC’s own page, as passing from armadillo to human in the southern United States, though the mechanism, once again, is left unspecified. Growing a bacterium in a live animal is not the same as culturing it. The vast majority of M. leprae-positive armadillos are asymptomatic. Attributing human cases to armadillo contact does not demonstrate transmission; it identifies a correlation of unknown direction. The armadillo is a workaround for a bacterium that fails every direct test, not an answer to the question the establishment claims to have answered.

The Cascade of Confessions

The establishment position on leprosy, when its own statements are laid side by side, is internally incoherent. The CDC and HRSA both state that around 95 percent of the human population, in the paradigm’s phrasing, has “natural immunity” to the bacterium and cannot be made to develop the disease even under prolonged exposure.¹³ ¹⁴ The observation is real. The label is the establishment’s attempt to explain away the observation without confronting what it implies: if the bacterium fails to produce the disease in 95 percent of those it reaches, the bacterium is not the cause. The IDRI review of vaccine development, funded by the Bill and Melinda Gates Foundation, notes that 30 to 75 percent of “infections” resolve spontaneously without any treatment.¹⁵ The WHO fact sheet reports an incubation period ranging from one to twenty years and states, without further explanation, that this anomaly exists.¹⁶ The CDC concedes that the mode of transmission is not known.¹⁷ The reviewers of the vaccine literature, writing in Human Vaccines, describe the condition as one of the least understood diseases in medicine.¹⁸

Koch’s first postulate requires that the microorganism be found in all those with the disease, and not in those without. Both criteria are violated. M. leprae is found in armadillos, in soil samples, in nasal secretions of healthy contacts, in patients who never develop symptoms, and is absent, or undetectable, in a fraction of clinical cases. Peter Duesberg’s dictum applies: “A single exception would be enough to pronounce the microbe innocent of creating that disease.”¹⁹ The exceptions here are not single. They are the majority.

The establishment’s response to these violations has been to elaborate rather than to reconsider. The concept of “natural immunity” was retrofitted onto the observation that most exposed people do not become ill. The concept of an “asymptomatic carrier state” was retrofitted onto the observation that the bacterium is found in healthy people. The concept of “spontaneous clearance” was retrofitted onto the observation that most people who develop the bacterium eliminate it without any treatment. Each addition preserves the causation claim while explaining why the causation cannot be observed. What the additions cannot preserve is the claim that Koch’s postulates have been met. They have not been. The vaccine literature admits this openly, then continues to develop the vaccine.

The pattern operates in real time. A 2023 case report in the CDC’s own Emerging Infectious Diseases journal documented a Central Florida man with no travel history, no immigration background, and no known armadillo contact, who nonetheless received a leprosy diagnosis. The authors declared central Florida an endemic zone and appealed for expanded surveillance, then reproduced the standard cascade: transmission mechanism unclear, most people naturally immune, incubation possibly exceeding a decade, further study needed. The case adds a leprosy diagnosis to a state whose environmental toxicity profile, from mercury deposition in the Everglades to agrochemical exposure in the citrus belt, is documented and, once again, not investigated as a leprosy factor.²⁰

The medical literature concedes a further point that undermines its own model. M. leprae is acknowledged in the mainstream literature to be pleomorphic: it changes form in response to the conditions of its environment, appears as bacillary rods under some conditions and as coccoid or cell-wall-deficient variants under others, and cannot be assigned the fixed morphology and pure-culture identity Koch required.²¹ This is what an environmental caretaker organism looks like. It is not what a specific pathogen with a stable causal identity looks like.

What is being protected here is not the science. It cannot be the science, because the science, on its own admissions, does not support what is claimed. What is protected is the institutional structure that names the disease, that trains the specialists, that manufactures and distributes the antibiotics, that operates the national leprosaria (Carville, until 1999) and international programs, and that funds the coming vaccine. The bacterium never grown supports a global industry that requires it to exist as an infectious agent.

Norway: The Natural Experiment That Ran for Fifty Years

The cleanest data set on leprosy transmission in the historical record comes from Norway. The National Leprosy Registry, established in 1856, tracked every diagnosed case in the country by name, address, date of onset, hospital admission, death, and emigration. It is the oldest disease registry of its kind in the world. It was analyzed most rigorously by Meima, Irgens, and Habbema in a paper published in the International Journal of Epidemiology in 2002.²² Their conclusion, using conventional epidemiological modeling: “The decline cannot be explained fully by the Norwegian policy of isolation of patients; an autonomous decrease in transmission, reflecting improvements in for instance living conditions, must also be assumed.”²³

The Norwegian caseload fell from 1,800 known cases in 1875 to 575 in 1901 to essentially zero by 1920. The Leprosy Acts of 1877 and 1885 mandated isolation of cases the acts labeled infectious, but the modeling shows that the decline began before the acts and continued at a pace the isolation policy alone cannot account for. Something else was working. Living conditions, in Norway during this period, meant food security, indoor space per person, ventilation, reduced dampness, and less industrial toxicity. The disease tracked those conditions more closely than it tracked the isolation policy.

The Minnesota data are more striking. Between 1857 and 1895, roughly 5,053 new cases of leprosy occurred in Norway. Approximately 170 of the patients emigrated to the American Midwest, settling primarily in the Norwegian farming communities of Minnesota, Iowa, and Wisconsin.²⁴ The 1942 US Public Health Service report on the episode noted the finding: “Although no new cases of leprosy developed in the Scandinavian settlement during the first 50 years, seven cases occurred between 1895 and 1916, most of them in families of the imported cases. None have occurred since then.”²⁵

Between 160 and 200 Scandinavian leprosy patients settled among Norwegian-American immigrant communities living in close family and cultural contact. In fifty years, no secondary cases appeared. Seven appeared in the second half-century, all in the families of the original patients. Then the disease stopped. If leprosy were meaningfully contagious in the sense germ theory claims, some measurable fraction of the Norwegian-American community should have contracted it from prolonged close-quarters contact with the imported cases. None did. The disease did not travel.

Dr. J.H. Holmboe, the Bergen leprosy hospital surgeon, visited the Minnesota settlements in 1864 to assess exactly this question. He found twelve cases, one of which had recovered entirely after arrival. His conclusion, on returning to Norway, was that the patients’ condition of health was better in America than it would have been at home.²⁶ Professor William Boeck of Christiania made a follow-up visit in 1869–70 and confirmed the general pattern: transplanted patients did well, some improved dramatically, and where new cases appeared they appeared almost entirely within the families of the original imported patients, not among the wider community.²⁷ The controlling factor was not exposure to the bacterium. The controlling factor was the terrain the exposed people were living in.

The Norwegian data, taken as a whole, dismantle the contagion hypothesis on the paradigm’s own historical record. Same people. Same bacterium. Same close contact. Different terrain, different food, different housing, different work. No transmission. This is a natural experiment of a rigor the establishment cannot ordinarily obtain, and its result is that the disease disappeared without any specific medical intervention against it and did not follow the exposed populations to a healthier place.

Dr. Gerhard Buchwald, writing in Vaccination: A Business Based in Fear, captures the wider pattern: “Leprosy was a constant guest in the times when increasing numbers of people lived together in the most cramped spaces as the city walls made the expansion of cities difficult. As soon as the cities grew beyond the city walls and people had more space available, leprosy disappeared.”²⁸ The gap between the retreat of leprosy from Europe and the introduction of any specific medical intervention against it is five hundred years. Whatever removed the disease from Europe operated in the absence of any germ-theoretic understanding of what it was, and without any deliberate targeting of the alleged causative organism.

The Toxicological Convergence

If the bacterium is not the cause, the symptoms attributed to leprosy require an explanation. The medical literature provides one, hidden in the sections marked “differential diagnosis” and “other causes.” Every major symptom the establishment attributes to M. leprae has a well-documented chemical origin that the treating physician is trained to consider only after the bacterium has been excluded.

Peripheral neuropathy, the numbness and eventual disfigurement of the hands and feet that defines the most feared form of leprosy, is a textbook consequence of arsenic, lead, and mercury poisoning. A 2017 review in the Annals of Indian Academy of Neurology on the epidemiology of peripheral neuropathy in India, where nearly 60 percent of the world’s leprosy cases occur, catalogs the neurotoxic exposures that cause the identical clinical picture: arsenic, lead, mercury, and a range of pharmaceutical chemotherapeutic agents “with a propensity to affect peripheral nerves.”²⁹ The Indian subcontinent has extensive arsenic contamination of groundwater. West Bengal and Bihar carry some of the highest measured arsenic exposures in the world. The distribution of peripheral neuropathy across the region maps more accurately onto arsenic contamination than onto any bacterial transmission model.

The skin symptoms of leprosy are similarly overdetermined by chemical exposure. A 2000 study in the International Journal of Dermatology, titled High prevalence of vitiligo in lepromatous leprosy, reported that pigment loss frequently co-occurs with leprosy but is rarely reported in the literature.³⁰ A 2010 review in the Indian Journal of Dermatology, on chemical leucoderma, identifies the responsible substances directly: “Chemical leucoderma is an industrial disorder in developed countries and the common causative chemicals are phenols and catechols.”³¹ Phenols and catechols are petrochemical derivatives. The list of chemicals known to be toxic to melanocytes, the pigment-producing cells whose destruction produces the depigmenting skin lesions of leprosy, includes mercury, arsenic, phenols, catechols, and azo dyes, the last a family of synthetic industrial colorants used in textile, leather, food, and cosmetic manufacture across the Indian subcontinent.³²

The physical toxins are documented. So is the pharmaceutical toxicology. From the 1300s until the twentieth century, the standard treatment for leprosy skin lesions was mercury ointment. Dr. Carolyn Dean, in Death by Modern Medicine, records the assessment: “Mercury is second only to plutonium in toxicity. When it first began to be used, centuries ago, nobody really knew its dangers. Mercury ointment was a treatment for the skin lesions of leprosy, beginning in the 1300’s.”³³ For six hundred years the treatment was itself neurotoxic, dermatotoxic, and nephrotoxic. Every mercury-treated patient added mercury poisoning to whatever else was producing the symptoms. Chronic mercury exposure produces peripheral neuropathy, cognitive decline, skin lesions, and progressive breakdown of the body’s cleansing and repair capacity. The treatment was capable, on its own, of producing every symptom of the disease it was applied to.

The pattern extends to smallpox vaccination, in which mercury and calf lymph and other biologically foreign material were introduced directly under the skin of nineteenth-century populations. Eleanor McBean, writing in Swine Flu Expose, cites the observation that had circulated among sanitarians throughout the period: “Many vaccines also cause other diseases besides the one for which they are given. For instance, smallpox vaccine often causes syphilis, paralysis, leprosy, and cancer.”³⁴ The claim is easy to dismiss until one considers that the toxic and antigenic loads introduced by nineteenth-century vaccinia inoculation would have been more than sufficient to trigger the sensitization response Charles Richet later documented for the injection of any foreign protein.

The geography of leprosy in the present tense confirms the toxicological reading. According to the WHO’s Global Leprosy Strategy 2016–2020, Brazil, India, and Indonesia together account for 81 percent of new cases globally.³⁵ These are the three largest developing economies where industrial pollution, groundwater contamination with heavy metals, occupational chemical exposure, and persistent malnutrition coexist at population scale. Brazil’s principal endemic zones overlap with the mining regions, particularly the artisanal small-scale gold mining that releases mercury directly into rivers used for drinking water and fishing.³⁶ India’s endemic zones overlap with arsenic-contaminated aquifers, chemical dye industries, and heavy pesticide use. Indonesia’s endemic zones overlap with the industrial pollution of the outer islands, the deforestation-agrochemical corridor, and mining runoff. The disease appears where the terrain is toxic. It disappears where the terrain is clean. The bacterium is the CDC’s marker of last resort, the label placed on a chemical injury for which no other diagnosis has been sought.

On the Body

In its milder tuberculoid form, leprosy leaves patches of skin without feeling. A patient can burn a hand on a stove and not know it until the smell of the burning flesh reaches the nose. Feet develop unnoticed ulcers that eat down to the bone. Thickened peripheral nerves can be felt beneath the skin at the elbows and wrists. In the more severe lepromatous form, the face coarsens: thickened forehead, collapsed nasal bridge, pendulous earlobes. Medicine calls the pattern leonine facies, the face of a lion. Fingers shorten as bone resorbs beneath insensate skin. Feet drop. Eyebrows fall out. This is the presentation that produced the leprosarium, and this is what any honest account of the disease has to explain.

A modern patient placed on multidrug therapy for the twenty-four months of the standard course does not escape the picture. The rifampicin turns urine, tears, and sweat red. The dapsone destroys red blood cells and produces the fatigue and breathlessness of chronic anemia, methemoglobinemia in a fraction of recipients, and, on longer exposure, its own peripheral neuropathy. The clofazimine colors the skin reddish, then brown, then, in some patients, almost black, and adds abdominal pain and diarrhea from crystal deposition in the gut. Two years in, the patient is discolored, exhausted, and, if the drug-induced neuropathy has progressed, losing sensation in the exact pattern the disease is claimed to produce. The regimen is described in the fact sheets as curative.

The Poisons Called Cure

The current WHO-recommended treatment for leprosy is multidrug therapy (MDT), comprising dapsone, rifampicin, and, for multibacillary cases, clofazimine. The regimen is provided free of charge by the WHO through pharmaceutical donations.³⁷ It is described in the fact sheets as curative.

Dapsone (4,4’-diaminodiphenylsulfone) was introduced in the 1940s as a sulfone drug related to the earlier sulfa antibacterials. Its documented adverse effect profile includes dose-dependent hemolytic anemia (the destruction of red blood cells), methemoglobinemia (the conversion of hemoglobin to a form that cannot carry oxygen), agranulocytosis (collapse of the body’s infection-fighting white cell count), hepatotoxicity progressing in severe cases to vanishing bile duct syndrome and acute liver failure, and three severe skin reactions: DRESS syndrome, Stevens-Johnson syndrome, and toxic epidermal necrolysis, each of which produces widespread skin loss, systemic organ involvement, and, at the severe end, death.³⁸ ³⁹ The list is not obscure. It is on the drug’s label, in the standard pharmacology references, and in the NIH LiverTox database.

The most instructive of dapsone’s documented adverse effects, given the disease it is prescribed for, is peripheral neuropathy. Dapsone directly damages the long nerve fibers of the arms and legs, and the damage progresses with the dose.⁴⁰ The principal drug in the treatment of a disease whose defining severe manifestation is peripheral neuropathy causes peripheral neuropathy. A patient diagnosed with leprosy on the basis of nerve damage, then treated with dapsone, will have any subsequent nerve damage attributed to progression of the disease. There is no clinical test that can distinguish drug-induced neuropathy from disease-induced neuropathy in a patient receiving both. The pharmacology literature admits the toxicity. The clinical literature does not credit the drug for the progression.

Rifampicin, the second drug in the regimen, produces liver toxicity in a substantial fraction of recipients. Chronic rifampicin exposure ramps up the liver’s main drug-processing enzymes, altering the metabolism of every other drug the patient is taking and depleting endogenous compounds the liver would otherwise process. Clofazimine, the third, colors the patient’s skin reddish to almost black, produces gastrointestinal disturbances that include nausea, vomiting, and diarrhea, and, at higher doses, forms crystalline deposits in body tissues including the small intestine, where they can cause bowel obstruction.⁴¹ The medication that turns the patient’s skin the color of the disease it is treating is a treatment in name only.

The establishment defends the toxicity of the regimen with the argument of “resistance.” When dapsone monotherapy began to fail in the 1970s, the interpretation was that M. leprae had developed resistance to the drug. The multidrug protocol was introduced to “overcome” this. Every antibiotic used against leprosy has, in due course, produced “resistance” in the same way, requiring the addition of new drugs. The alternative interpretation, that the drugs are not treating what the establishment claims and that continued dosing progressively poisons an already toxin-burdened patient, is not entertained. The failure of the drug is treated as evidence of the cleverness of the bacterium rather than as evidence of the wrongness of the paradigm.

Historically, the same pattern held. Chaulmoogra oil, adopted from Indian medicine by Western physicians in the early twentieth century, produced apparent improvements that medicine attributed to antibacterial activity. Whether the benefit reflected any specific action, or the general effect of removing the patient from active mercury treatment while providing dietary fat in an often malnourished population, is a question the establishment did not ask.

BCG, the Coming Vaccine, and What History Records

The BCG vaccine, developed for tuberculosis, is also deployed against leprosy on the argument that M. leprae and M. tuberculosis are structurally similar. If the two bacteria are similar enough that a vaccine against one protects against the other, they cannot be responsible for two entirely distinct diseases. The medical account holds both positions.

The BCG data are, in any case, unimpressive. A large field trial conducted by the WHO in India between 1968 and 1971 vaccinated approximately 364,000 people across 309 villages, with a comparable unvaccinated area used for comparison. The results showed no protective effect against tuberculosis, and in some age groups more cases occurred in the vaccinated area than in the unvaccinated one.⁴² The vaccine is still administered on the basis that whatever it does, it is better than nothing.

A dedicated leprosy vaccine has been in development for over a decade. The Infectious Disease Research Institute (IDRI), funded by the Bill and Melinda Gates Foundation, moved a candidate called LepVax into Phase I human trials in 2017.⁴³ The vaccine is being developed on the basis that MDT is not working, that “resistance” is spreading, and that a specific leprosy vaccine is needed to close the gap. The reasoning is circular. The MDT protocol was introduced because dapsone monotherapy failed. The vaccine is being developed because MDT is failing. Each failure justifies the next intervention against the same alleged causative organism. Each institutional failure is treated, by the institutions, as evidence that more of the same is needed.

The observation about vaccines and leprosy is not a fringe claim. Vaccinia and other nineteenth-century injections were noted repeatedly in the sanitarian literature to precipitate skin conditions, chronic ill health, and occasional cases of what was diagnosed as leprosy. Charles Richet’s Nobel-winning 1913 work on anaphylaxis established that injection of foreign proteins produces sensitization; subsequent exposure produces escalating and eventually severe response.⁴⁴ Mass injection of biological material into malnourished populations across the nineteenth and twentieth centuries may have precipitated some measurable fraction of the cases the establishment subsequently attributed to bacterial transmission. Investigating this would implicate the vaccine industry in producing the disease the vaccine industry is now developing a new product to prevent.

What Leprosy Actually Is

In a body burdened with mercury from six centuries of medical treatment, arsenic from the groundwater, lead from the roofing, phenols from the workplace, and a diet from which industrial processing has stripped its mineral cofactors, the appearance of M. leprae is not the origin of the disease. It is the arrival of the cleanup crew at a site of terrain collapse. The bacterium is a marker, not a cause. Its presence indicates that the terrain has failed, not that the terrain is under attack.

The disease disappeared from Europe not because the bacterium was killed, but because the terrain improved. Leprosy tracked the terrain, not the bacterium.

Medicine has been here before. Helicobacter pylori was identified in stomach tissue in the 1980s, declared the cause of peptic ulcer disease, and treated with triple antibiotic therapy. Barry Marshall and Robin Warren shared the 2005 Nobel Prize for the identification.⁴⁵ Two decades on, the picture has quietly collapsed into something more complicated. More than half of the world’s population carries H. pylori. Only a small fraction develop ulcers. The bacterium is now positioned as one factor among several, alongside non-steroidal anti-inflammatory drugs, chronic stress, and other terrain conditions. The antibiotic protocol persists as the standard of care, but the specific-cause claim that produced the Nobel Prize is no longer defended in the form in which it was made. Leprosy is on the same trajectory, several decades further along. The bacterium is a marker of something, not the cause of everything the diagnosis names. The paradigm eventually admits this. It does so slowly, without acknowledging how badly it got the story wrong, and it never revisits the interventions it prescribed on the basis of the original error.

The persistence of the paradigm in the face of this record is not a scientific problem. It is an institutional one. The bacterium sustains a global program: the WHO’s MDT distribution, the pharmaceutical companies producing dapsone and rifampicin and clofazimine, the research institutes developing the vaccine, the specialist physicians whose careers depend on the diagnostic category, and the national leprosy programs of the affected countries. A terrain reading of leprosy would dismantle this apparatus. The apparatus has an interest in the bacterium’s continued causal status. The interest is not in truth.

Kari Nielsdatter Spidsøen, whose eye Hansen tried to inoculate, did not develop the more severe form of leprosy after the assault. She had had the mild form for seventeen years and continued to live with it. She remained in the Bergen leprosarium, having been the subject of the most direct transmission attempt the establishment ever conducted, which produced a null result. Her name appears in the historical footnotes because she resisted the knife. The bacterium she was inoculated with was never grown in a laboratory dish. It has not been grown since. The disease she carried, the disease Hansen claimed to have identified the cause of, was made by the terrain Hansen never asked about: the mercury on her skin, the crowding of her village, the water she drank. The microscope was pointed at the wrong thing.

How To Explain It To A 6 Year Old

A long time ago, people were very afraid of a sickness that made spots on the skin. The spots did not go away. Sometimes fingers and toes went numb and stopped working. People with this sickness had to leave their families and live in special houses far away from the town. They had to ring a bell so that everyone would know they were coming and could stay away.

The name of the sickness was leprosy. For a very long time nobody knew what made people sick with it. Some doctors thought it was in the food. Some thought it was in the air. Some thought it was punishment from God. The way they treated the sickness was to put mercury paste on the skin. Mercury is a metal that is very poisonous. So the medicine was making the sickness worse, but the doctors did not know that.

Then a doctor in Norway named Hansen looked into a microscope one day in 1873 and saw a tiny thing in the skin of a sick person. He decided this tiny thing was what made the person sick. He wanted to prove it. He tried to make animals sick with it, twelve times, and could not do it. He tried to grow the tiny thing in a dish. It would not grow. Then, on a day in 1879, he grabbed a woman named Kari who lived in his hospital, held her down, and tried to push some of the tiny thing into her eye with a knife. She fought him off. She told the priest. The priest told the police. Hansen went to court and lost his job at the hospital.

The tiny thing still would not grow in a dish. It still will not grow in a dish today, 152 years later. Nobody has been able to make it grow in a dish, ever. But everyone was told that the tiny thing was what made people sick, and this is still what they are told now.

The leprosy sickness went away from Europe hundreds of years ago, before any doctor had a medicine for it. It went away because the towns got bigger, people had more room to live in, they got more food, they had cleaner water, and they stopped putting mercury paste on their skin. Where the towns are still crowded and the water is dirty and the workers touch bad chemicals, the sickness is still there. Where the towns and water and work are clean, the sickness goes away.

The medicine that doctors give people with leprosy today is called dapsone. One of the things dapsone does to people is make their hands and feet go numb. This is one of the same things leprosy does. So when a person on the medicine gets more numb, the doctor says the sickness is getting worse and gives more medicine. Nobody says the medicine is the reason.

The story people are told about leprosy is not right. The tiny thing Hansen saw is a real tiny thing. But it is not the reason for the sickness. It is like a fire truck that shows up when there is a fire. Nobody thinks the fire truck started the fire. The fire truck is there to help clean up. The tiny thing is there to help clean up too. The fire is the poison in the water and the bad food and the mercury on the skin and the smoke from the factories. Take those things away and the sickness goes away, whether the tiny thing is there or not.

References

1. “Silence on the plate: revisiting the enigma of Mycobacterium leprae cultivation.” (2025). Frontiers in Microbiology. Published May 2025. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2025.1708557/full

2. Centers for Disease Control and Prevention. Transmission: How Hansen’s Disease Spreads. https://www.cdc.gov/leprosy/transmission/index.html

3. Ibid.

4. Duthie MS, Gillis TP, Reed SG. (2011). “Advances and hurdles on the way toward a leprosy vaccine.” Human Vaccines, 7(11):1172-1183. Cited in Lester D, Parker D. (2019). What Really Makes You Ill? Why Everything You Thought You Knew About Disease Is Wrong.

5. Ibid.

6. Shelton HM. Natural Hygiene: Man’s Pristine Way of Life. Cited in Lester & Parker (2019), op. cit.

7. The Leprosy Mission International. The History of Leprosy. https://www.leprosymission.org/what-is-leprosy/the-history-of-leprosy/

8. Grokipedia. History of leprosy, citing Irgens LM et al. on peak prevalence in Bergen c. 1850s reaching approximately 25 per 1,000. https://grokipedia.com/page/History_of_leprosy

9. Høvik LV. (2018). “Armauer Hansen’s Experiment and the Discovery of the Lepra Bacilli.” Historical account reviewing Vogelsang, Blom, and primary Norwegian sources. https://medium.com/@hoevik/armauer-hansens-experiment-and-the-discovery-of-the-lepra-bacilli-b78bb3727fa9

10. Lanska DJ. (2025). “Gerhard Armauer Hansen’s unethical person-to-person leprosy transmission experiment in 1879.” Hektoen International. https://hekint.org/2025/07/10/gerhard-armauer-hansens-unethical-person-to-person-leprosy-transmission-experiment-in-1879/

11. Vogelsang TM. (1963). “A serious sentence passed against the discoverer of the leprosy bacillus (Gerhard Armauer Hansen), in 1880.” Medical History, 7(2):182-186. See also Blom K. (1973). “Armauer Hansen and human leprosy transmission. Medical ethics and legal rights.” International Journal of Leprosy and Other Mycobacterial Diseases, 41(2):199-207.

12. Centers for Disease Control and Prevention. About Leprosy (Hansen’s Disease). https://www.cdc.gov/leprosy/about/index.html

13. Ibid.

14. Health Resources and Services Administration. Frequently Asked Questions About Hansen’s Disease. https://www.hrsa.gov/hansens-disease/frequently-asked-questions

15. Duthie MS et al. (2011), op. cit.

16. World Health Organization. Leprosy Fact Sheet, March 2019 edition, cited in Lester & Parker (2019), op. cit.

17. CDC Transmission, op. cit.

18. Duthie MS et al. (2011), op. cit.

19. Duesberg P. (1996). Inventing the AIDS Virus. Cited in Lester & Parker (2019), op. cit.

20. Bhukhan A, Dunn C, Nathoo R. (2023). “Case Report of Leprosy in Central Florida, USA, 2022.” Emerging Infectious Diseases, 29(8):1698-1700. https://wwwnc.cdc.gov/eid/article/29/8/22-0367_article

21. Pleomorphism of M. leprae documented in the mainstream literature; see Job CK, Karat AB, Karat S. (1966). “The histopathological appearance of leprous rhinitis and pathogenesis of septal perforation in leprosy.” Journal of Laryngology & Otology, 80(7):718-732; and cell-wall-deficient / L-form observations reviewed in Mattman LH. (2001). Cell Wall Deficient Forms: Stealth Pathogens, 3rd ed., CRC Press. Summarized in Lester & Parker (2019), op. cit.

22. Meima A, Irgens LM, Habbema JDF. (2002). “Disappearance of leprosy from Norway: an exploration of critical factors using an epidemiological modelling approach.” International Journal of Epidemiology, 31(5):991-1000. https://pubmed.ncbi.nlm.nih.gov/12435774/

23. Ibid.

24. Public Health Service, US. (1942). Public Health Reports, Vol. 57, No. 18, May 1, 1942. Report on leprosy in Minnesota, Iowa, and Wisconsin. https://stacks.cdc.gov/view/cdc/70218/cdc_70218_DS1.pdf

25. Ibid.

26. Holmboe JH. (1864). Report on Norwegian-American leprosy cases in the Midwest. Cited in Grønvold C. (1879). “Notes of Four Cases of Leprosy in Minnesota.” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824979/

27. Boeck W. (1870). Investigation report. Nordiskt Medicinskt Archiv, Band III, No. 1. Cited in Grønvold (1879), op. cit.

28. Buchwald G. Vaccination: A Business Based in Fear. Cited in Lester & Parker (2019), op. cit.

29. Trivedi S, Pandit A, Ganguly G, Das SK. (2017). “Epidemiology of Peripheral Neuropathy: An Indian Perspective.” Annals of Indian Academy of Neurology, 20(3):173-184. https://pubmed.ncbi.nlm.nih.gov/28904445/

30. High prevalence of vitiligo in lepromatous leprosy. (2000). International Journal of Dermatology. https://www.ncbi.nlm.nih.gov/pubmed/11123444

31. Bajaj AK, Saraswat A, Srivastav PK. (2010). “Chemical leucoderma: Indian scenario, prognosis and treatment.” Indian Journal of Dermatology, 55(3):250-254. https://pubmed.ncbi.nlm.nih.gov/21063517/

32. Ibid.

33. Dean C. Death by Modern Medicine. Cited in Lester & Parker (2019), op. cit.

34. McBean E. Swine Flu Expose. Cited in Lester & Parker (2019), op. cit.

35. World Health Organization. Global Leprosy Strategy 2016–2020. http://www.searo.who.int/entity/global_leprosy_programme/documents/global_leprosy_strategy_2020/en/

36. Global Burden of Disease of Mercury Used in Artisanal Small-Scale Gold Mining. Environmental Health Perspectives, 2017. https://www.sciencedirect.com/science/article/pii/S2214999616308207

37. WHO Leprosy Fact Sheet, op. cit.

38. National Institutes of Health. Dapsone. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. https://www.ncbi.nlm.nih.gov/books/NBK548936/

39. Dapsone pharmacology summarized in ScienceDirect Topics. https://www.sciencedirect.com/topics/neuroscience/dapsone

40. Ibid. Dapsone-induced peripheral neuropathy documented as axonal, primarily motor, dose-dependent.

41. WHO. Guidelines for the Diagnosis, Treatment and Prevention of Leprosy, adverse effect profiles of clofazimine documented within.

42. WHO field trial of BCG for tuberculosis, Chingleput, India, 1968–1971. Results summarized in Lester & Parker (2019), op. cit.

43. Infectious Disease Research Institute press release, October 2017. Promising New Leprosy Vaccine Moves into Human Trials. https://www.idri.org/promising-new-leprosy-vaccine/

44. Richet C. (1913). Nobel Prize in Physiology or Medicine, awarded for work on anaphylaxis. Background documented in Lester & Parker (2019), op. cit.

45. Marshall BJ, Warren JR. (1984). “Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.” Lancet, 1(8390):1311-1315. Nobel Prize in Physiology or Medicine awarded to Marshall and Warren, 2005. https://www.nobelprize.org/prizes/medicine/2005/summary/

Author’s Note

Two registers operate in this essay. When mainstream science is being examined, the establishment’s language and citations appear. When the terrain framework is being stated, terrain language takes over. The reader should always know which register is operating.

The biogeochemistry described here is not fringe science. It is one of the best-documented planetary systems in the mainstream literature. The paradigm-relevant question is not whether the sulfur cycle exists, but why its practical implications for human health have been quietly removed from public conversation, and what recovering them looks like.

Marine phytoplankton produce roughly one billion tons of dimethylsulfoniopropionate every year.¹ The compound gives the ocean its characteristic smell, seeds the clouds that shape the earth’s radiation balance, and delivers sulfur to plants, animals, and humans on land through a chain that has been mapped in mainstream science for more than fifty years.

A reader mentioned this week that he remembered learning about this cycle from a New Scientist article around 1985. He added, without prompting, that the magazine at that time was “not so narrative driven and more focused on dispensing knowledge.” The article he remembered was almost certainly part of the coverage around James Lovelock’s work, which reached its most influential statement in the 1987 Nature paper by Charlson, Lovelock, Andreae, and Warren titled Oceanic phytoplankton, atmospheric sulphur, cloud albedo and climate.² Lovelock’s foundational observation appeared in Nature fifteen years earlier.³ Between 1972 and 1987, the science press treated this material as knowledge worth transmitting to a lay audience. A reader who kept it in his head for forty years is evidence that the transmission worked.

Today the same material is buried under advertising copy. The compound at the center of the cycle is now sold as a joint supplement in capsules, with no reference to the biosphere-wide chain that used to deliver it into the body without industry mediation.

The Compound the Ocean Makes

Dimethylsulfoniopropionate, or DMSP, is synthesized by marine phytoplankton, several species of coral, some seagrasses, and certain marine bacteria.⁴ Inside the cell it works as an osmolyte, balancing internal salt against surrounding seawater. It also acts as an antioxidant⁵ and as a cryoprotectant. When phytoplankton are grazed by zooplankton, die, or are metabolized by marine bacteria, DMSP is cleaved into a gas: dimethyl sulfide, or DMS.

DMS is what your nose registers as the smell of the sea. At the low concentrations found in coastal air, it is faint and unmistakable. Behind that smell sits the chemistry of trillions of cells across the ocean surface, releasing a gas that has been part of ocean life for as far back as ocean life can be traced.

The gas does not stay dissolved. Roughly 300 million tons of DMS escape into the atmosphere each year, making it the largest natural source of sulfur gas over the global ocean.⁶ Once airborne, DMS reacts with hydroxyl radicals and other oxidants in a stepwise chain:

DMS → DMSO (dimethyl sulfoxide) → DMSO₂ (dimethyl sulfone, also called MSM) → methanesulfonic acid and sulfate.⁷

Each step adds an oxygen atom to the sulfur. The end products act as cloud condensation nuclei, the microscopic particles that let atmospheric water vapor form droplets. Higher DMS emissions produce more of these particles, which produce more clouds, which reflect more sunlight back into space and cool the surface below.

This feedback loop was named the CLAW hypothesis after its authors. The tightness of the climate coupling has been challenged in the mainstream literature; Quinn and Bates published a critical review in Nature in 2011 arguing that the tight feedback cannot be demonstrated.⁸ The underlying chain, however, is not disputed. Phytoplankton make DMSP. Bacteria cleave it to DMS. DMS enters the atmosphere. The oxidation products form cloud nuclei and return to earth in rain. A reader in 1985 could learn this. A reader in 2026 has to hunt for it.

From Ocean to Rain to Table

DMSO and MSM are both water-soluble. When they form in the atmosphere from DMS oxidation, they dissolve in atmospheric moisture and fall in rainfall. Plants take them up through their roots. MSM is retained in plant tissue and delivered into the food chain from there.⁹

Measurements find MSM in most fresh fruits and vegetables at concentrations of roughly 1 to 4 milligrams per kilogram.¹⁰ Raw milk from pastured cows carries 2 to 5 milligrams per kilogram.¹⁰ Breast milk contains it. Whole grains contain trace amounts. Coffee and beer show detectable levels because fermentation and roasting preserve some fraction of what the plant deposited.

The compound is heat-sensitive and volatile. Cooking destroys much of it. Pasteurization eliminates almost all of it from milk. Long storage reduces it. Industrial processing strips it. What survives is what arrives on the plate raw or minimally cooked, or in a glass of untreated milk from a cow that grazed on pasture watered by unpolluted rain.

Sulfur is the seventh most abundant element in the human body.¹¹ It sits in the structure of connective tissue. It powers the methylation cycle. It forms the backbone of the amino acids methionine and cysteine. It is central to glutathione synthesis, to the redox architecture that governs cellular energy, and to hundreds of enzyme systems that cannot operate without it. When sulfur supply falls short, connective tissue lacks material for its structural proteins. Detoxification pathways that depend on sulfur substrate slow down. Cellular energy production falters wherever sulfur-containing cofactors are needed to run the mitochondrial machinery.¹²

The chain runs from ocean surface, through gas emission and atmospheric oxidation, into rainfall, then through soil and plant and animal and food, into the body. Each step has been measured by mainstream biogeochemistry. What the mainstream literature does not do is add up what modern life does to each step of this cycle.

Six Interruptions

Glyphosate. The active ingredient in Roundup and its generics chelates manganese, cobalt, iron, and other minerals in the soil and in the plant.¹³ It also interferes with the shikimate pathway, which plants use to synthesize sulfur-containing amino acids. Sprayed plants have lower sulfur content than unsprayed plants grown in the same soil. This is standard agronomy, not disputed. The result: a food supply that carries less sulfur to the eater, meal by meal, decade after decade.

Industrial agriculture. Soil that has been continuously cropped with synthetic nitrogen fertilizers, without return of organic matter, becomes depleted of the microbial life that mediates sulfur cycling in the root zone. Sulfur deficiency in agricultural soils is now widespread enough that agronomists have begun recommending elemental sulfur applications to restore yields. That recommendation is an admission, not framed as one, that the soil no longer contains what the plant needs, and therefore that the plant no longer contains what the eater needs.

Pasteurization. Raw pastured milk carries MSM at 2 to 5 milligrams per kilogram. Pasteurized milk contains almost none.¹⁰ The heat process regulators claim protects the public also destroys one of the compounds by which the sulfur cycle delivers into human nutrition. The regulatory framework was built as if MSM did not exist. Whether the regulators knew is a separate question. The compound is destroyed regardless.

Cooking and processing. The volatility that lets MSM enter the atmosphere lets it leave a saucepan. Long cooking, high heat, dehydration, and industrial processing all reduce it. A diet composed largely of processed food, restaurant meals, and long-cooked vegetables receives a fraction of what fresh, raw, and minimally cooked produce would deliver.

Organophosphates. Mark Purdey’s work is the clearest terrain reading of a disease the establishment declared infectious. Purdey was a Somerset organic dairy farmer, not an academic, when he refused to apply the government-mandated organophosphate warble-fly treatment to his herd in the 1980s. He took the Ministry of Agriculture to court over the mandate and won. His own cattle stayed BSE-free while herds around him did not. From that observation he began two decades of self-funded international investigation, tracing the same pattern through transmissible spongiform encephalopathy clusters in Colorado, Iceland, Slovakia, and Sardinia.¹⁴

The mechanism he identified: chronic organophosphate exposure combined with excess manganese in supplemental feed and depleted copper in the soil, resulting in the substitution of manganese for sulfur-bound copper at the active site of the prion protein.¹⁵ Organophosphates disrupt sulfur metabolism at the cellular level; manganese loading fills the gap the depleted copper leaves; the prion protein bends into the folded configuration that mainstream researchers then call infectious. Every geographical BSE cluster Purdey investigated showed the same signature of these three factors converging.

The mainstream framing calls BSE an infectious prion disease transmitted through rendered animal feed. Purdey’s terrain reading called it a metabolic disorder driven by sulfur-cycle disruption in specific chemical zones. His analysis appeared in peer-reviewed journals, most consistently in Medical Hypotheses. It was never refuted in the literature. It was simply not funded to continue. Purdey died in 2006 at fifty-two, from a brain tumor, in circumstances his family found questionable. The prion story remains the official account. The industry that manufactures organophosphates has never had to answer for the evidence he assembled.

Air pollution. In heavily polluted urban environments, the ambient DMS signal from the ocean is overlaid with anthropogenic sulfur dioxide from combustion, and the atmospheric chemistry above the city runs on different pathways than the chemistry above a coastline. Sulfur-cycle exposure through the airway is not what it was.

Any one of these interruptions would matter. Six operate simultaneously on the same population, and they compound. A person eating processed, pasteurized, glyphosate-treated food, grown on depleted soil, in a polluted city, receives a fraction of what an intact cycle was configured to deliver. The mainstream health literature does not track this. It tracks isolated nutrients in isolated capsules and calls the resulting picture nutritional science.

The MSM Question

Both DMSO and MSM are now sold as commercial products. DMSO as a topical solvent and therapeutic. MSM as a joint-health supplement in capsules.

The compounds are not inert. Robert Herschler filed the original MSM patents beginning in 1981.¹⁶ Stanley Jacob and colleagues documented clinical use in thousands of patients through the 1980s and 1990s, spanning joint pain, connective tissue disorders, allergy symptoms, and inflammatory conditions.¹⁷ Engelke and colleagues confirmed MSM presence in human cerebrospinal fluid and blood plasma using NMR spectroscopy.¹⁸

The paradigm question is not whether the compound works. The paradigm question is what selling it in isolation, at concentrations no food provides, without reference to the cycle it belongs to, represents.

It represents the same structure this work has criticized elsewhere. A compound is isolated from its biological context, manufactured industrially, marketed as a deficiency correction, and sold in a bottle. What goes unmentioned is that the entire industrial food and water infrastructure has been engineered to remove this compound from the eater’s diet, and that reversing that engineering is the actual solution. The bottle becomes a permanent product because the interruption of the cycle is permanent.

MSM in a capsule and MSM in raw pastured milk are the same molecule. What differs is everything around the molecule: the cofactor matrix, the whole-food delivery, the enzymes that survived the pasteurization that did not happen, the calcium and magnesium and fat-soluble compounds that arrived with it, the microbiome that would have processed it, the entire biological context that arrives when the cycle is intact. The supplement industry sells one molecule. The terrain framework asks for the whole system.

DMSO is a different case. It is not a nutritional compound but a pharmacological and physical agent with specific therapeutic uses documented across the medical literature from the 1960s onward. Applications include pain relief, transport of other substances through the skin, tissue repair, and uses in ophthalmology, dermatology, and musculoskeletal medicine.¹⁹ Its utility does not depend on framing it as a nutrient. Used as what it is, it is a genuine terrain-compatible tool. My book on DMSO covers the clinical applications and the suppression history in full; what belongs in this essay is only its position on the sulfur oxidation chain and the distinction between it and MSM.

The distinction matters. Reject the vitamin-and-supplement paradigm where it applies. Recognize a real pharmacological agent where the evidence supports one.

Practical Restoration

Six items, ranked roughly by strength of effect.

Live near the sea, or visit often. Coastal air carries the ambient DMS signal and its oxidation products in dilute form. Nineteenth-century sanatoria placed tuberculosis and convalescent patients on cliffs and coastlines for reasons the physicians observed clinically even though they could not name the chemistry. Whatever the sea air was doing then, it is still doing now. Coastline is free. A morning walk on wet sand delivers what no capsule ever will.

Eat raw and minimally cooked produce in season. Alliums such as garlic, onion, and leek. Crucifers such as broccoli, cabbage, kale, and Brussels sprouts. Sulfur-rich herbs. These foods deliver the sulfur amino acid backbone the body uses to build every sulfur-dependent structure. Raw or lightly steamed preserves what long cooking destroys.

Drink raw milk from pastured animals where legally accessible. The MSM is there. The living enzymes are there. The fat-soluble compounds are there. The intact matrix is there. Pasteurization removes all of it. This is not a supplement; it is a whole food that was, until very recently, the default form of dairy for most of human history.

Eat sulfur-rich whole foods for the amino acid backbone. Pastured eggs. Organ meats, particularly liver and kidney. Bone-in cuts and bone broth. Wild-caught fish. Grass-fed red meat. These supply methionine and cysteine, the sulfur amino acids that form the structural pool the body draws on. MSM is a delivery vehicle; the amino acids are the building material.

Use DMSO topically for the applications it is documented to serve. Pain, inflammation, tissue repair, transport of other therapeutic compounds through the skin. It is a real therapeutic with a real evidence base going back sixty years. Use it as what it is.

Sulfur springs, mineral baths, and hot springs where geography permits. Traditional healing practice worldwide, ignored by modern medicine, structurally consistent with what the sulfur cycle does. Not a substitute for food-chain delivery, but not nothing either.

None of these requires a bottle, and every one predates the supplement industry by centuries.

What the Reader Noticed

The reader’s aside about the magazine carried more weight than he may have known. He remembered New Scientist treating the sulfur cycle as knowledge to be transmitted, and noticed that the same magazine no longer does that. The chemistry has not changed since 1985. What has changed is what the science press does with knowledge like this. A person searching for information about MSM today finds advertising copy for capsules. A person searching for DMS finds either climate policy debates or industrial safety data sheets. The connective tissue is missing. The story of how the ocean feeds the land through the atmosphere, and how modern life has interrupted every step of that delivery, has been removed from public view.

The information is not classified. Every claim above sits in the mainstream literature and can be checked. What has been removed is the frame that lets a reader see the whole system at once. In its place: fragments of a story sold as isolated products, framed as isolated deficiencies.

The terrain paradigm is, in part, an insistence on putting the connective tissue back. Claude Bernard called it the milieu intérieur when he was working out the biology of internal regulation in the nineteenth century. Lovelock extended the same principle to planetary scale with his Gaia framework a hundred years later. And Purdey worked at the smallest scale of all, tracing the sulfur-manganese chemistry that broke down in his neighbors’ cattle when it did not break down in his. The principle operates the same way at every scale. Living systems are integrated systems, and health is what happens when the integration is intact.

Phytoplankton produce this molecule for their own cellular purposes. It escapes as gas, condenses in clouds, falls as rain onto pasture, and reaches the child through raw milk, where the sulfur takes up residence in connective tissue for a lifetime. This is what an intact biosphere does, and what a curious reader in 1985 could still be told.

How To Explain It To A 6 Year Old

Tiny plants in the ocean, so small you can’t see them, make a special kind of smell. That smell is what makes the beach smell like the beach. The smell rises up into the sky, gets turned into invisible bits of dust, and those bits help make the clouds. When the clouds rain, the rain carries something the plants on land need to grow strong. When you eat those plants, or when you drink milk from a cow that ate the grass, you get some of that same something too. It helps hold your body together, from your skin to your joints to everything in between.

Grown-ups have made the rain dirtier, they cook the food too long, they clean the milk in a way that takes the good part out, and they spray the plants with chemicals that stop the plants making the good part in the first place. So people don’t get as much as they used to. Then someone puts it in a little bottle and sells it back to them.

The best answer is to go to the beach, eat food that isn’t cooked to death, drink milk the way it comes out of the cow if you can, and remember that the ocean is helping you every time you take a breath of sea air.

Disclaimer: This essay discusses biochemistry, agricultural practice, and general nutrition. It is not medical advice. Anyone considering changes to diet, use of DMSO or other therapeutic agents, or consumption of raw dairy should educate themselves independently and consider their own circumstances. Nothing here is a treatment recommendation for any specific condition.

References

¹ Curson, A. R. J., et al. (2018). DSYB catalyses the key step of dimethylsulfoniopropionate biosynthesis in many phytoplankton. Nature Microbiology, 3(4), 430–439.

² Charlson, R. J., Lovelock, J. E., Andreae, M. O., & Warren, S. G. (1987). Oceanic phytoplankton, atmospheric sulphur, cloud albedo and climate. Nature, 326(6114), 655–661.

³ Lovelock, J. E., Maggs, R. J., & Rasmussen, R. A. (1972). Atmospheric dimethyl sulphide and the natural sulphur cycle. Nature, 237, 452–453.

⁴ Curson, A. R. J., Todd, J. D., Sullivan, M. J., & Johnston, A. W. B. (2011). Catabolism of dimethylsulphoniopropionate: microorganisms, enzymes and genes. Nature Reviews Microbiology, 9(12), 849–859.

⁵ Sunda, W., Kieber, D. J., Kiene, R. P., & Huntsman, S. (2002). An antioxidant function for DMSP and DMS in marine algae. Nature, 418(6895), 317–320.

⁶ Kettle, A. J., & Andreae, M. O. (2000). Flux of dimethylsulfide from the oceans: A comparison of updated data sets and flux models. Journal of Geophysical Research: Atmospheres, 105(D22), 26793–26808.

⁷ Barnes, I., Hjorth, J., & Mihalopoulos, N. (2006). Dimethyl sulfide and dimethyl sulfoxide and their oxidation in the atmosphere. Chemical Reviews, 106(3), 940–975.

⁸ Quinn, P. K., & Bates, T. S. (2011). The case against climate regulation via oceanic phytoplankton sulphur emissions. Nature, 480(7375), 51–56.

⁹ Herschler, R. J. (1990). Use of methylsulfonylmethane to enhance diet of an animal. United States Patent 5,071,878.

¹⁰ Herschler, R. J. (1986). Methylsulfonylmethane in dietary products. United States Patent 4,616,039.

¹¹ Nimni, M. E., Han, B., & Cordoba, F. (2007). Are we getting enough sulfur in our diet? Nutrition & Metabolism, 4, 24.

¹² Parcell, S. (2002). Sulfur in human nutrition and applications in medicine. Alternative Medicine Review, 7(1), 22–44.

¹³ Samsel, A., & Seneff, S. (2013). Glyphosate, pathways to modern diseases II: Celiac sprue and gluten intolerance. Interdisciplinary Toxicology, 6(4), 159–184.

¹⁴ Purdey, M. (1998). High-dose exposure to systemic phosmet insecticide modifies the phosphatidylinositol anchor on the prion protein: the origins of new variant transmissible spongiform encephalopathies? Medical Hypotheses, 50(2), 91–111.

¹⁵ Purdey, M. (2000). Ecosystems supporting clusters of sporadic TSEs demonstrate excesses of the radical-generating divalent cation manganese and deficiencies of antioxidant cofactors Cu, Se, Fe, Zn. Medical Hypotheses, 54(2), 278–306.

¹⁶ Herschler, R. J. (1981). Methylsulfonylmethane and methods of use. United States Patent 4,296,130.

¹⁷ Jacob, S. W., Lawrence, R. M., & Zucker, M. (1999). The Miracle of MSM: The Natural Solution for Pain. Berkley Publishing.

¹⁸ Engelke, U. F. H., Tangerman, A., Willemsen, M. A. A. P., et al. (2005). Dimethyl sulfone in human cerebrospinal fluid and blood plasma confirmed by one-dimensional ¹H and two-dimensional ¹H-¹³C NMR. NMR in Biomedicine, 18(5), 331–336.

¹⁹ Jacob, S. W., & de la Torre, J. C. (2015). Dimethyl Sulfoxide (DMSO) in Trauma and Disease. CRC Press.

Additional Sources

Cowan, T. S. Human Heart, Cosmic Heart. Chelsea Green, 2016.

Cowan, T. S. Cancer and the New Biology of Water. Chelsea Green, 2019.

Lester, D., & Parker, D. What Really Makes You Ill? Why Everything You Thought You Knew About Disease Is Wrong. Independently published, 2019.

Purdey, M. Animal Pharm: One Man’s Struggle to Discover the Truth about Mad Cow Disease and Variant CJD. Clairview Books, 2007.

Lovelock, J. E. The Ages of Gaia: A Biography of Our Living Earth. Oxford University Press, 1988.

Lovelock, J. E. The Revenge of Gaia. Penguin, 2006.

Price, W. A. Nutrition and Physical Degeneration. Price-Pottenger Nutrition Foundation, 1939.

Unbekoming. DMSO: The Persecuted Molecule. (Author’s book on DMSO.)

The Microbiologist. “The smell of the sea: how microbes shape Earth’s sulfur story.” Feature article, 2025.

Chemistry World. “The secrets of the sulfur cycle.” Feature article.

Germ theory has a test.

The Controlled Human Infection Model. Take the alleged pathogen from a sick person, transfer it to a healthy person by whatever route the theory says is sufficient, and observe whether the healthy person becomes sick.

Where the test has been run honestly, across every major disease attributed to microbial contagion, it has failed. Smallpox. Measles. Influenza. Yellow fever. HIV. SARS-CoV-2. Healthy volunteers deliberately exposed do not fall ill at the rates the theory predicts. They do not fall ill at all.

No Contagion is the catalogue of that failure. 258 controlled human infection experiments spanning three centuries — the studies germ theory’s defenders do not cite, the ones published and then quietly forgotten. Each entry documents the pathogen, the method, the exposure route, the number of subjects, and the outcome.

I’ve been a supporter of Jamie’s work long before I interviewed him last year — that interview turned out to be the most-read one I published in 2025. His research on contagion already existed as a long Substack piece. When I proposed bringing it to life as a printed book, I was over the moon that he agreed. My part was to publish and shape it into a book you can hand to someone. Then I wrote the foreword.

That was the point: to be the book you can put in front of a family member, a friend, and say “read this.” A physical book on a coffee table is not a tweet. It doesn’t get you the reflexive “conspiracy theorist” dismissal that anything online now attracts. It’s a book. It has an index. It has appendices. It reads like a reference. Because that’s what it is.

There is no shortage of books making the case against vaccination anymore. But too many of the good people leading that fight remain trapped inside the iron grip of virology and its evil twin, contagion. That is why this book matters. That is why I was so motivated to do it with Jamie.

The Index of Diseases at the front lets a reader look up any specific disease — measles, polio, chickenpox, whooping cough, cholera, HIV — and jump straight to the studies that tested it. Grouped under three headings: What medicine calls Viruses, then Bacteria and Parasites.

The two case appendices at the back — developed for this edition — go deep on the two most-cited epidemics in the germ theory record. Appendix I documents the connection between polio and the arsenic-DDT pesticide era, 1869 to 1960 — a pesticide-poisoning history sold as a viral epidemic. Appendix II covers the 1918 flu — First World War chemical warfare and the Rockefeller Institute’s meningitis vaccine trial at Camp Funston. The “what actually happened” answer for the two events germ theory keeps pointing to.

Jamie wrote his own launch post yesterday from his side of the collaboration — read it here.

The book is on sale now, print only, ships worldwide in 3-5 business days:

Buy No Contagion on Lulu

Buy one to keep. Buy one to give away.

In 1908, a Russian physician published a novel in which a Martian astronomer, in the course of arguing for the extermination of Earth’s population, made the following observation about socialism: any regime established in isolated countries surrounded by a hostile capitalist sea would be “perverted deeply and for a long time to come by years of encirclement, unavoidable terror and militarism, and the barbarian patriotism that is their inevitable consequence.” Nine years later, the Bolshevik Revolution took place. Twenty years later, Stalin’s consolidation fulfilled the description almost exactly. The novel was Red Star, and its author was one of the original twenty-two Bolsheviks Lenin had gathered in Switzerland four years earlier to build a disciplined revolutionary group. The Indiana University Press edition of 1984, edited by Loren R. Graham and Richard Stites, collects Red Star, its 1913 prequel Engineer Menni, and a 1924 poem sketching a third novel Bogdanov never completed.

Alexander Bogdanov (1873–1928) took his medical degree in 1899 after studying science and psychology in Moscow and Kharkov. By that point he had already moved from Populism into Marxism and was working in the underground network of the Russian Social Democratic Party. Among the Social Democrat leaders he was one of the best informed about actual factory conditions inside Russia, having spent the years 1904 to 1907 running the underground cells while Lenin remained in emigration. He broke with Lenin over both philosophy (his embrace of Ernst Mach’s epistemology in a system he called empiriomonism) and tactics (his insistence that armed uprising remained possible after 1907). Lenin answered the philosophy in the polemical Materialism and Empiriocriticism (1908). The tactical dispute ended their partnership permanently. Bogdanov went on to teach at the Capri school for workers with Gorky and Lunacharsky, to write the three-volume Tektology now cited as an early sketch of cybernetics and systems theory, and in 1926 to found the Institute for Blood Transfusion. He was written out of the official Bolshevik story after his death and not reprinted in the Soviet Union for nearly fifty years.

The novel appeared in the aftermath of the failed 1905 Revolution, at a moment when the Tsarist regime had answered a nationwide uprising with martial law, drumhead trials, punitive expeditions, and the massacre of the radical wing. Bogdanov saw what superior military technology could do against insufficiently armed forces, and his tactical quarrel with Lenin over whether the revolution was over drew him toward the writing of a utopia. The Russian science fiction of the period was already crowded with visions of Mars, drawing on Giovanni Schiaparelli’s canali observations and Percival Lowell’s Mars and Its Canals (1906). Kurd Lasswitz had brought large-eyed Martians to Earth in 1897; H.G. Wells had published War of the Worlds in 1897–98; Konstantin Tsiolkovsky was publishing on space flight in the same years. What Bogdanov added to this tradition was a fully worked communist utopia on the red planet, complete with a Central Institute of Statistics that computed labor requirements hour by hour and broadcast them on shifting display boards at every factory. Beneath that surface, without announcement, he installed a second story about the problems the utopia had not solved.

Bogdanov’s political defeat did not end his influence, which arguably grew more consequential after 1928 than during his life. Tektology, his proposed universal organisational science, is now cited by systems theorists as the precursor to Ludwig von Bertalanffy’s General Systems Theory and Norbert Wiener’s Cybernetics. He devised Input-Output Analysis, the technique for tracking circulatory flows through a system, decades before Wassily Leontief received a Nobel Prize for its formal development. A version of the Gaia Hypothesis appears in his work long before Lovelock formalised it. I came to Bogdanov through the work of esc, whose Substack has documented the continuous line from Bogdanov’s twin projects (Tektology as the science of organisation, Proletkult as the cultural and educational arm) to the contemporary machinery of Adaptive Management embedded in pandemic planning, environmental policy, supply chain governance, urban planning, and the Digital Twin architecture of the Fourth Industrial Revolution. What esc calls “second-order Marxism,” the embedding of Marxist analytical principles into scientific, systemic, and institutional structures rather than their explicit teaching, is precisely the framework Bogdanov proposed to Lenin as an alternative to violent class struggle. Lenin rejected it. Its principles now run through the pipeline connecting the ICSU (now the ISC) to UNESCO to the school curriculum. The utopian architect who lost the political fight quietly won the organisational one.

Bogdanov’s acknowledged place in the historical record remains his role as the founder of Soviet science fiction. Darko Suvin has called him the progenitor of the entire genre, whose 1920s explosion produced roughly two hundred works largely reworking his themes; Zamyatin’s We (1920) is an emphatic repudiation of the utopia, Alexis Tolstoy’s Aelita an inversion.

The full summary unpacks the material behind the 1908 prophecy of encirclement-perverted socialism; the dystopian second layer of the Martian utopia (radioactive fuel depletion, forests destroyed for minerals, suicide clinics generated by medical life extension, tragedy as the planet’s favorite dramatic form); and the extermination debate in which the astronomer Sterni argues for the annihilation of Earth’s population and Netti replies with what Graham reads as an early ecological defense of irreplaceable biological and cultural diversity. On April 7, 1928, Bogdanov exchanged his own blood with that of a young student suffering from malaria and tuberculosis, continuing to take clinical notes on his own condition until the last minutes of his life. It was one day after Stalin’s Central Committee plenum on the Shakhty trial, which prosecuted engineers along the lines Bogdanov’s Engineer Menni had described as “wrecking” fifteen years earlier.

Read more

Author’s Note

This essay operates in two registers. When examining what the establishment claims, I use its vocabulary (virus, isolation, contamination, promoter) to show where the establishment’s own evidence contradicts its story. When stating my own view, I use terrain language. The body is a self-healing organism poisoned by four things: toxic exposure, nutritional depletion, electromagnetic radiation, and psychological strain. Injection of foreign biological matter is toxic exposure of the most direct kind. Cancer is what happens when the cell’s internal environment is corrupted by that exposure. SV40, in both its imagined and manufactured forms, is a mechanism for delivering that corruption.

Two groups argue online about SV40, and neither has the whole story.

One group says SV40 is imaginary. A monkey virus that was never isolated and never shown to cause disease. The other waves plasmid maps and points to Kevin McKernan’s laboratory findings of “SV40 promoter sequences” inside Pfizer mRNA vials, and calls the first group unhinged.

Sasha Latypova, a former pharmaceutical industry executive who has spent the last four years documenting the manufacturing fraud behind the covid injections, has done something more useful than pick a side. She has explained what both groups are actually looking at.¹

The natural monkey virus called SV40 was never isolated. The bubbles the Merck scientists photographed in 1960 and named “vacuolating virus” were cellular debris in a dying culture of the wrong species of monkey. Nothing was purified from a sick person and shown to cause disease.

The chemical compound sold today under the label “SV40 promoter” is an industrial construct. It has almost nothing in common with the 1960 bubbles except the name. It is a stack of synthetic DNA sequences built on ceramic beads through automated washes of acids, solvents, and corrosive reagents, designed to force a target cell into rapid, chaotic division.

Both truths point in the same direction. The story of SV40 is the story of an industry that learned how to manufacture cancer by injection and built a regulatory framework to protect the practice.

Audio Deep Dive (for Paid Subscribers)

Two Things Are Being Called SV40

The confusion is entirely upstream of the science. It sits in the word itself.

When people say “SV40,” they might mean one of two things.

The first meaning is historical. A monkey particle allegedly discovered in 1960 by Merck scientists Ben Sweet and Maurice Hilleman, which they called “vacuolating virus” because it caused foamy bubbles (vacuoles) in the kidney cells they were poisoning. This is what Herbert Ratner and Michele Carbone would later look for in preserved 1955 Salk polio vaccine vials.¹

The second meaning is chemical. A class of synthetic DNA constructs designed decades later to drive cells into rapid division. This is what Kevin McKernan detected in Pfizer mRNA vials in 2023. McKernan, a geneticist whose laboratory ran the first independent sequencing of the covid injection contents, found the sequences at nanogram-to-microgram quantities per dose. This is a product of chemical manufacture, not a biological entity.

The two things do not share a lineage. The chemical was not extracted from the monkey. The chemical was designed. Once the functional effects of the 1960 “bubbles” were experimentally described (irritation, rapid division, abnormal cellular structures), laboratories began building synthetic constructs that would produce those same effects on command. Today’s SV40 promoter is a chemical tool, sold by biotech supply catalogs, with a family tree that runs through automated DNA synthesis equipment and not through any monkey.¹

Both of the arguing groups are right about their own object. One is right that no natural monkey virus was ever isolated. The other is right that a chemical labeled “SV40” exists and turns up where it should not. Both truths damn the establishment story. Neither truth requires the other.

Peyton Rous and the Prize for a Population Weapon

To understand where SV40 comes from, follow the Nobel money back to 1911.

Peyton Rous, a young pathologist at the Rockefeller Institute in New York, was handed a Plymouth Rock hen with a sarcoma. He minced the tumor, passed the extract through a filter fine enough to remove all visible cells, and injected the cell-free filtrate into healthy chickens. Some of them developed tumors.²

Rous concluded that an invisible causative agent had been transmitted. He himself hedged, conceding in his 1911 paper in the Journal of Experimental Medicine that “an agency of another sort is not out of the question.”² Mark Bailey, reviewing the paper more than a century later, points out that Rous did not isolate anything, and that his own control experiments (which used unfiltered tumor material) produced larger tumors than the filtered version. The experiment demonstrated something simpler than a viral agent. It showed that diseased tissue introduced by an unnatural route into another animal can cause that animal to exhibit a similar disease process.²

The finding was ignored as a curiosity for over half a century. Then, in 1966, the Nobel Committee awarded Rous the Prize in Physiology or Medicine. What had changed was not the evidence. What had changed was the industry.

By the mid-1960s the pharmaceutical sector had discovered the marketing power of the phrase “cancer-causing virus.” If cancer had a viral agent, then a vaccine could be developed. If a vaccine could be developed, patents could be filed. If patents could be filed, indemnified markets could be captured. Rous’s Prize was the seal on an industrial hypothesis, and it launched a search that continues to consume public research budgets to the present day.

The mechanism Rous had described was straightforward once stripped of viral framing. Introduce cell-free filtrate (ground-up organs and tumors passed through a fine filter) into the bloodstream or organs of another animal by injection, and that animal’s cells will do what cells do when foreign biological matter reaches them. They will attempt to expel the material. In the process some of them will divide chaotically, and some of those divisions will produce tumors.

Rous had discovered how to induce cancer by injection. The industry called it a virus and gave him a Prize.

Bernice Eddy and the Mouse Experiments

Bernice Eddy is often remembered as a public health heroine. She was the government scientist at the U.S. National Institutes of Health who, in 1954, warned her superiors that Salk’s polio vaccine was paralyzing test monkeys. She was ignored. The vaccine was released. Within weeks children began developing polio from the injections.³

The rest of Eddy’s work is quieter in the historical record and more important. Through the late 1950s she injected mice with ground-up organs of other mice known to contain leukemia, and she observed the development of aggressive, unrelated tumors. Cancers that appeared faster and struck younger animals than anything seen in nature.

Sasha Latypova reads Eddy’s work through a colder lens. A brick does not know what building it is holding up. That is the point of compartmentalization, and it is how large research apparatuses are organized. In the 1950s the U.S. government’s biologics division sat inside a broader research apparatus that also funded covert chemical and biological weapons programs. Eddy worked inside that apparatus. The stated purpose of her mouse experiments was to find the cause of cancer so that a cure could be developed. The operational reality was that she was building the mechanism for inducing cancer reliably, aggressively, and at younger ages, by injection.

Eddy may have been sincere in the stated purpose. That does not change what her results were used to build. Her mouse experiments were preserved and scaled by an industry that had been given the marketing hypothesis (cancer-causing virus) and the regulatory infrastructure (mass vaccine rollout) to deploy them. The brick did its job. The building went up.¹

Eddy did whistleblow, in her limited way, when she found that the Salk vaccine was causing tumors in test hamsters. She was silenced by her superiors and forced out of polio research. The work she did on inducing tumors by injection did not stop. It became the foundation of an industry.

What Merck Actually Photographed in 1960

This is where the first argument (no natural virus was ever isolated) becomes concrete. The original 1960 paper by Sweet and Hilleman is a peculiar document. It declared the existence of a previously undetectable monkey virus and named it “vacuolating virus SV40.” SV stood for “simian virus.” The 40 was for the fortieth such alleged agent cataloged.¹

Two features of the paper deserve close attention.

First, the alleged virus was not detected in the monkey species it was said to infect. Rhesus monkey kidney cells (the substrate on which Salk’s polio vaccine was grown) did not display the effect. Instead, the effect appeared when material from those cells was inoculated onto kidney cells of a different monkey species. Grivet monkeys. African green monkeys. In these cells the cultures developed vacuoles, foamy bubbles that Merck interpreted as evidence of viral replication.¹

Second, the Merck team ran no control experiments. They did not perform the same procedure on cultures that had never been exposed to Salk material. They did not test whether the vacuolation was produced by the culture conditions themselves, by the starvation and antibiotic poisoning and mechanical trauma that make up the standard virology protocol. Sasha Latypova reads the methods section plainly. What Merck produced was foam in dying cell cultures.¹

Foam is what breaking cells do. When cells are starved, poisoned, and mechanically disturbed, they release internal contents, form vesicles and vacuoles, and eventually disintegrate. This process is called cytopathic effect in the virology literature, and it is attributed to viral invasion. The same process occurs, at identical rates, in cultures that have never been exposed to any patient material. Stefan Lanka has demonstrated this with control experiments that produced the “measles virus” cytopathic effect using nothing but the standard laboratory poisoning protocol.⁴

The 1960 Merck paper established the existence of “SV40” the same way virology has established every alleged virus. By declaring cellular breakdown to be a biological entity. The “vacuolating virus” was cellular debris in a dying culture.

That declared entity, foam in the wrong species of monkey, was then used to justify sixty years of cancer research, and eventually to name the synthetic construct McKernan would detect in the covid injections.

The Ratner Vials and the Carbone Analysis

The Ratner-Carbone finding is where the two arguments start to look like they might collide. Herbert Ratner, director of the Oak Park Health Department in Illinois, kept a small cardboard box of Salk vaccine vials in his refrigerator from 1955 until his death. He was one of the few figures in American public health who did not trust the vaccine, and he preserved the vials because he suspected that whatever was in them would need to be examined by future generations who had not been captured by the story.³

In 1997, Ratner gave some of the vials to Michele Carbone, a molecular pathologist. Carbone tested them using PCR, a technique that did not exist in 1960 and one that has significant limitations. What Carbone found, published in 1999, was that the 1955 vials contained two versions of “SV40.” One with a single 72-base-pair enhancer sequence, one with two.¹

Two problems with Carbone’s finding are worth stating directly.

The first is methodological. Testing biological material that has sat in a refrigerator for forty-four years is not testing what was originally in the vial. Whatever process of degradation, contamination, and interaction occurred over four decades produced the material Carbone tested. What Carbone found in 1999 is not necessarily what Ratner had put in his refrigerator in 1955.

The second problem is deeper. PCR does not detect whole organisms. It works by looking for short fragments of nucleic acid that match a reference sequence programmed into the test. When a laboratory says it “found SV40” in a sample, what it means is that it found sequences that match a database entry labeled “SV40.” The database entry itself was assembled from earlier PCR runs on earlier cultures, tracing back eventually to the 1960 Merck bubbles. The whole chain rests on the assumption that a real organism corresponds to the database sequence. If no such organism ever existed, PCR is chasing an echo of an assumption.¹

What Carbone actually demonstrated is that the 1955 vials contained genetic material matching an established laboratory reference. That is a real finding. It does not establish that a natural monkey virus existed. It establishes that whatever chemical, biological, or degradation products were in the Salk vaccine vials produced sequences resembling the reference. That is enough to indict the vaccine, a vaccine that was administered to tens of millions of Americans between 1955 and 1963 and to millions more worldwide. What was in it is not what the public was told was in it.

The children of Niles, Illinois, eight of whom developed leukemia in the years after their 1955 vaccinations, knew this before anyone had the tools to test for it.³

What Schaeffer Actually Demonstrated

Standard oncology places the cause of cancer in the cell nucleus. Damaged DNA, activated oncogenes, mutations accumulated over years, all located, as the theory has it, in the genetic code. This framing has consumed sixty years of federal cancer research budgets and produced little clinical improvement.

Two experiments in the late 1980s should have ended the genetic theory. Warren Schaeffer at the University of Vermont and Jerry Shay at UT Southwestern independently performed nuclear transfers between cancerous and healthy cells.⁵ The design was straightforward. Take the nucleus of a cancer cell, containing all the mutated DNA supposedly driving the cancer, and transplant it into a healthy cell whose own nucleus had been removed. Do the reverse. Observe.

Cancerous nucleus in healthy cytoplasm produced one tumor out of sixty-eight recipient cells. Healthy nucleus in cancerous cytoplasm produced cancerous cells ninety-seven percent of the time.

The disease was not in the nucleus. It was in the cytoplasm, the watery, mitochondrial, structured interior of the cell where division actually takes place. The mechanism by which that interior loses the electrical charge and gel-phase structure that respiration requires is developed at length in What Is Cancer? in this series, drawing on Cowan, Pollack, Warburg, and Riddick.⁶ For present purposes, only the endpoint of that chain matters. When the cytoplasm loses its structure, mitochondria cannot respire. Cells shift to fermentation. The body walls off the region. The wall is what medicine calls a tumor.

Sasha Latypova has read Schaeffer’s experiment for what it actually shows.¹ Seyfried cites it as evidence for his metabolic theory of cancer. He does not ask what property of the transferred material produced the ninety-seven percent effect. Latypova asks. What Schaeffer did, mechanically, was introduce foreign cytoplasmic material across the membrane of a healthy cell (proteinaceous debris, damaged organelles, fragments of no identified provenance). The recipient cell attempted to expel what it could not identify as its own, divided haphazardly in the process, and passed the compromised state to its descendants. This is a model of transfection. Schaeffer performed it with a pipette and cancerous cytoplasm. An injection performs it with a needle and whatever is in the vial.

The lipid nanoparticle platforms industrialize this. LNPs were built to solve the very problem Schaeffer’s setup addressed manually: the cellular barriers that historically limited how much injected material reached the cytoplasm. The stated design purpose of the platform is transfection.⁷ What Schaeffer’s experiment demonstrated is what a cell does after transfection has occurred. His result was the tumor.

The “SV40 promoter” sequences McKernan detected are not incidental contaminants. They are functional tools. Their purpose in manufacturing is to force cells to import and process the surrounding chemical cargo. Their effect on a living cell, once injected, is to do the same thing at scale. Every recipient cell that took up an LNP performed the Schaeffer transfer on itself. What pathologists began reporting in 2021 is the population-scale endpoint of that operation.¹

The mainstream position calls this an unfortunate contamination. The mechanism suggests something more direct.

What “Synthetic SV40” Actually Is

This is what the second argument (SV40 exists as a chemical in the vials) is pointing to. The modern SV40 construct is not a virus. It is not even biology. It is a specific stack of chemical residue on a ceramic bead.

Sasha Latypova has provided the clearest description of oligonucleotide manufacturing to appear in general circulation. The process bears no resemblance to any biological event. It resembles semiconductor manufacturing, and it uses some of the same equipment.¹

The synthesis begins with a small ceramic bead that carries one of four starting molecules, described as the “letters” of DNA. The bead is subjected to sequential chemical washes in a fully automated reactor. Each wash adds one more molecule to the growing chain.

The reagents used at each step are all industrially hazardous. Trichloroacetic acid in dichloromethane serves as the deprotection wash, a corrosive acid combined with a carcinogenic solvent. Tetrazole and its derivatives activate the coupling step, all explosive or flammable and all classified as respiratory irritants. Acetic anhydride and N-methylimidazole cap the unreacted chains, both causing severe skin burns on contact. Iodine dissolved in water, pyridine, and tetrahydrofuran oxidizes the phosphate backbone, the latter two being flammable carcinogens. Final cleavage is performed with ammonium hydroxide, sometimes combined with methylamine, both severely corrosive.¹

The chain grows through hundreds of these wash cycles. Each one adds one base while contributing measurable error rates. Manufacturers claim per-step efficiency of 99 to 99.5 percent. Compounded across hundreds of steps, that efficiency collapses.

After 10 bases, roughly 90 percent of the resulting molecules are correct. After 50 bases, roughly 60 percent. After 100 bases, roughly 37 percent. At 200 bases, the typical length of a commercial building block, the fraction of perfectly-formed molecules is a minority. The rest are errors. Partial chains, mis-inserted bases, side reactions with the toxic solvents that leave chemical modifications no one intended and no one tests for.¹

The “SV40 promoter” delivered in mRNA injections is a sequence roughly 500 base pairs long, assembled from multiple smaller fragments and stitched together using PCR. Each fragment carries its own error distribution. The final construct is a chemical soup of intended sequence, misassembled variants, and impurities from every solvent used in every wash. This is what is being injected into people, alongside the surrounding lipid nanoparticle payload, at concentrations several orders of magnitude above anything that would ever appear from a biological source.

The oligonucleotide industry sells these constructs for laboratory use with explicit disclaimers that they are not for medical purposes. Even when a manufacturer claims cGMP (current good manufacturing practice) compliance, the guarantee typically covers only 60 to 70 percent of the product shipped. The regulatory pathway that allowed such material to be injected into hundreds of millions of people during the covid rollout is documented in Sasha’s earlier work on the U.S. Department of Defense contracts and the PREP Act indemnification structure.¹ ⁷

The relevance for SV40 is precise. Whatever effects the modern “SV40 promoter” produces in a recipient’s cells (cellular irritation, forced import of foreign chemical material, aberrant division, disruption of cellular architecture) are produced not by a virus but by a stack of industrial chemicals with declared carcinogenic and toxic properties, delivered directly to the cytoplasm and nucleus by design.

The mainstream story asks whether there is SV40 contamination in the mRNA injections. The correct question is what this chemical is, what it does to cells, and why it is being injected into anyone at all.

The Closed Loop

The pattern that emerges once the pieces are placed side by side is not a series of accidents.

Peyton Rous demonstrates in 1911 that injecting cell-free filtrates of ground tumor tissue produces tumors in recipient animals. The industry names his finding a virus. Bernice Eddy in the 1950s establishes that injecting cellular material from leukemic mice produces aggressive tumors in unrelated tissues in healthy mice. The Salk polio vaccine, grown on monkey kidney cells, is administered to over a hundred million people. Sweet and Hilleman at Merck, in 1960, find “SV40” in the vaccine. Foam in the wrong species of monkey, declared to be a virus, quietly acknowledged behind closed doors, publicly denied. The vaccine is left on shelves for another eighteen months while a substitute is prepared. The 1955 vials are almost all destroyed. The children of Niles begin developing leukemia. Herbert Ratner keeps his refrigerator running.

The Rous Nobel Prize is awarded in 1966. The cancer-causing-virus framework becomes the organizing hypothesis of cancer research for the next half-century. Federal research dollars flow into virus hunting. The chemical structure of the “SV40” construct is worked out through the 1970s and 1980s. By the 1990s the sequence is available in laboratory supply catalogs as a promoter tool. Automated DNA synthesis technology, developed alongside the semiconductor industry, allows manufacturers to produce the construct on demand.

The covid mRNA injections, developed under U.S. Department of Defense contracts and delivered to billions of people worldwide, contain synthetic SV40 promoter sequences at concentrations that surprised even the researchers who found them. Regulators acknowledge the presence of the sequences and decline to act on the finding. The PREP Act, passed in 2005, protects the manufacturers from liability. Judges have ruled that the presence of undeclared toxic ingredients in vaccine vials does not constitute willful misconduct, because it is the U.S. government’s policy to permit those ingredients to be there.¹ Sasha Latypova has argued that the amplification of the SV40 story itself serves to focus outrage on Pfizer while shielding the U.S. Department of Defense program that produced the injections.¹

The loop is closed. What Rous demonstrated with a syringe and a chicken has been industrialized. Injection of foreign biological and chemical material into healthy people produces cancer, at scale, in a population that has been told the injections prevent disease. The Nobel Prize identified the mechanism, the industry scaled it, and the regulatory apparatus protected the whole arrangement.

What Is Being Delivered Now

What the pathologists are calling turbo cancer is what this mechanism looks like at population scale. Aggressive tumors in young patients, multi-focal presentations, recurrences within weeks of surgery: the pattern falls out of the same causal chain, compressed onto a shorter timeline. SV40 is not the whole input. The Diblasi analysis published in 2024 cataloged fifty-five other undeclared chemical elements in the injectables, twelve of the fifteen lanthanides among them. The fuller mechanistic and clinical picture is developed in What Is Turbo Cancer? in this series.⁸

The word “SV40,” first attached to bubbles in a dying monkey kidney culture, later attached to a synthetic chemical designed to force cellular division, is what ties the historical origin to the present product.

Both groups arguing online are right about the piece of the story they can see. The natural monkey virus never existed. The synthetic chemical does exist and is now inside a substantial fraction of the world’s population. Neither fact is the whole picture. The whole picture is that “cancer-causing virus” was a marketing invention that grew into a manufacturing capability, and the population is the market.

The document is publicly available. The signatures are on it. The mechanism was published in 1911. The children of Niles were the first cohort. They were not the last.

How To Explain It To A 6 Year Old

Imagine a story with two versions.

In the first version, a scary monster is hiding inside your body. You cannot see it. Scientists say they found it long ago in some monkeys, and it might give you cancer. They want to make a medicine to fight it.

In the second version, there was never a monster. What the scientists found in the monkeys was just broken pieces of the monkeys themselves, because the scientists had poisoned the monkey cells to make them break. They mistook the broken pieces for a monster.

But here is the strange part. The scientists took what they thought was the monster shape, and they built something new. A real chemical, made in a factory, still called by the monster’s name. When they mixed this factory chemical into other medicines, it made cells go wild and grow into lumps.

The monster was never real. The factory chemical is real, and it is being put into things and given to people. Both things are true at the same time. That is what makes the story confusing, and that is what this essay is about.

References

¹ Sasha Latypova, “’SV40’: How to turn bubbles into a vaccine injury cover up and a multi-billion industry, too,” Due Diligence and Art, July 2026. See also Latypova, “The SV40 Promoter in Covid Injections,” September 2023, and “Breaking: Pfizer is going under the bus...,” October 2023, for the argument that the SV40 discourse itself has been amplified as a Pfizer-focused distraction from the broader Department of Defense program. See also Latypova, “Is cancer a metabolic disease? Critical review of Dr. Thomas Seyfried’s presentation,” Due Diligence and Art, April 2026, for the transfection reading of the Schaeffer cytoplasm-transfer experiment.

² Peyton Rous, “A Sarcoma of the Fowl Transmissible by an Agent Separable from the Tumor Cells,” Journal of Experimental Medicine, 1911. Analysis by Mark Bailey in A Farewell to Virology (Expert Edition), September 2022, and in Mark Gober, Sam Bailey, Mark Bailey, and Stefan Lanka, An End to Upside Down Medicine, Waterside Productions, 2023.

³ Helen Ratner Dietz, “Salk vaccine cover-up resonates today,” Oak Leaves, July 20, 2005. See also Torsten Engelbrecht, Claus Köhnlein, Samantha Bailey, and Mark Bailey, Virus Mania, third edition, 2021.

⁴ Stefan Lanka, control experiments on the measles virus cytopathic effect, documented in Mark Gober et al., An End to Upside Down Medicine, Waterside Productions, 2023.

⁵ Israel BA, Schaeffer WI, “Cytoplasmic suppression of malignancy,” In Vitro Cellular & Developmental Biology, 1987;23(9):627–632. Howell AN, Sager R, “Tumorigenicity and its suppression in cybrids of mouse and Chinese hamster cell lines,” Proceedings of the National Academy of Sciences, 1978;75(5):2358–2362. See also Thomas Seyfried, Cancer as a Metabolic Disease, Wiley, 2012, for the broader metabolic framework in which the Schaeffer experiment is typically cited.

⁶ Unbekoming, “What Is Cancer? An Essay on the Warburg Shift, the Cytoplasm, and the Particle in the Vial,” Lies are Unbekoming, July 2026.

⁷ Sasha Latypova, extensive documentation on the covid-19 countermeasure programs, U.S. Department of Defense contracting, PREP Act indemnification, LNP platform design, and manufacturing quality failures, published across Due Diligence and Art, 2022 through 2026.

⁸ Unbekoming, “What Is Turbo Cancer? An Essay on the Cocktail in the Vial, the Cation Charge State, and the Cancer That Is Not New,” Lies are Unbekoming, July 2026.

Additional Sources

Michele Carbone and colleagues, “SV40-Like Sequences in Human Bone Tumors,” Oncogene, 1996. Carbone and Ratner analysis of preserved 1955 Salk vaccine vials, published 1999.

B.H. Sweet and M.R. Hilleman, “The Vacuolating Virus, S.V. 40,” Proceedings of the Society for Experimental Biology and Medicine, 1960.

Kevin McKernan, “Sequencing of bivalent Moderna and Pfizer mRNA vaccines reveals nanogram to microgram quantities of expression vector dsDNA per dose,” Anandamide Substack, 2023.

Otto Warburg, “On the origin of cancer cells,” Science, 1956.

Thomas Cowan, Cancer and the New Biology of Water, Chelsea Green, 2019.

Thomas Cowan and Sally Fallon Morell, The Contagion Myth, Skyhorse, 2020.

Dawn Lester and David Parker, What Really Makes You Ill?, independently published, 2019.

Christopher Exley, “The toxicity of aluminum in humans,” Morphologie, 2016.

Herbert Shelton, Natural Hygiene articles on vaccination and anaphylaxis.

Lida Mattman, Cell Wall Deficient Forms: Stealth Pathogens, CRC Press, 2000.

Diblasi J, et al., “True or False? At Least 55 Undeclared Chemical Elements Have Been Detected by ICP-MS in COVID-19 ‘Vaccines,’” International Journal of Vaccine Theory, Practice, and Research, 2024.

Sixteen teachers in a single California school. Eighteen cancers between them. The cohort was 137, hired between 1988 and 2005. When the classrooms were tested, levels of high-frequency voltage transients — what Magda Havas and her colleagues call “dirty electricity” — were far above what should exist on a clean 60-hertz sine wave. The study was published in 2008, has never been repeated, and is one of many pieces of evidence Dr. Havas has spent the last three decades assembling.

She came to electromagnetic pollution from acid rain. Her fieldwork in the Canadian Arctic and at Hubbard Brook, and her role as Science Advisor to the Canadian Coalition on Acid Rain, helped pass the 1985 Eastern Canadian Acid Rain Program that cut sulphur dioxide emissions by 30%. When the lakes began recovering faster than expected, she went looking for the next problem. She found dirty electricity in the wiring, radiofrequency radiation from wireless technology, and ground current from unbalanced distribution systems — and has since published over 200 papers on how these exposures affect blood sugar in diabetics, heart rhythm in adults exposed to 2.4 GHz cordless phones, cognitive function in firefighters working under cell towers, and behaviour in schoolchildren. The environmental variable she has spent thirty years documenting is real. What it does inside any given body depends on what that body is already carrying.

The regulatory sequence she describes is familiar. Asbestos, lead, mercury, DDT, PCBs, CFCs, glyphosate, tobacco — each time the same pattern. Industry-funded advisory bodies counsel governments. Governments counsel doctors. Doctors counsel patients. Legislation trails the damage by decades. What follows is the specific evidence: the studies, the mechanisms, the schools where installing filters produced measurable improvements in teacher health within six weeks, and the practical steps any reader can take today. Her strongest recommendations cost nothing.

With thanks to Dr. Magda Havas.

1. Your career has covered everything from acid rain in the Canadian Arctic to electromagnetic pollution in classrooms. Can you walk us through that journey and what connected one chapter to the next?

Both acid rain and electromagnetic radiation (EMR) are types of environmental pollution, which is what I study as an environmental toxicologist. Acid rain was controversial in its hay day as is EMR today. I’m drawn to controversial issues because it implies that the science isn’t yet definite or at least not widely accepted. It provides a challenge and I enjoy scientific challenges.

2. For someone who’s never heard the term, how would you describe “dirty electricity” in plain language, and where is it most likely lurking in a typical home?

The analogy I use it that dirty electricity is like dirty water that is contaminated by chemicals, bacteria or particulate. Clean electricity is a smooth sine wave, whereas dirty electricity is contaminated with something called high frequency voltage transients (HFVT) or Intermediate Frequency (IF) Radiation. It is generated by electronic devices like computers, smart meters, energy efficient lighting, dimmer switches, treadmills, solar power, wind turbines and arching on powerlines. It is virtually ubiquitous but there is relatively little research on the biological effects of dirty electricity. DE is a form of electromagnetic interferences (EMI) that is well known among electricians and electrical engineers. Surge suppressors were used to protect your computer from these “surges” and now we have capacitive filters that short out these higher frequencies and purify the electricity. Audiophiles use power conditions to improve the quality of music on their stereos and to protect their equipment.

3. You made a significant pivot in the 1990s from established environmental toxicology into a much more contested area. Was there a specific moment, patient story, or piece of data that convinced you this was worth staking your reputation on?

I made a pivot because we had clean air legislation that reduce sulphur dioxide emissions in both Canada and the United States in the 1990s. For a few years I studied the recovery of lakes in Ontario, which occurred much more quickly than expected, and I realized that one of the reasons I was doing this research was to improve air quality. We were successful and I lost interest in continuing with air quality research. I was looking for another challenge, and I stumbled across electromagnetic fields. At the time, several studies suggested that children who lived near powerlines had a greater risk of developing cancer. I began to read the research and found it was at an early stage with lots of scientific disagreement. It took me three years before I came to the conclusion that the risk to children was real and that was after I devoured the literature not only on childhood cancer but on cancers and occupational exposure, the role of natural EMFs, the healing potential of EMFs. I then started research on DE, ground current and microwave radiation generated by wireless technology. I began to work with people who were intolerant of EMFs trying to understand the mechanisms involved. I didn’t view this a “staking my reputation”. I was simply curious–a very useful trait of young children, scientists and those with an inquiring mind.

4. Some of your most surprising findings involve diabetes — people reportedly needing less insulin once their electrical environment was filtered. How did you first stumble onto that link, and how do you explain what might be happening biologically?

I was working with a power quality expert, Dave Stetzer in Wisconsin, who was prediabetic. He told me his blood sugar increased when he was working on powerlines. From a scientific perspective this was an ideal opportunity since we can objectively measure blood sugar but can’t control it voluntarily. I began to work with both type 1 and type 2 diabetics and published our findings. When someone is stressed, their body releases sugar for action (fight or flight). For non-diabetics the insulin kicks in and reduces the excess sugar if it is not needed. Diabetics have difficulty with their insulin so the sugar remains elevated for longer periods and can be measured. (Link: https://pubmed.ncbi.nlm.nih.gov/18568931/ )

5. Your school studies, from the La Quinta cancer cluster to schools in Minnesota and Ontario, keep returning to vulnerable populations. What patterns kept showing up across very different schools that made you think you weren’t seeing coincidences?

The La Quinta cancer cluster was research done by Milham and Morgan showing that teachers in classrooms with high levels of dirty electricity had a greater incidence of various types of cancers. It was the first study of its kind and hasn’t yet been repeated. (Link: https://pubmed.ncbi.nlm.nih.gov/18512243/ )

I had just published research on electric and magnetic field levels in the downtown core of 60 cities/town in Ontario that was reported in the Toronto Star. A woman in Toronto read the article and began to tell me about her daughter who was attending a private school in Toronto and who became ill by noon and had to go home. This woman mentioned that there were “filters” that reduced dirty electricity and she purchased these filters for her home and had remarkable results from a health perspective for all family members include her two dogs who were much better behaved.

She contacted the principal of the school and asked if she could plug filters in the school to protect her daughter. She contacted me to see if I would be willing to do a study at the school because she believed that others would also benefit from these filters. I was sceptical but agreed to conduct a study because she was a mom who was ready to go the extra mile for her daughter and because from a scientific perspective, either the filters worked or they didn’t and we could document this. Either response was useful from a scientific perspective. When it was time to analyse the data collected daily during a 6-week period I couldn’t believe the results. Back then (2003) we believed that approximately 3% of the population was sensitive to electromagnetic pollution. We would need to test at least 100 teachers with 3 or more reacting positively to accurately test the teachers. However, in our test only 19 teachers responded enough days for us to assess the results. Instead, what we found is that approximately 30% to 40% of the teachers had a net positive response when the filters were plugged in. In other words, their health, energy and mood improved substantially. Student behaviour also improved especially in the elementary grades.

(Link: https://www.electricalpollution.com/documents/WWcolour.pdf )

I then learned about a school in Wisconsin that had sick building syndrome. They eventually tested for power quality and found high levels of DE in the school because of the computers and fluorescent lighting. When the School Board installed these filters, teacher and student health both improved. (Link: https://stetzerelectric.com/how-melrose-mindoro-school-district-restored-health-and-learning-by-eliminating-dirty-electricity/ )

We then repeated the study in 3 Minnesota schools with more teachers, better monitoring of the DE and more filters and had the same results we got for the Toronto school. Teacher health improved for about 35% of the teachers and student behaviour improved especially in elementary and middle school, less in high school. So, we had evidence from schools in three different locations all with similar results. This was a game changer and that led me to do more research with diabetics and people who had MS. (link: https://www.sciencedirect.com/science/article/abs/pii/S0048969708004634 )

6. You ran a double-blind, peer-reviewed study showing cordless phones could trigger heart arrhythmia. For a curious but skeptical reader, can you explain how a double-blind setup actually works in this kind of research and why that design matters so much?

I began to work with people who told me they were sensitive to wireless technology. Several mentioned that it affected their heart with either irregular or very rapid pulse. Once again, this is something we can objectively measure. Our first study was in Colorado with 25 volunteers only some of whom believed they were sensitive. We used the base station of a cordless phone that generates 2.4 GHz frequencies (same as WiFi). Forty percent of the subjects experienced some changes in their HRV attributable to digitally pulsed (100 Hz) MW radiation. For some the response was extreme (tachycardia), for others moderate to mild (changes in sympathetic nervous system and/or parasympathetic nervous system). and for some there was no observable reaction either because of high adaptive capacity or because of systemic neurovegetative exhaustion. In other word, their nervous system was so dysfunctional they were unable to respond to a physiological stress. Here is a link to a follow-up study with HRV. (Link: https://esmed.org/MRA/mra/article/view/2605 )

Double-Blind Aspect; There is something called a placebo effect and a nocebo effect. Both involve the thoughts of a person influencing how they feel/respond to a “treatment”. If we told those who perceive themselves as being “sensitive” that we were now going to expose them to microwave radiation, this could–by itself–cause a physiological reaction.

Example: Consider someone sitting in a dark room and they perceive something coiled near their foot. They think it is a snake and their heartbeat increases immediately. When they turn on the lights, they realize it is a coiled rope, and their heartbeat and blood pressure begins to return to normal.

By keeping the subject blinded (i.e., they don’t know when they are being exposed) they are unable to respond psychologically. This would be considered a single-blind study.

However, when researchers are interpreting the results of individuals, if they don’t know when that person is exposed, they can remain objective. For most studies, ideally both the subject and researcher should be blinded, and this is called a double-blind study. Dr. Marrongelle who is a HRV expert and who has conducted hundreds of thousands of tests with his patients was blinded to their exposure.

7. Mainstream bodies like the WHO and ICNIRP have generally taken a more cautious position on health effects from non-ionizing radiation at everyday exposure levels. How do you engage with that disagreement, and what do you wish more of your scientific colleagues understood about your work?

I would not use the term “cautious”. I would use to term “favourable to the industry”. The “experts” at ICNIRP are known to be pro-industry. Many of them either work or are funded by industry. The WHO has drifted from its fundamental role of protecting the public. They receive funding from Bill Gates (pro-industry) and quite recently the U.S. has decided to defund the WHO for failing to do their job.

Also, when it comes to any environmental pollutant, pro-industry agencies try to deflect from the real problem to prevent legal action and to maintain their market advantage. This happens repeatedly. Asbestos, lead, mercury, DDT, PCBs, CFC, glyphosate, food additives, smoking are all examples of this and, as a result, appropriate and protective legislation is delayed for decades. Sadly, there is nothing new about this.

Scientists with different areas of expertise and medical doctors who have not been taught about the harmful effects of environmental toxins turn to our government agencies for advice and the advice they are given is pro-industry and anti-health.

8. Electromagnetic hypersensitivity is one of the most debated parts of this field — some studies suggest symptoms don’t reliably track with actual exposure when people are blinded to it. How do you respond to readers who’ve encountered that critique?

Many of the “provocation” studies that have been conducted have failed to consider the following:

• Was the person being tested exposed to EMFs on their way to the clinic/lab where the testing was done?

• Were all forms of EMFs (RFR, dirty electricity, low frequency electric and magnetic fields) minimized in the test environment? This is seldom the case. Even having fluorescent lights turned on can trigger responses in sensitive individuals even when their exposure to cell phone radiation is being test.

• How quickly do people respond? Some respond immediately while others have a delayed response. In our HRV study, we measured ONLY immediate responders and hence some of those we labelled “non-responders” may also be sensitive, but the testing didn’t allow for that.

• How quickly do people recover from exposure. Once again, it could be immediate and, in some cases, it could take hours, day and even weeks to recover. That is why the first bullet is important and why provocation tests are often not sufficiently sensitive to identify EHS.

• Do those with EHS know when they are exposed to EM pollution? Some do but most don’t. Knowing whether you are exposed isn’t a criterion for detecting EHS, yet many of the provocation studies use this as “lack of evidence”.

9. You helped draft Resolution 15 for the International Association of Firefighters, opposing cell towers on fire stations. What was happening with firefighters specifically that made this issue feel urgent and unmistakable to them?

Increasingly the telecom industry has been placing cell towers on the top of firehalls. This exposes those in the firehall to an environmental toxin. Dr. Gunnar Heuser, MD did SPECT brain scans on fire fighters and found abnormalities. The firefighters complained of confusion, short-term memory loss, inability to focus, migraine headaches, slowed reaction time insomnia, “brain fog”, infertility, depression, tremors and vertigo. Image a firefighter working and trying to save lives in a burning building with even one of those symptoms other than infertility. These symptoms place the firefighter, his/her colleagues, and the job they are trying to do a risk. We presented a short lecture to Canadian firefighters at the Boston meeting and after our lecture, the firefighters lined up to share with the presenters privately their symptoms that they were unwilling to share with their union because they feared for their jobs. Here is more information. (Link: https://mdsafetech.org/2019/09/28/firefighters-fighting-fires-and-now-cell-towers/ )

10. For a reader who finishes this interview wanting to do something today, what are the simplest, no-cost changes anyone can make in their home to lower their exposure before they spend a dollar on equipment?

The bottom line is the electrosmog is a pollutant and we need to minimize our exposure as much as possible. The www.electrosensitivesociety.com provides many tips that are free and some that require a small investment. I list some of them here: Link: https://www.electrosensitivity.co/practical-advice-1.html

1. You yourself

• Do not use a cellphone (mobile phone) or Bluetooth.
  Use a land-line telephone instead.

• Do not use an iPad or tablet with wireless switched on.
  Make sure the wireless is switched off; use only cable connections.

• Do not use virtual home assistants, such as Amazon Echo, Alexa or Google Home, especially if there are children, pregnant women or elderly people in the home.
  Instead use cabled devices without wireless.

2. Your home and office

• Do not use a cordless (DECT) phone.
  Use a wired phone with a landline instead.

• Do not have a wireless smart meter fitted.
  Keep an analogue one without wireless.

• Do not have WiFi
  Use cables or DLAN plugs instead (but keep away from the wiring).

• Remove as many electrical devices from your sleeping area and near your bed as possible.
  Avoid having clock radios and chargers near your bed.
  Do not use an electric blanket while in bed.
  Keep your sleeping area free of electromagnetic exposure.

• Do not use virtual home assistants, such as Amazon Echo, Alexa or Google Home, especially if there are children, pregnant women or elderly people in the home.
  Instead use cabled devices without wireless.

3. Your environment and housing area

• Avoid living near a cellphone tower or phone mast, including apartments below roof antennas.

• Avoid living near neighbours with WiFi and wireless smart meters or ask them to replace wireless devices with wired ones.

• Avoid living near an airport with radar in your direction.

• Avoid living near overhead power cables, mains supplies or substations.

4. Your daily activities

• Avoid where possible all schools, medical centres, shops, buses, trains and aircraft with WiFi.
  Wear protective clothing if necessary.

11. If someone does decide to measure and filter, how would you advise them to prioritize? Is it the bedroom where they sleep, the room a child uses, the home office, somewhere else entirely?

You identified the most important areas in your home. Electromagnetic hygiene in the areas where you spend the most amount of time.

12. After more than 370 presentations in over 30 countries, what’s the most stubborn misconception about this topic that you find yourself correcting again and again?

It is not so much a “topic” but rather an “attitude”. Scepticism is healthy. A closed mind is not. When I encounter the later, I disengage in the conversation as it is a waste of time.

13. Your acid rain advocacy helped push through legislation that cut sulfur dioxide emissions by 30%. Do you see a realistic policy pathway for electromagnetic pollution, and what would a sensible first step look like in a country like Canada or the US?

Yes, and I’m very hopeful that Bobby Kennedy, who is currently the Secretary at Human and Health Services (HHS) will alter policy regarding wireless technology in particular. President Trump, with the help of Kennedy, recently brought in policy to reduce the current number of vaccines injections in children. This was an election promise. Kennedy has advocated for a very long time about electromagnetic pollution as well. He has two more years to fulfill that promise and I am very hopeful he will succeed.

14. You officially retired from teaching at Trent in 2018, but by all accounts you’re as busy as ever. What questions or projects are taking up most of your attention right now, and is there anything you’re working on that readers should keep an eye out for?

I love what I do … learning and teaching … so yes, I’m as busy as ever in retirement. An area of research we did not discuss is my work with beneficial electromagnetic applications as it is NOT all bad news. Some types of EMFs are beneficial including light therapy and PEMF therapy (pulsed electromagnetic fields).

We just completed several studies that I’m excited about.

• One is with bees. Here is the link to the publication: https://www.tandfonline.com/doi/full/10.1080/15368378.2026.2644215 We placed a purewave magnetic disc in bee hives and it improved their resilience and their over winter survival. The bee hives with the disc were calmer and required fewer queen bee replacements.

• Sheena Symington (Director of the Electromagnetic Society) and I just completed some research on Auricular Chromotherapy (ACT) that help people dealing with trauma and anxiety resolve their issues. In this research light is shone on the ear at acupuncture points that relate to memory and emotions. The method takes just a few minutes with remarkable success rate. Here is a link to the article we just published: https://townsendletter.com/auricular-chromotherapy-act-for-anxiety-and-trauma/

• In the past few years, we have published articles on PEMF therapy for

  • reducing symptoms of arthritis (Centurion, link: https://juniperpublishers.com/ntab/NTAB.MS.ID.555571.php)

  • improving health of the autonomic nervous system, (Seqex link: https://esmed.org/MRA/mra/article/view/3208)

  • reducing pleural effusion after open heart surgery (ONDAMED link: https://www.researchgate.net/publication/322903832_Case_Study_Pulsed_Electromagnetic_Field_PEMF_Therapy_Relieves_Pleural_Effusion_Following_Open_Heart_Surgery

15. For readers who want to follow your research, read the studies you’ve referenced today, or get in touch directly, what’s the best way for them to stay connected with your work?

They can visit my websites:

www.magdahavas.com for the harmful effects of electrosmog

www.theroselab.com for the beneficial effects of PEMF and Light therapy

www.youtube.com/magdahavas for educational videos

I can be reached at drmagdahavas@gmail.com

Author’s Note: When examining the mainstream framework, I use its vocabulary because the argument requires meeting the establishment on its own ground. In my own voice, the twelve events treated here are not manifestations of disease. They are the body’s intelligent responses to insult, whether toxic exposure, nutritional depletion, electromagnetic burden, or sustained stress. The response is the healing. Suppression of the response is the pathology.

The Pharmacy Shelf

Herbert Shelton, in 1964, identified suppression of the body’s elimination and self-defense as “the most frequent cause of death.”¹

Every over-the-counter shelf in every pharmacy on earth is a monument to the position that sentence opposes.

Tylenol lowers the fever, Advil the swelling, Robitussin the cough, Imodium the diarrhea, Zofran the vomiting, hydrocortisone the rash, Sudafed the mucus, Adderall the fatigue, Marinol the missing appetite, Lasix the retained fluid, oxycodone the pain, paroxetine the night sweats. Every one of them works, meaning every one of them successfully stops what the body is trying to do.

The premise underneath the entire product category is identical: the symptom is the disease, and suppression is the treatment. If the premise is correct, modern pharmacy is a triumph of applied science. If the premise is wrong, modern pharmacy is the most extensive iatrogenic disaster in human history, systematically interrupting the body’s repair processes and converting acute events into chronic conditions.

The premise is wrong.

The Framework

The body does not make mistakes. When damaged by toxic exposure, nutritional depletion, electromagnetic exposure, or sustained stress, it initiates an intelligent response designed to restore homeostasis. Vomiting expels stomach contents. Diarrhea flushes the intestine. Fatigue reallocates energy from muscular activity to internal repair. Appetite loss frees the digestive system so its resources can be redirected. Every mechanism is designed to protect the organism, and every one produces symptoms.

Shelton articulated the acute-to-chronic sequence with characteristic directness. An insult damages tissue. The body responds with elimination or repair, producing symptoms. Those symptoms are suppressed with drugs, which add their own toxic burden to what was already present. New symptoms emerge in response and are suppressed in turn. Over time the cumulative burden exceeds the body’s capacity to eliminate. What was acute becomes chronic, then progressive, and the patient is placed on lifelong medication.²

Constantine Hering, working in the nineteenth century, documented the directional signature of the process. Genuine healing proceeds from interior to exterior, from above downward, from more critical organs to less critical. Suppression runs the pattern in reverse: from surface to interior, from mild to serious, from less critical structures to more critical ones. Each round of suppression drives the underlying disorder to a deeper location, where it re-expresses itself as what medicine reads as a new and unrelated condition.³

The mechanism is not theoretical. It operates with clinical predictability across the twelve categories catalogued below. Each is the body doing exactly what it should do. Each has an industry organized around stopping it.

1. Fever

When Matthew Kluger placed lizards with acute febrile illness on a temperature gradient in the 1970s, the sick lizards crawled to the warm end and stayed there. Their body temperature rose. When Kluger prevented them from reaching the warm end, or administered fever-suppressing drugs, they died at higher rates than the lizards allowed to run their fever.⁴ The finding has held across decades and species. Fever is not the disease; it is the response.

Robert Mendelsohn, a pediatrician who spent decades warning parents about the excesses of his own profession, documented what the mainstream pediatric literature has recorded. Fevers arising from ordinary illness do not exceed 106°F, because the body maintains internal mechanisms that prevent dangerous elevation.⁵ The febrile convulsions that terrify parents are triggered by the rate at which the temperature rises, not by the peak it reaches. By the time the parent notices the child is hot enough to be concerned, the rapid rise has already occurred and the seizure risk has passed. Mendelsohn attributed the prescription of fever reducers in this context to a specific motive: reassuring the parent that the doctor has intervened, at the cost of interrupting what the fever was accomplishing.

The mechanism is metabolic. Elevated temperature enhances enzymatic reactions, mobilizes stored waste, and drives the body’s effort to expel accumulated toxic material. Thomas Cowan attributes therapeutic power to heat itself: anything one can do to heat the cellular gel and allow it to cleanse itself through fever moves the body toward healing.⁶ William Coley documented tumor regression in cancer patients who developed acute febrile illness, and later provoked fever with bacterial toxins to reproduce the effect.⁷ The Natural Hygiene tradition summarized it plainly: fever is Nature’s bonfire.⁸

The pharmaceutical response is antipyretic. Acetaminophen (Tylenol, paracetamol) is the most widely used drug on earth. Its mechanism of action was not fully understood for over a century, and it operates in part by depleting cellular glutathione, the master antioxidant the body uses for detoxification. That depletion is the mechanism by which acetaminophen produces acute liver failure. It is now the leading cause of acute liver failure in the United States and the United Kingdom.⁹

Aspirin lowers fever by inhibiting prostaglandin synthesis. When given to children during acute febrile illness, it triggers Reye’s syndrome, a condition affecting the brain and liver with a fatality rate historically approaching thirty percent. Approximately ninety percent of pediatric Reye’s cases were associated with aspirin use before the practice was formally discontinued.¹⁰ Aspirin was never withdrawn from the market; the recommendation for pediatric use was revised while the drug remained available for adults.

Ibuprofen (Advil, Motrin) operates by the same prostaglandin-blocking mechanism, with documented harms including gastrointestinal bleeding, kidney damage, and elevated cardiovascular risk.¹¹

The cost of the suppression is not the drug’s toxicity alone. When the fever is chemically abolished, the body’s clearing effort is chemically abolished with it. Metabolic acceleration, waste mobilization, and the elevated temperature assisting cellular repair all shut down together. The patient feels better. The insult that provoked the fever remains, unaddressed, waiting.

2. Inflammation

Inflammation is a hydraulic event. Herbert Shelton reduced it to mechanical reality: an increase in blood supply to a circumscribed area of the body, producing the four classical signs of heat, redness, swelling, and pain.¹² The purpose is delivery. Blood carries repair materials to damaged tissue. When the damage is repaired, the volume normalizes and inflammation resolves.

Cowan offered a metaphor that carries the mechanism cleanly. Inflammation is demolition. Before the body can build new tissue at a damaged site, it must clear the damaged material. Inflammatory mediators dissolve what shouldn’t be there. The redness, swelling, heat, and pain are the demolition in progress. Suppress the demolition and no rebuilding follows.¹³

The pharmaceutical response is the largest single drug category in medicine. NSAIDs (ibuprofen, naproxen, aspirin, diclofenac, celecoxib) constitute a market valued at over twenty-two billion dollars annually.¹⁴ Corticosteroids (prednisone, dexamethasone, hydrocortisone) suppress inflammation systemically at the cost of muscle wasting, bone thinning, elevated blood glucose, and adrenal dependence. Biologics prescribed for conditions labeled autoimmune, including Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab), generated $238 billion in lifetime revenue for Humira alone before biosimilar competition began eroding its dominance.¹⁵

Vioxx (rofecoxib) is the case study that ought to have ended the industry. Between 1999 and 2004, the COX-2 inhibitor produced an estimated 88,000 to 139,000 heart attacks in the United States, with a fatality rate between thirty and forty percent. FDA scientist David Graham, testifying to the Senate Finance Committee, called it “a disaster unparalleled” in American history.¹⁶ Vioxx, an anti-inflammatory drug prescribed to suppress the body’s repair response in arthritic joints, killed tens of thousands.

Every drug in the anti-inflammatory class carries documented harm. Methotrexate is a chemotherapy agent repurposed as maintenance for rheumatoid arthritis; azathioprine was developed to suppress organ rejection after transplantation; TNF-alpha inhibitors carry FDA-mandated black-box warnings for lymphoma, serious infections, and heart failure. The cascade of drug additions that follows (a hepatoprotectant to counter methotrexate, a bisphosphonate to counter corticosteroid bone loss, a proton pump inhibitor to counter NSAID stomach damage) is the mechanism by which a single inflammatory condition becomes a multi-drug, multi-organ, chronic patient profile.

3. Mucus

Mucus is a transport medium. The respiratory tract lines itself with mucus continuously and increases production when irritants must be captured and expelled. Daniel Roytas, reviewing the mainstream respiratory literature, documented what occurs during cold and flu-like illness. Mucus membranes release inflammatory chemicals including histamine and bradykinin. Both chemicals produce the classic cold symptoms of nasal congestion, sneezing, sore throat, and cough when inoculated experimentally into the airways of healthy individuals.¹⁷

The purpose is elimination. Roytas: sick people experience fevers and sweat profusely to excrete waste through the skin, and the respiratory mucus response operates on the same principle.¹⁸ Historical use of snus, powdered tobacco taken nasally to induce sneezing and mucus flow, was a deliberate application of the principle. The mucus is the mechanism by which the airways stay clear.

D.C. Jarvis, the Vermont country doctor who documented four decades of observing farmers and their animals, recorded the mechanism in dairy cows. Cows presenting with wet eyes, wet noses, and excess mucus stopped producing it when their potassium was corrected by adding apple cider vinegar to their feed. The eye, nose, and cough manifestations were the body’s spontaneous effort to shed excess water, and supplying the needed potassium through the ration corrected the underlying imbalance that had produced the load.¹⁹ The mucus was doing its job. What needed correction was what had provoked it.

The pharmaceutical response is antihistamines and decongestants. First-generation antihistamines including diphenhydramine (Benadryl) block histamine at H1 receptors and cross the blood-brain barrier, producing sedation. A 2015 University of Washington study led by Shelly Gray found that cumulative anticholinergic burden, of which first-generation antihistamines are a major source, correlated with elevated incidence of dementia and Alzheimer’s disease.²⁰ Second-generation antihistamines including loratadine (Claritin), cetirizine (Zyrtec), and fexofenadine (Allegra) reduce sedation but retain the underlying suppressive mechanism.

Decongestants operate by vasoconstriction. Pseudoephedrine (Sudafed) constricts the swollen nasal blood vessels, providing symptomatic relief while raising blood pressure systemically. Phenylephrine, marketed as the safer alternative after pseudoephedrine restrictions, was determined by an FDA advisory committee in September 2023 to be ineffective at labeled oral doses. Billions of doses were sold for decades with no measurable decongestant effect.²¹

The cost of the suppression is retention. Mucus that was carrying irritants out of the respiratory tract is chemically prevented from doing so. Shelton’s mechanism: the acute catarrhal response, repeatedly suppressed, becomes chronic catarrh, then ulceration, then the conditions labeled allergic rhinitis, chronic sinusitis, and hay fever.²

4. Diarrhea

Diarrhea is emergency elimination through the intestine. Shelton stated it with characteristic economy. A poison is taken into the stomach, the organism senses the presence of a non-usable and harmful substance, and it acts. The material is sent out by vomiting, or sent along the digestive tract into the colon and expelled by violent diarrhea.²² The intestinal wall pours fluid into the lumen, peristalsis accelerates, and toxic material is flushed out before it can be absorbed.

The response is not restricted to ingested food-borne toxins. Chemical residues from pharmaceuticals, pesticide contamination, heavy-metal exposure, and toxins in contaminated water all provoke acute diarrhea as protective response. The WHO attributes diarrheal conditions to germs infecting via the fecal-oral route. Lester’s response is direct: diarrhea is a symptom not a disease, and it is the body’s reaction to toxic substances such as fecally contaminated water, representing its efforts to expel them.²³

The pharmaceutical response is loperamide (Imodium), diphenoxylate (Lomotil), and bismuth subsalicylate (Pepto-Bismol). Loperamide acts on opioid receptors in the intestinal wall, slowing peristalsis and reducing fluid secretion into the lumen. The material the body was attempting to expel is retained and absorbed. Loperamide overdose, particularly among individuals seeking opioid effects, has caused sudden cardiac death through QT prolongation, prompting FDA warnings in 2016 and dosage restrictions in 2018.²⁴ Diphenoxylate operates by the same opioid slowing; bismuth subsalicylate shares aspirin’s salicylate mechanism and toxicity.

The cost of the suppression is absorption of what the body determined must not be absorbed. Whatever toxin, chemical, or waste material provoked the diarrhea remains in the intestinal tract, in contact with the absorptive surface, for the additional hours or days the drug retains it there. The bowel movement stops. The exposure continues.

5. Vomiting

Vomiting is emergency elimination through the stomach. The reflex is centrally coordinated, involving the brainstem, autonomic nervous system, and the diaphragm and abdominal musculature. It is not a malfunction; it is one of the body’s most rapid and effective defensive mechanisms.

Signals that trigger vomiting include ingested toxins, pharmaceutical residues, motion perception mismatches, elevated intracranial pressure, and metabolic disturbance. Morning sickness during pregnancy may represent protective response to substances the developing fetus would be sensitive to, a hypothesis with empirical support from the epidemiology of pregnancy outcomes.

The pharmaceutical response is antiemetic. Ondansetron (Zofran) blocks serotonin 5-HT3 receptors in the gut and central nervous system. Its use in pregnancy for morning sickness was widespread despite the drug’s FDA-listed cardiac risks, including QT interval prolongation and Torsades de Pointes. Ondansetron has been associated with congenital cardiac malformations in exposed pregnancies in multiple observational studies, though the manufacturer’s position and regulatory classification have varied.²⁵

Promethazine (Phenergan), a first-generation antihistamine prescribed for nausea, carries a black-box warning against use in children under two for respiratory depression and can cause tissue necrosis when given intravenously.²⁶

Metoclopramide (Reglan) increases intestinal motility centrally, forcing material downward against the body’s decision to expel it upward. Long-term use produces tardive dyskinesia, an irreversible movement disorder, resulting in a black-box warning and successful class-action litigation.²⁷

The cost of the suppression is retention of the material the body identified as unacceptable. What was to be expelled is forced to remain, and the signal that initiated the vomiting is still active in the body.

6. Skin Eruptions

The skin is an elimination organ. Henry Bieler articulated the principle: when bile poisons in the blood come out through the skin, various skin irritations follow.²⁸ When primary elimination routes such as liver, kidneys, and bowel are overloaded, the body attempts elimination through secondary routes. Toxins deposit in tissues, and the body mounts an inflammatory response to dissolve the deposits and push them outward, producing the rashes, hives, boils, and pustules visible at the surface.

Childhood eruptive illnesses labeled measles, chickenpox, and rubella were understood in the Natural Hygiene tradition as elimination events. John Tilden: measles is the manner in which a child’s body throws off toxemia.²⁹ The rash was diagnostic evidence that the elimination was proceeding correctly through the skin. Traditional practice was to keep the child warm, hydrated, and rested until the elimination completed.

Contact dermatitis, eczema, and acne have documented associations with specific toxic exposures. NIOSH recognizes dermal exposure to hazardous agents as a cause of both localized skin disease and systemic toxicity;³⁰ WHO documentation confirms that industrial solvents applied to skin become systemically available in considerable amounts.³¹ The personal care products, textiles, and household cleaners a person contacts daily are the vector.

The pharmaceutical response is topical and systemic corticosteroids. Hydrocortisone, the mildest, is available over the counter. Prescription strengths ascend through triamcinolone, betamethasone, and clobetasol. All operate by suppressing the inflammatory response, stopping the elimination event visible at the skin surface. Documented harms include skin thinning (atrophy), telangiectasia (visible capillaries), striae (stretch marks), and adrenal suppression from systemic absorption.

Topical steroid withdrawal syndrome is the mechanism through which chronic use produces dependence. When the drug is stopped, the suppressed elimination event returns with greater intensity. The accumulated toxic burden the drug had held back is now released, producing severe rebound eruptions. Patients are told they have “steroid withdrawal syndrome” or that their underlying eczema has worsened, and are placed back on the drug at higher potency.³²

The cost of the suppression is retention of the material the skin was expelling. When Bieler’s bile poisons cannot come out through the skin, they remain in the tissues, migrate to other sites, or overwhelm the primary elimination organs the body was trying to relieve.

7. Fatigue

Fatigue is enforced rest. When the body’s repair burden exceeds its available energy, it reallocates. Muscular activity is limited, cognitive activity is reduced, appetite drops, freeing digestive energy for repair, and the individual is pulled toward sleep. Shelton: complete rest is the greatest therapeutic measure, because slowing the expenditure of energy accelerates the recruiting of energy for restorative work.³³

Christopher Gian-Cursio described the mechanism in the Hygienic Review in 1942. A sick person needs not only sleep sufficient to balance daily expenditure but sleep beyond that, to facilitate curative action. During sleep, and to a lesser degree while resting, the body makes its greatest advances in removing the immediate causes of disease.³⁴

The suppression takes multiple forms. Prescription stimulants including amphetamine salts (Adderall), lisdexamfetamine (Vyvanse), methylphenidate (Ritalin, Concerta), and modafinil (Provigil) force wakefulness and activity by pharmacologically overriding the body’s demand for rest. All produce dependence. All produce cardiovascular effects including elevated blood pressure and heart rate. Long-term amphetamine use is associated with cardiomyopathy, stroke, and sudden cardiac death.³⁵

The suppression extends past prescription drugs into industrial-dose caffeine (approximately 300 milligrams daily for the average American, more from energy drinks), nicotine, and the widespread pattern of combining caffeine with analgesics.

Medical culture participates. Patients presenting with unexplained fatigue are frequently tested, imaged, and referred. If no discrete disease is identified, they are told they have chronic fatigue syndrome, given SSRIs, or advised that stress management is the issue. What they are almost never told is what Shelton wrote in 1964: the fatigue is the body’s demand for rest sufficient to complete the repair, and the appropriate response is to grant it.

The cost of the suppression is denial of the repair the fatigue was requesting. The insult that provoked the fatigue continues. The energy that should have gone to repair is instead expended on forced activity. When the individual finally collapses, the accumulated damage has been compounded by months or years of drug-driven overexertion.

8. Appetite Loss

Loss of appetite during illness is not a defect. It is a coordinated instruction. The digestive process requires substantial energy in the form of blood flow to the gut, enzyme production, motility, and hepatic processing, and during illness that energy is required elsewhere. The body reduces demand for it by reducing hunger. Fasting during illness allows resources to be reallocated to repair and elimination.

Cowan set out the metabolic mechanism. The body shifts into a catabolic state after twelve hours without food, breaking down stored fat and mobilizing toxins previously sequestered in tissue. Any impairment involving deposition, whether atherosclerotic plaque, joint calcification, or tissue deposits, is served by regular time in this catabolic state. When illness is present, the body prioritizes the shift, which is why appetite falls at the onset of nearly every acute condition.³⁶

The traditional practice in Natural Hygiene sanatoriums was extended fasting during acute illness. Ulric Williams noted the pattern: hunger returns as the signal that elimination is complete, when the tongue clears and natural hunger emerges.³⁷

The pharmaceutical response has multiple angles. Mirtazapine (Remeron) is an antidepressant with pronounced weight-gain effects, prescribed off-label as an appetite stimulant. Megestrol acetate (Megace) is a synthetic progestogen prescribed for cachexia in cancer and AIDS, with documented risks including thromboembolic events and adrenal suppression. Dronabinol (Marinol) is synthetic THC prescribed for AIDS-associated anorexia. Cyproheptadine (Periactin) is an antihistamine repurposed for pediatric appetite stimulation.

The cultural response is more consequential than any single drug. Hospitalized patients who lose their appetite are pressured to eat, given nutritional supplements such as Ensure and Boost that are high-sugar processed formulations, and progressed to nasogastric or intravenous feeding if resistance continues. The medical logic is that the body cannot heal without nutrition. The terrain logic is that the body cannot heal while digesting.

The cost of the suppression is diversion of resources. The energy the body allocated to repair and elimination is instead consumed by digestion of food it did not want. Elimination stalls. Recovery is prolonged. In the extreme case, a cancer cachexia patient force-fed high-caloric formula while chemotherapy proceeds, the body’s final effort to conserve resources for essential function is chemically overridden, and the patient dies from the intervention rather than the underlying condition.

9. Coughing

Coughing is airway clearing. The cough reflex is a coordinated action of the diaphragm, abdominal muscles, and glottis producing an explosive expulsion of air designed to move material out of the respiratory tract. The material may be mucus containing captured particulates, aspirated food or fluid, inhaled irritants, or debris from damaged tissue. Without the cough reflex, the lungs cannot remain clear.

Shelton was direct about the consequences of interference. If coughing is checked by the depression of the nerves of respiration that follows the taking of certain drugs, the substances in the respiratory tract that the coughing was intended to remove are left there to produce the very harm their removal would have prevented.³⁸ The suppression is not neutral. It leaves the material in the lungs.

The pharmaceutical response is cough suppressants. Dextromethorphan (Robitussin DM, Delsym, NyQuil) acts centrally on the cough center in the medulla. It is the most common over-the-counter cough suppressant and is subject to widespread abuse at high doses for dissociative effects. Codeine and hydrocodone-containing cough syrups suppress the cough reflex by opioid mechanism, producing dependence and respiratory depression. Benzonatate (Tessalon) has caused fatal cardiac arrhythmia in children after accidental ingestion.³⁹

The cost of the suppression is retained material in the airways. The body’s mechanism for clearing the lungs is disabled while the reason for the mechanism, the particulate, the irritant, the mucus load, remains in place. The acute cough that would have cleared the lungs in days becomes chronic, then bronchial, then pneumonic. Pneumonia in hospitalized patients frequently follows cough suppressant administration for what began as acute upper respiratory illness. Postoperative pneumonia is common enough that respiratory therapists are employed specifically to encourage coughing, breathing exercises, and airway clearance, a hospital service that exists because the drugs the hospital administered are known to compromise the mechanism.

10. Swelling

Swelling is fluid mobilization. When tissue is damaged, the body dilates capillaries and increases fluid delivery to the site, producing the visible swelling that is one of the four classical signs of inflammation. When systemic conditions produce fluid retention, whether from cardiac inefficiency, kidney impairment, liver stress, or protein imbalance, the fluid accumulation may represent the body’s response to compromised circulation or accumulated metabolic waste. In each case, the fluid is present because the body directed it there.

Ankle edema in an elderly patient may reflect impaired venous return, dietary sodium excess, cardiac inefficiency, or the toxic burden of accumulated pharmaceutical residues. Joint swelling reflects the inflammatory demolition event described earlier: extra blood volume delivering repair materials to damaged tissue.

The pharmaceutical response is diuretic. Furosemide (Lasix) is a loop diuretic acting on the kidney’s water-reabsorption mechanism, forcing rapid excretion of water and sodium. Its immediate effect is visible. Swelling reduces, urine output increases, weight drops. Its ancillary effects include depletion of potassium, magnesium, and other electrolytes, with cardiac and neuromuscular consequences. Chronic Lasix use damages hearing (ototoxicity) and kidney function.⁴⁰ Hydrochlorothiazide (HCTZ), the thiazide prescribed for hypertension, depletes electrolytes on the same principle; spironolactone spares potassium but disrupts hormone signaling, producing breast development in men and menstrual irregularity in women.

The cost of the suppression is disruption of the body’s fluid regulation. The swelling was the body’s response to a specific condition; the drug removes the fluid without correcting the condition. The underlying insult continues, and electrolyte depletion adds new burdens on cardiac and renal function that were already stressed. Elderly patients on chronic diuretic therapy are among the most drug-burdened cohorts in medicine, with the drug prescribed to counter the visible sign of a condition the drug does not address.

11. Pain

Pain is the body’s most direct communication. The nociceptive system alerts the organism to tissue damage, restricts movement of the injured part to permit repair, and imposes behavioral consequences that discourage further damage. Shelton: pain, redness, swelling, heat and impairment of function are the local response to injury, all due to the excess of blood at the site.⁴¹ Pain is the sensory dimension of inflammation. Without it, the individual would continue damaging the injured tissue.

The mechanism is instruction, not information. Pain enforces the rest and immobilization that permits repair to proceed. A sprained ankle hurts because walking on it would prevent healing; abdominal pain from an intestinal insult enforces the fasting the digestive tract requires; chest pain from cardiac stress halts exertion. Pain is the body giving orders.

The pharmaceutical response is the largest documented catastrophe in modern medicine. Opioids including oxycodone (OxyContin), hydrocodone (Vicodin, Norco), morphine, fentanyl, and tramadol produced over 500,000 overdose deaths in the United States between 1999 and 2019, according to CDC accounting. The Sackler family’s Purdue Pharma marketed OxyContin as non-addictive on the basis of a single misinterpreted paragraph from a 1980 letter to the New England Journal of Medicine, generating over $35 billion in sales and initiating the epidemic that continues at the time of writing.⁴²

NSAIDs (ibuprofen, naproxen, celecoxib) suppress pain by inhibiting prostaglandin synthesis, with the cardiovascular, gastrointestinal, and renal toxicity discussed under inflammation. Acetaminophen suppresses pain by mechanisms including glutathione depletion, with liver toxicity discussed under fever. Gabapentinoids (gabapentin/Neurontin, pregabalin/Lyrica) were originally approved for seizure disorders and were subsequently marketed off-label for chronic pain, generating billions in revenue and a growing catalog of documented harms including sedation, edema, cognitive impairment, and dependence.⁴³

Beyond the drug toxicity, the suppression removes the body’s instruction. A patient with pharmaceutically silenced pain from a damaged joint continues to use it, and a patient with suppressed back pain returns to the activity that provoked the injury. The pain that was designed to enforce healing is chemically silenced, and the underlying condition worsens under the drug’s cover.

Cowan’s inverse approach to arthritis illustrates the alternative. Bee venom stings are administered directly to the inflamed joint, intensifying the inflammation and driving the demolition phase to completion. When the swelling resolves, the joint is better than before the sting.¹³ The pain was the mechanism of repair; permitting it allows the repair to complete, while suppressing it allows the damage to accumulate.

12. Night Sweats

Sweating is skin-based elimination. The skin is the body’s largest organ, and it is bidirectional. It absorbs toxins and it expels them. When elimination through the primary channels of bowel, kidney, and lung is inadequate to the toxic burden, the skin takes up secondary elimination duty. The moisture carries waste out through the sweat glands.

Roytas is direct on the mechanism. Sick people experience fevers and sweat profusely to excrete waste through the skin.¹⁸ Night sweats, the drenching sweat episodes that wake patients with soaked bedding, represent the body’s elimination effort proceeding during rest, when digestive and muscular demands are minimal and the elimination systems can operate at capacity.

Medicine treats night sweats as a workup trigger, testing systematically for cancer (lymphoma), endocrine dysfunction (hyperthyroidism), and the conditions labeled infectious (tuberculosis, HIV, endocarditis), as well as menopause. The differential diagnosis approach misses the shared mechanism. In every case, the body has determined that skin-based elimination is required.

The pharmaceutical response varies by attributed cause. Menopausal night sweats are treated with hormone replacement therapy (estrogen, progestin), SSRIs (paroxetine/Paxil, escitalopram/Lexapro), SNRIs (venlafaxine/Effexor), gabapentin, and clonidine. Hormone replacement therapy was pulled back after the Women’s Health Initiative demonstrated elevated risks of breast cancer, heart disease, stroke, and dementia in long-term users.⁴⁴ SSRI use in perimenopausal women is associated with weight gain, sexual dysfunction, and withdrawal syndromes on discontinuation.

Anticholinergic drugs (oxybutynin, glycopyrrolate) block sweat gland function directly, chemically closing the elimination route. Long-term use carries the same dementia risk demonstrated with first-generation antihistamines.²⁰ Botulinum toxin (Botox), one of the fastest-growing pharmaceutical categories for this indication, is injected into sweat glands to paralyze them for months at a time. The route is disabled rather than closed, but the effect on skin-based elimination is the same.

The cost of the suppression is retention. Waste material the body was expelling through the skin remains in the tissues. Primary elimination systems, already overloaded (which is why the skin was recruited), must attempt to handle the additional burden. The nighttime sweating stops. The toxic burden that provoked it continues to accumulate.

The Cascade

The twelve mechanisms operate simultaneously. In a real patient, an acute illness rarely presents as a single symptom. A respiratory event labeled viral produces fever, mucus, cough, fatigue, and appetite loss in the same person. A gastrointestinal event produces vomiting, diarrhea, fatigue, and appetite loss together. An arthritic joint produces pain, swelling, and inflammation as a coordinated package. The body’s response is integrated across systems.

The pharmaceutical response is equally coordinated in the opposite direction. The patient with the respiratory illness receives an antipyretic for the fever, an antihistamine for the mucus, a cough suppressant for the cough, a stimulant or coffee for the fatigue, and pressure to eat despite the appetite loss. Every one of the body’s five simultaneous elimination and repair mechanisms is chemically countered.

The question of how thousands of physicians participate in the pattern without seeing it has an answer in the training. Andrew Kaufman, a psychiatrist who broke ranks with his profession, has documented what medical education actually accomplishes. Students undergo intense shared experiences, information overload, and professional incentive structures that create powerful psychological bonds discouraging critical questioning.⁴⁵ Residents face institutional pressure to prescribe, or to justify why they have not prescribed, so that not prescribing appears as deviant conduct requiring explanation. The physician writing the prescription is not concealing knowledge of what the drug does to the body’s response. He was trained in a system in which the question was never presented.

Richard Pitcairn, after fifty years of veterinary practice, documented the trajectory the suppression produces. A dog presents with a skin problem. Cortisone is prescribed. The skin clears. Weeks or months later, the same dog develops calcification of the spine, pancreatitis, or joint breakdown. A cat presents with an inflamed bladder. The bladder symptoms subside under treatment. Later, the cat presents with kidney failure, diabetes, or hyperthyroidism.⁴⁶ Each new condition is treated as unrelated to the previous one. In the terrain framework and in the pattern Hering described, they are the same disorder driven deeper. The skin was the outermost route the body had. Closing it forced the elimination inward, where it re-expressed itself in a more critical structure.

The veterinary setting removes the objection that muddies human cases. The dog is not aging into unrelated diseases. The cat is not developing new conditions from unrelated lifestyle choices. The animal presents with an acute event, the event is suppressed, and the disorder appears months later in a deeper organ system. Repeat across a fifty-year practice and the pattern is not deniable.

The same trajectory operates in humans. The child with eczema treated with topical steroid develops asthma. The asthmatic treated with inhaled corticosteroids develops the conditions labeled autoimmune. Immunosuppressants are added, and cancer follows. Each stage generates its own diagnosis, its own specialist, its own pharmaceutical stack. The medical record shows a person with many unrelated diseases. The physiological reality is one process, driven deeper at each intervention.

The result is what Shelton described in 1964 and what the establishment now calls chronic disease. The acute event that would have resolved in three to seven days with rest, hydration, warmth, and fasting is pharmacologically extended and complicated. Material that was to be expelled is retained. Repair that was to be completed is interrupted. Energy that was to be allocated to healing is consumed instead by digestion, activity, and the metabolic processing of the drugs administered. The patient does not fully recover.

Six months later, some fraction of the acute events remain, now labeled chronic bronchitis, chronic sinusitis, chronic diarrhea, or fibromyalgia. New drugs are added. The cascade proceeds. By the time the patient is sixty, they are on ten to fifteen daily medications, each addressing a symptom created or perpetuated by the previous drug, and no one has looked at the pattern.

The clinical test Cowan proposed for rheumatology applies across every specialty. Walk into any specialist’s office and ask how many patients they have cured. The word means the condition resolved and the patient walked away with a functioning body and no prescription. Managed, stabilized, or medicated with reduced symptoms is not the same thing.¹³ The answer is zero. It has to be zero, because the treatment model is designed to prevent cure. The body’s efforts are chemically obstructed. The insults that provoked those efforts are never addressed.

What This Means

The twelve symptoms are not the disease. They are the intelligence the body brings to what has damaged it. Fever burns off accumulated waste. Mucus carries irritants out of the airways. Appetite falls because digestion consumes energy the body needs for repair. Fatigue is the body’s demand for rest sufficient to complete that repair. The skin picks up secondary elimination duty when the liver, kidneys, and bowel cannot handle the burden alone. Pain is the instruction that stops movement so healing can proceed.

The pharmaceutical response, applied over decades, produces the population’s disease profile. The chronic conditions that dominate modern medicine (cardiovascular disease, the conditions labeled autoimmune, chronic pain syndromes, chronic respiratory disease, chronic gastrointestinal disease, and the neurodegenerative disorders) all bear the fingerprints of the suppression cycle. The insults that provoked the original acute responses were never removed. The responses were chemically interrupted. Both compounded, for years, for decades. The result fills modern hospitals and pharmacies.

Barbara Starfield, then head of health policy at Johns Hopkins, published an estimate in 2000 that properly prescribed pharmaceuticals cause approximately 106,000 US deaths annually, with total iatrogenic mortality of around 225,000.⁴⁷ That figure placed medical intervention as the third leading cause of death in the country. Later analyses from independent researchers place it higher. The number is not a fringe claim. It is establishment epidemiology, published in JAMA, and it has been broadly ignored in the practice of medicine ever since.

The escape from the pattern begins with recognizing what the twelve responses are for. The body producing them is not failing. It is doing exactly what it should do. The task is to identify what is provoking the response and remove it, then to permit the response to complete. Everything else is delay and damage.

The pharmacy shelf has not changed. The bottles that opened this essay, Tylenol and Advil and Robitussin and the rest, still work the way they always did. They still stop what the body is doing. What has changed is what those bottles look like to a reader who has followed the argument. They are twelve drug classes designed to interrupt twelve mechanisms the body was using to save itself, at costs the labels do not describe.

How To Explain It To A 6 Year Old

Your body is smart. When something is wrong, it does things to try to fix it.

If you eat something bad, your tummy pushes it out, either by vomiting it up or by making poop come out really fast. That’s not the sickness. That’s your body cleaning itself out.

If you catch a cold, you get a fever, your nose runs, and you cough. Your body warms itself up to burn off the bad stuff. Your nose makes goo to catch things and push them out. Your cough clears out your lungs. You don’t want to eat, because your body is busy. You want to sleep a lot, because your body needs the energy for cleaning up.

If you fall down and scrape your knee, the skin turns red and puffy and warm and it hurts. That’s your body sending its repair crew to fix the scrape. The redness is extra blood arriving. The hurt is your body telling you to be careful with that knee while the work gets done.

Every one of these things, the fever, the coughing, the runny nose, the not being hungry, the sleeping, the puffy skin, the hurt, is your body doing its job.

Now imagine a doctor comes and says, “The fever is bad. Take this pill to make the fever go away.” You take the pill. The fever goes away. But the bad stuff your body was trying to burn off is still there, and now your body can’t burn it off because the pill stopped it.

Then the doctor says, “The runny nose is bad. Take this pill to make the runny nose stop.” Now the goo can’t come out either. The bad stuff stays inside.

Then the doctor says, “The cough is bad. Take this syrup to stop the cough.” Now your lungs can’t clear themselves out.

Then the doctor says, “You need to eat. Here is some food.” So your body has to spend energy digesting food when it needed the energy for cleaning up.

After a few months, you feel worse instead of better. You have a chest full of stuff that never got coughed out, a body full of stuff that never got burned off, and a nose full of stuff that never got blown out. So the doctor gives you stronger pills.

The doctor is trying to help. But the doctor has the wrong idea about what your body was doing. Your body wasn’t broken. Your body was fixing itself. The pills stopped the fixing.

The rule is simple. Find out what is making your body sick. Take that thing away. Let your body do what it knows how to do. Give it warm blankets, water, quiet, and time. The body will finish the job by itself.

References

¹ Herbert M. Shelton, “Enervation — Toxemia,” Hygienic Review, Vol. XXV, August 1964, No. 12.

² Herbert M. Shelton, cited throughout Dawn Lester and David Parker, What Really Makes You Ill? Why Everything You Thought You Knew About Disease Is Wrong (2019).

³ Constantine Hering, nineteenth-century observations later formalized as “Hering’s Law of Cure.” Discussed in Don Hamilton, Homeopathic Care for Cats and Dogs (North Atlantic Books, 2010).

⁴ H.A. Bernheim and Matthew J. Kluger, “Fever and antipyresis in the lizard Dipsosaurus dorsalis,” American Journal of Physiology 231, no. 1 (1976): 198–203; Matthew J. Kluger, D.H. Ringler, and M.R. Anver, “Fever and survival,” Science 188, no. 4184 (1975): 166–168. See also Kluger, Fever: Its Biology, Evolution, and Function (Princeton University Press, 1979).

⁵ Robert S. Mendelsohn, How to Raise a Healthy Child in Spite of Your Doctor (Ballantine, 1984), chapter on fever. Also Confessions of a Medical Heretic (Contemporary Books, 1979).

⁶ Thomas Cowan, Cancer and the New Biology of Water (Chelsea Green, 2019).

⁷ William B. Coley, “The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas,” American Journal of the Medical Sciences 105 (1893): 487-511. Historical documentation compiled in Cowan, Cancer and the New Biology of Water.

⁸ Ulric Williams, compiled in Terrain Therapy (2022), on fever as “Nature’s bonfire.”

⁹ William M. Lee, “Acetaminophen (APAP) hepatotoxicity: Isn’t it time for APAP to go away?” Journal of Hepatology 67, no. 6 (2017): 1324-1331. Also documented in Lester and Parker, chapter on pharmaceuticals.

¹⁰ Eugene S. Hurwitz et al., “Public Health Service Study of Reye’s Syndrome and Medications,” JAMA 257, no. 14 (April 10, 1987): 1905-1911. National Reye’s Syndrome Foundation, www.reyessyndrome.org.

¹¹ David J. Graham et al., “Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs,” The Lancet 365, no. 9458 (2005): 475-481.

¹² Herbert Shelton, Natural Hygiene: Man’s Pristine Way of Life, cited in Lester and Parker.

¹³ Thomas Cowan, Wednesday Webinar, April 15, 2026.

¹⁴ Grand View Research, “Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report, 2024-2030.” Market valued at USD 22.58 billion in 2024.

¹⁵ AbbVie annual reports and compiled Humira revenue data through 2024. Peak year revenue $21.2 billion (2022).

¹⁶ David Graham, testimony before the U.S. Senate Finance Committee, November 18, 2004.

¹⁷ Daniel Roytas, Can You Catch a Cold? Untold History and Human Experiments, chapter on respiratory illness and inflammatory mediators.

¹⁸ Roytas, Can You Catch a Cold?, on sweat and skin elimination during febrile illness.

¹⁹ D.C. Jarvis, Folk Medicine: A Doctor’s Guide to Good Health (Pan Books, 1961), chapter titled “Relation of Potassium to Mucus.”

²⁰ Shelly L. Gray et al., “Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study,” JAMA Internal Medicine 175, no. 3 (2015): 401-407.

²¹ FDA Nonprescription Drug Advisory Committee, September 11-12, 2023 meeting, findings on oral phenylephrine ineffectiveness.

²² Herbert Shelton, on the body’s elimination of ingested poisons via vomiting or diarrhea, cited in Lester and Parker.

²³ Dawn Lester and David Parker, What Really Makes You Ill?, on the WHO framing of diarrheal disease and its terrain interpretation.

²⁴ FDA Drug Safety Communication, “FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium),” June 7, 2016; updated with dosing restrictions, January 30, 2018.

²⁵ Björn Pasternak et al., “Ondansetron in Pregnancy and Risk of Adverse Fetal Outcomes,” New England Journal of Medicine 368, no. 9 (2013): 814-823. Contradictory findings in Andersen et al., Reproductive Toxicology 43 (2014): 108-116.

²⁶ FDA Public Health Advisory, “Deaths related to intravenous injection of Promethazine (Phenergan) and other narcotic medications,” September 2006. Black-box warning for children under age 2 issued 2004.

²⁷ FDA Safety Alert, black-box warning for metoclopramide (Reglan) and tardive dyskinesia, February 26, 2009.

²⁸ Henry G. Bieler, Food is Your Best Medicine (Random House, 1965), cited in Lester and Parker.

²⁹ John H. Tilden, Impaired Health: Its Cause and Cure, Volume 2, cited in Lester and Parker.

³⁰ CDC/NIOSH, “Skin Exposures and Effects,” www.cdc.gov/niosh, accessed via Lester and Parker citation.

³¹ IPCS (WHO/ILO/UNEP), Dermal Absorption (2006) and Dermal Exposure (2014). Environmental Health Criteria series.

³² Marvin J. Rapaport and Marc Rapaport, “Eyelid Dermatitis to Red Face Syndrome to Cure: Clinical Experiences in 100 Cases,” Journal of the American Academy of Dermatology 41 (1999): 435-442. International Topical Steroid Awareness Network (ITSAN), www.itsan.org.

³³ Herbert M. Shelton, “The Importance of Rest in Disease,” Hygienic Review Vol. IV, November 1942, No. 3.

³⁴ Christopher Gian-Cursio, “The Importance of Rest in Disease,” Hygienic Review Vol. IV, November 1942, No. 3.

³⁵ FDA product labeling for amphetamine mixed salts (Adderall) and related stimulants. Cardiovascular warnings updated 2007 following FDA Pediatric Advisory Committee review.

³⁶ Thomas Cowan, Human Heart, Cosmic Heart (Chelsea Green, 2016), on intermittent fasting and the catabolic state.

³⁷ Ulric Williams, compiled in Terrain Therapy (2022), on hunger and fasting.

³⁸ Herbert M. Shelton, “Enervation — Toxemia,” Hygienic Review, August 1964, on the consequences of cough and diarrhea suppression.

³⁹ FDA Drug Safety Communication, “Death resulting from overdose after accidental ingestion of Tessalon (benzonatate) by children under 10 years of age,” December 14, 2010.

⁴⁰ Rybak LP, “Ototoxicity of loop diuretics,” Otolaryngologic Clinics of North America 26, no. 5 (October 1993): 829-844. FDA product labeling for furosemide.

⁴¹ Herbert Shelton, on inflammation and the local response to injury, cited in Lester and Parker.

⁴² Centers for Disease Control and Prevention WONDER database, opioid overdose mortality 1999-2019. Purdue Pharma marketing history documented in Patrick Radden Keefe, Empire of Pain: The Secret History of the Sackler Dynasty (2021), and U.S. Department of Justice settlement documentation.

⁴³ Christopher W. Goodman and Allan S. Brett, “Gabapentin and Pregabalin for Pain — Is Increased Prescribing a Cause for Concern?” New England Journal of Medicine 377 (2017): 411-414. Parke-Davis whistleblower litigation settled 2004.

⁴⁴ Jacques E. Rossouw et al., “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women’s Health Initiative Randomized Controlled Trial,” JAMA 288, no. 3 (2002): 321-333.

⁴⁵ Andrew Kaufman, MD, recorded interviews and lectures on medical education, psychiatric training, and institutional conditioning within medicine.

⁴⁶ Richard Pitcairn, Dr. Pitcairn’s Complete Guide to Natural Health for Dogs and Cats (Rodale, multiple editions).

⁴⁷ Barbara Starfield, “Is US Health Really the Best in the World?” JAMA 284, no. 4 (July 26, 2000): 483–485.

Additional Sources

Herbert M. Shelton, Natural Hygiene: Man’s Pristine Way of Life and the Hygienic Review archive John H. Tilden, Toxemia Explained: The True Interpretation of the Cause of Disease Dawn Lester and David Parker, What Really Makes You Ill? Daniel Roytas, Can You Catch a Cold? Untold History and Human Experiments Thomas Cowan, The Contagion Myth, Cancer and the New Biology of Water, Human Heart, Cosmic Heart Ulric Williams compilations, Terrain Therapy (2022) Henry Bieler, Food is Your Best Medicine D.C. Jarvis, Folk Medicine and Arthritis and Folk Medicine Richard Pitcairn, Dr. Pitcairn’s Complete Guide to Natural Health for Dogs and Cats Robert S. Mendelsohn, How to Raise a Healthy Child in Spite of Your Doctor and Confessions of a Medical Heretic Andrew Kaufman, recorded interviews and lectures on medical education and psychiatric training Matthew J. Kluger, Fever: Its Biology, Evolution, and Function Constantine Hering, on the direction of cure Barbara Starfield, “Is US Health Really the Best in the World?” JAMA (2000) Carolyn Dean, Death by Modern Medicine Torsten Engelbrecht et al., Virus Mania (3rd edition) Mark Gober et al., An End to Upside Down Medicine Mark Bailey, The Final Pandemic: An Antidote

This essay is educational and represents the author’s paradigm interpretation. Nothing in it constitutes medical advice. Decisions about medication should be made in consultation with a qualified practitioner familiar with the individual’s circumstances.

In the first three minutes after the infant is delivered, if the umbilical cord is left intact, approximately one hundred milliliters of blood transfers from the placenta into the newborn.¹ That is roughly a third of the infant’s total blood volume. The transfer is not passive. The umbilical vessels contain their own smooth muscle. They close on their own schedule when the transfer is complete, usually within three to ten minutes. At that point the cord blanches, the pulsation stops, and the vessels seal.

In the United States, this process is interrupted, on average, within thirty to sixty seconds. The infant loses roughly thirty percent of the blood the physiology was constructed to deliver. The practice is defended on grounds that shift as the literature closes on it: it prevents jaundice (it does not, at any clinically meaningful rate), it reduces polycythemia (rarely, and asymptomatically), it is what the obstetrician was trained to do (this last is accurate). The iron the infant would have used for the next six months goes into a red plastic bag with the placenta.

This essay is about what happens in the first sixty minutes after birth in a standard American hospital, and about the biology of the first sixty minutes as it existed before the interventions displaced it. There are seven interventions in the standard sequence. Each one displaces a specific biological event. The essay traces the seven in the order they occur, and then examines the second casualty of the hour, which is the mother.

The argument is not that any single intervention is catastrophic in isolation. It is that the biology of the first hour was doing something, and hospital protocol displaces the entire sequence in favor of procedures whose cumulative effect has never been studied. What the interventions replace is a sequence humans arrived with. What replaced it was assembled between roughly 1930 and 1991, most of it introduced without controlled trial, and none of it evaluated as the sequence it now is.

The infant born in a Kansas farmhouse in 1890 received the first hour by default. The infant born in a Manhattan delivery room in 2026 receives the first hour only if the parents have prepared for months to protect it against interventions the hospital considers routine.

Audio Deep Dive (for Paid Subscribers)

The Placental Transfer

The Cochrane review on the timing of umbilical cord clamping in term infants pools twenty-five trials involving more than three thousand mother-infant pairs. Delayed clamping (variously defined as one to three minutes, or until pulsation ceases) is associated with higher hemoglobin at birth, higher ferritin at three and six months, and lower rates of iron deficiency in infancy.² The World Health Organization recommends delaying cord clamping for at least one minute after birth.³ The American College of Obstetricians and Gynecologists, in Committee Opinion Number 814 (January 2020), endorsed a delay of at least thirty to sixty seconds. Actual hospital practice in the United States has moved reluctantly, and inconsistently, toward the low end of that range.

Ola Andersson and colleagues at Uppsala University randomized four hundred term infants to early clamping (within ten seconds) or delayed clamping (at least three minutes) and followed them at four months and at four years. At four months, the delayed-clamping infants had ferritin levels forty-five percent higher than the early-clamping group.⁴ At four years, the delayed-clamping children scored higher on fine motor and social skills.⁵ The trial was published in the BMJ and in JAMA Pediatrics. It has not changed what happens in the room where the baby comes out.

The infant delivered at term arrives with approximately eighty milliliters of blood per kilogram in circulation. The placenta at the moment of birth contains roughly one third of the total fetal blood volume. That fraction is not surplus. The umbilical arteries and vein complete the redistribution while the infant’s lungs open and the ductus arteriosus and foramen ovale begin the transition from fetal to neonatal circulation. The iron load carried in the umbilical vessels at three minutes postpartum is approximately 70 milligrams. The daily iron requirement of the term infant during the first six months, met almost entirely from stores laid down before and during the third trimester, is approximately 0.27 milligrams. The math is not subtle. Three minutes of transfer delivers nine months of iron.

The American replacement is a plastic clamp on a still-pulsing cord, and a pair of scissors thirty seconds later. The consequences are measurable at four months (ferritin, hemoglobin), at six months (iron sufficiency), and at four years (fine motor and social scoring). The intervention has no informed consent process. The mother will rarely be told that the WHO and ACOG recommendations both call for a longer delay than the hospital in fact provides, and she will almost never be told what the delayed-clamping trials measured at four years.

The Approach to the Breast

The infant placed on the mother’s abdomen immediately after birth, undisturbed, dry but not washed, performs a sequence of movements that has been documented on video and named. Ann-Marie Widström and colleagues in Sweden videotaped twenty-eight undisturbed term newborns and identified nine sequential stages: birth cry, relaxation, awakening, activity, crawling, resting, familiarization, suckling, and sleeping.⁶ The sequence completes, on average, in the first sixty to ninety minutes after birth. The infant uses head-lifting movements, hand-mouth coordination with the mother’s nipple, and a slow crawl up the mother’s abdomen to the breast. The first latch, when the infant is left to accomplish it, typically occurs somewhere between sixty and ninety minutes after birth, with substantial variation between infants.

The Cochrane systematic review on early skin-to-skin contact between mother and healthy newborn pools forty-six trials with more than three thousand mother-infant pairs. Infants who received skin-to-skin contact in the first hour, without separation for measurement or procedure, breastfed earlier, breastfed longer, maintained more stable blood glucose, thermoregulated more efficiently, and cried less in the following twenty-four hours.⁷ Maternal outcomes included lower rates of breastfeeding cessation before six weeks and lower postpartum depression scores.

Standard American hospital practice moves the infant to a warmer within the first minute. There the infant is weighed, measured, footprinted, given an Apgar score, injected with the compound sold as vitamin K, and treated with erythromycin eye ointment. The infant is then wrapped in a receiving blanket and returned to the mother. The nine-stage sequence has been interrupted at stage three. The rest of the stages do not resume. The first latch, if it occurs in the first hour at all, occurs against the mother’s blanket-wrapped chest, with an infant whose hand-mouth coordination has been disrupted, whose skin has been rubbed with an absorbent towel, and whose eyes have been coated with antibiotic ointment.

What is displaced in the assessment ritual is the imprinting window. The infant returned to the mother wrapped, cleaned, and processed does not get the first hour. Neither does the mother.

The First Injection

The compound sold as vitamin K is administered to the American newborn by intramuscular injection, typically in the thigh, within the first fifteen minutes of life. The standard dose is one milligram. Endogenous plasma phylloquinone in the term newborn is approximately 0.05 nanograms per milliliter. The injection delivers a bolus at roughly twenty thousand times endogenous. The formulation includes polysorbate 80, benzyl alcohol, and propylene glycol.⁸ The active compound, phytonadione, is a synthetic form of phylloquinone.

The intervention has a real underlying observation. What mainstream pediatrics calls vitamin K-dependent bleeding, formerly labeled hemorrhagic disease of the newborn, occurs in a small fraction of untreated infants during the first week of life and, in a smaller fraction, between two weeks and six months. The late-onset form can produce intracranial hemorrhage and carries substantial mortality when it occurs. The bleeding phenomenon is not disputed. What is disputed is what to do about it.

The American Academy of Pediatrics adopted routine intramuscular prophylaxis in 1961.⁹ The route was chosen for the assurance of absorption, not because oral phytonadione does not work. Multiple oral regimens have been tested and are used in national protocols in the Netherlands, Denmark, Switzerland, and Germany. The Dutch protocol delivers 1 milligram at birth followed by 150 micrograms daily from day eight to week thirteen in breastfed infants. Rates of late-onset bleeding in the Dutch protocol are comparable to the American intramuscular protocol.¹⁰

Jean Golding and colleagues at Bristol published in the British Medical Journal in 1992 an analysis linking the intramuscular injection at birth to a doubling of childhood cancer, particularly leukemia, in the exposed cohort.¹¹ Subsequent studies were mixed. The mainstream position settled into “the balance of evidence does not support the association,” and the intramuscular protocol continued. The oral protocol, which delivers the same effect at physiologic dosing without the injection additives, was not adopted in the United States.

The additives merit examination on their own. Benzyl alcohol at neonatal doses has been associated with gasping syndrome in premature infants; the FDA issued a warning in 1982 restricting its use in that population.¹² The one-milligram vitamin K injection contains 9 milligrams of benzyl alcohol. Polysorbate 80 is a solubilizer with documented capacity to disrupt cellular membrane integrity and, in animal models, alter blood-brain barrier permeability. A prior essay developed the zeta-potential mechanism at length.¹³ The vitamin K injection is not the largest zeta-potential insult of the first hour. It is the first.

What the injection displaces is the intended pattern of vitamin K acquisition, which is neither zero nor bolus. The breastfed infant receives phylloquinone in milk at physiologic concentrations sustained across the first months. The intramuscular protocol delivers, in a single dose, an amount the physiology was constructed to receive across weeks.

For the reader wondering whether their own child received this injection: consent was almost certainly not obtained in any meaningful sense. A form signed on admission authorized the hospital’s standard newborn care. That form covered the injection.

The Ointment

Within the first thirty minutes, before the infant is returned to the mother, erythromycin ophthalmic ointment (0.5 percent) is applied to both eyes. The procedure is required by law in most states. The rationale, dating to Karl Credé’s 1881 protocol in Leipzig, was prevention of what mainstream medicine calls ophthalmia neonatorum, a neonatal eye inflammation the establishment attributes to gonococcal exposure during birth. Untreated, the condition was documented to progress to corneal ulceration and blindness in a subset of affected infants. Credé’s silver nitrate reduced the reported incidence in Leipzig from ten percent of newborns to less than one percent. The intervention reduced blindness. The intervention that replaced it, applied to a screened-negative population, does not.

Silver nitrate has since been replaced by erythromycin. The current protocol treats the infant of a screened mother not carrying the bacterium, in a population where gonorrhea prenatal screening is standard care.¹⁴ ACOG recommends screening at the first prenatal visit for all pregnant patients under twenty-five and for older patients with risk factors. A mother screened and treated presents what the establishment characterizes as no meaningful risk of transferring the bacterium. The ointment is applied anyway. The state mandate does not distinguish between screened-negative and unscreened mothers.

The ointment blurs the infant’s vision during the imprinting window. The newborn is optically calibrated to focus at eight to twelve inches, the distance from breast to mother’s face during nursing. Ointment-coated eyes cannot fix on that face. The ointment is also an antibiotic administered to the ocular surface at the moment the ocular microbiome is being established. No trial has ever measured what the ointment does to that colonization. The absence of the trial is the finding.

The eye ointment is one of the interventions parents can decline in most jurisdictions with a signed refusal form. It is rarely offered as an option. The nurse arriving with the tube does not typically pause to ask.

The Vaccination

At some point in the first twenty-four hours, and in some hospital protocols within the first hour or two, the newborn receives the first injection on the American vaccination schedule. The vaccine is the recombinant hepatitis B vaccine, marketed as Recombivax HB or Engerix-B, containing 5 to 10 micrograms of hepatitis B surface antigen and 250 micrograms of aluminum, as amorphous aluminum hydroxyphosphate sulfate (Recombivax) or aluminum hydroxide (Engerix-B).¹⁵

The rationale for administering this injection on the day of birth was established by the ACIP in 1991 as part of a strategy to eliminate what mainstream medicine calls hepatitis B transmission through universal infant vaccination.¹⁶ In the establishment framework, the condition is associated with blood-to-blood contact and sexual activity. The pediatric concern the ACIP named was vertical transfer from a mother carrying the surface antigen. Screening for that surface antigen has been standard prenatal care since 1988. The mother screened and confirmed negative delivers an infant whose risk of what the establishment calls hepatitis B in the first year of life, absent blood contact and sexual activity, approaches zero on the establishment’s own terms. The rationale for injecting that infant on the day of birth reduces to catching the infants of unscreened mothers, and to protecting against later transfer from a household member sharing razors. Both are surrogate arguments for injecting a screened-negative population.

The infant on day one receives 250 micrograms of aluminum in a single bolus. The FDA has identified 4 to 5 micrograms per kilogram per day as the exposure level at which parenteral aluminum accumulates to concentrations associated with central nervous system and bone toxicity in patients with impaired renal function.¹⁷ Applied to a 3.5-kilogram newborn, the FDA’s accumulation threshold works out to roughly 17 micrograms per day. The day-one injection delivers about fifteen times that amount, in a single bolus, into an infant whose kidneys are not yet fully working and whose blood-brain barrier will never again be this porous.

The aluminum-adjuvant literature, developed most extensively by Christopher Exley at Keele and Romain Gherardi at Créteil, documents that injected aluminum does not remain at the site. Macrophages carry it to lymph nodes, spleen, bone marrow, and, in Gherardi’s macrophagic myofasciitis series, to distant tissue including brain.¹⁸ ¹⁹ Clearance from tissue, once deposited, is measured in years. Zeta potential collapse in the neonatal blood following aluminum-adjuvant injection is the mechanism a separate essay in this series developed. The injection arrives when the infant is least prepared to receive it. The schedule is calibrated to that moment on purpose.

The 1986 National Childhood Vaccine Injury Act removed vaccine manufacturer liability for injuries arising from the recommended pediatric schedule.²⁰ A prior essay in this series traced the consequences of that legal structure. The injection administered to the newborn is the first of the schedule the Act protects. Consent is bundled into admission paperwork. The parent who declines is required to sign a separate refusal form. The counseling does not mention the aluminum load, the biodistribution literature, or the mother’s own negative screening.

The Vernix

The white coating on the newborn’s skin is not residue. It is a substance the infant made, for the infant, starting in the second trimester of gestation, composed of eighty percent water, ten percent protein, and ten percent lipid. The protein fraction contains at least forty-one distinct proteins identified in the Tollin proteomic analysis, of which roughly a third have direct antimicrobial activity.²¹ The active components include lysozyme, lactoferrin, cathelicidin LL-37, and a range of defensins active against gram-positive and gram-negative bacteria, fungi, and some enveloped particles. The lipid fraction, in composition and quantity, closely tracks the composition of the stratum corneum (the outermost skin layer) of the term infant. It is not a coincidence.

The vernix serves at least four documented functions. In utero it prevents maceration of the fetal skin by amniotic fluid across the third trimester. At delivery it eases passage through the birth canal. Post-delivery it retains warmth and moisture at the skin surface, providing thermoregulation and preventing transepidermal water loss. And it colonizes the infant’s skin with an antimicrobial coating whose peptides continue functioning during the hours in which the skin microbiome is being established.

The World Health Organization recommends delaying the first bath by at least twenty-four hours after birth.²² American hospital practice varies. Many hospitals wash the infant within the first several hours, sometimes with soap. The vernix is rubbed off with towels during drying and the residue is washed away in the bath.

What the vernix does that no substitute is offered for is the seeding of the infant’s skin surface with the mother’s microbiome combined with the fetal-secretion antimicrobial peptides. The infant delivered vaginally, placed on the mother’s chest unwashed, receives the mother’s flora onto skin coated with the vernix, which selects for the flora the peptides tolerate and against the flora the peptides suppress. The infant washed, wrapped in hospital linen, and handled by gloved hands receives hospital flora onto skin whose antimicrobial coating has been removed.

Maria Dominguez-Bello and colleagues have documented that the microbiome of the cesarean infant at one month differs measurably from the vaginally-delivered infant at one month, with the cesarean infant’s early flora more closely resembling adult skin flora than the mother’s vaginal flora.³⁰ Subsequent work has shown that at least some of the differences persist through infancy.

The vernix is not a candidate for pharmaceutical replacement. There is no product to sell in its place. It was produced by the infant, for the infant, and it functions in a window that closes within hours. What replaces the vernix in the hospital protocol is nothing. What is added is the antibiotic ointment, the alcohol wipe at the injection site, and the hospital-laundered blanket. The infant is now less colonized than it would be, and more colonized with what the hospital carries.

The First Meal

Some hospitals, at some times, supplement breastfed infants with formula in the nursery during the first hours after birth. The practice varies. It is more common when the mother is exhausted, when the infant is separated for observation, when the mother’s supply is judged inadequate, and when the hospital does not carry Baby-Friendly certification. The World Health Organization / UNICEF Baby-Friendly Hospital Initiative, launched in 1991, established ten steps designed to protect exclusive breastfeeding in the first days.²³ Step six is that no food or drink other than breast milk should be given to newborns unless medically indicated. Compliance is voluntary. A minority of American births occur in Baby-Friendly-designated hospitals.

The infant’s first meal is not decorative. Colostrum, produced by the mother’s breasts in the first hours to days after birth, is not milk in the mature sense. It is a thick, yellow-orange secretion containing at least twenty times the concentration of the protective proteins mainstream biochemistry classifies as secretory immunoglobulin A, compared to mature breast milk, plus lactoferrin, lysozyme, growth factors, and oligosaccharides that seed the infant’s gut microbiome selectively.²⁴ The newborn stomach at day one has a capacity of approximately five to seven milliliters. Colostrum production tracks this capacity. Formula, at the volume infants are commonly supplemented, does not.

The gut lining of the newborn is highly permeable in the first days. The tight junctions between epithelial cells have not yet closed. This permeability is a feature. It permits the passage of the intact protective proteins and growth factors in colostrum into the infant’s circulation. It also permits the passage of intact proteins from formula, including bovine milk proteins whose structure differs from human milk proteins and which the infant’s still-closing gut does not process the way it processes what it was constructed to receive.

The oligosaccharides in colostrum are indigestible to the infant. That is the point. They are metabolized by the Bifidobacterium species the mother’s flora deposited, feeding the microbes that will occupy the gut in the coming weeks. Formula lacks these oligosaccharides. Formula lacks the mother’s flora. The formula-supplemented infant, over the coming days and weeks, develops a gut microbiome that differs measurably from the exclusively-breastfed infant, and the difference persists.

The first meal is the culminating displacement of the first hour. It arrives to an infant who has been separated from the mother, injected, coated, and washed, and it delivers to that infant a substitute for the substance the biology laid down as the first food. The mother, watching this happen or unable to intervene because she has been medicated or exhausted, has already lost the imprinting window that was hers.

If you are a mother reading this, you were also in that room. Depending on what you were given for pain, you may remember very little. You were told the nurses knew what they were doing. You were not told that the sequence being performed on your infant was displacing a hormonal cascade that was also happening in you. Nobody said it aloud because the sequence has a name only in the physiology literature, and the physiology literature is not what the nurses were trained on.

The Mother’s Cascade

The mother’s biology in the first hour after birth is not incidental. It is a second event running in parallel to the infant’s, requiring the infant’s presence to sustain, and it is displaced by the same interventions.

Oxytocin production in the mother peaks in the minutes after delivery. The surge is triggered by uterine stretch during labor, by the ferguson reflex during crowning, and by direct skin-to-skin contact with the newborn in the minutes that follow.²⁵ The pulse at delivery is the highest circulating concentration of oxytocin a woman will produce in her lifetime. The hormone contracts the uterus, delivering the placenta and closing the vessels that fed it. It also acts centrally, producing a state that has been variously called maternal responsiveness, the imprinting state, or, in the phrasing of Michel Odent, the “cocktail of love hormones.”²⁶ Odent ran the maternity unit at the Pithiviers state hospital in France from 1962 to 1985 and documented what happened when the interventions were removed. Prolactin rises in the same window and initiates the transition from colostrum production to mature milk. The initiation depends on the infant’s suckling within the first hours. Delayed suckling delays the prolactin response and, in a subset of women, the milk-transition does not occur normally.

Sarah Buckley, in Hormonal Physiology of Childbearing, catalogs the full cascade.²⁷ Endorphins, elevated during labor, remain elevated postpartum and cross into breast milk. Catecholamines drop in the presence of the infant and rise again if the infant is separated. Vasopressin mediates maternal attention. The literature is not fringe. Klaus and Kennell developed it in the 1970s. Odent and Uvnäs-Moberg extended it. Buckley formally reviewed it for the National Partnership for Women and Families in 2015. The birth hormones are a system whose components require each other to complete. Interrupt any of them and the system does not deliver what it was constructed to deliver.

What displaces the mother’s cascade in the hospital delivery is the familiar sequence. The infant is taken to a warmer within the first minute. The mother loses skin-to-skin contact at the moment the oxytocin sustaining stimulus was constructed to arrive. She may receive synthetic oxytocin by intravenous drip for uterine contraction, which acts on peripheral receptors but does not cross the blood-brain barrier and does not reproduce the central effects of the endogenous surge. The synthetic drip contracts the uterus. It does not produce the maternal-responsiveness state. Meanwhile, her epidural has not fully worn off. She has received four to six liters of intravenous fluids. She is exhausted. She is being handed paperwork. When the infant is returned to her, wrapped and processed, the window has closed.

The consequences are measurable. Breastfeeding initiation rates track skin-to-skin contact in the first hour.²⁸ Postpartum depression rates track breastfeeding duration and, independently, track the interventions during labor and the first hour.²⁹ The mother who did not receive the first hour her physiology laid down is more likely to experience difficulty with breastfeeding at two weeks, with mood at six weeks, and with maternal attachment at six months.

None of this appears in standard prenatal care. The literature exists. It is not read. The mother arriving at the hospital in labor believes she is arriving to receive expert care for a medical event. She is not told that the event proceeds along a hormonal pathway hospital protocol is not calibrated to protect.

The second casualty of the first hour is the mother. She experiences the same interventions from a different position. Each act of separation displaces her cascade at the same moment it displaces the infant’s. The two biologies were constructed to complete together.

What the First Hour Was, Before

Humans lived and reproduced for the entire pre-industrial history of the species without the seven interventions this essay has cataloged. Cord clamping, in the form the American delivery room now practices it, is not a traditional intervention. The vitamin K injection was introduced in 1961. The universal newborn hepatitis B injection was recommended in 1991. Erythromycin eye ointment for gonococcal prophylaxis dates to the 1980s in its current formulation, replacing the silver nitrate protocol that began in 1881. Formula supplementation as routine hospital practice dates to the mid-twentieth century. Immediate bathing dates to the era when hospital birth replaced home birth, roughly the 1940s.

The first hour, before all of this, was not chaotic. It was structured, and the structure was biological. The infant arrived, was placed against the mother’s body, received the placental blood transfer over three to ten minutes, initiated the pulmonary transition with adequate volume, warmed against the mother’s skin, was colonized by the mother’s flora onto vernix-coated skin, self-attached to the breast within the first hour, and received colostrum. The mother, during those minutes, delivered the placenta by uterine contraction driven by the endogenous oxytocin surge, produced the imprinting state that oriented her to the infant, transitioned into prolactin-mediated lactation initiation, and completed the physiologic postpartum sequence.

This is what the first hour was. It is what the modern delivery room has displaced.

What the First Hour Is, When Nothing Interrupts

The infant emerges. Passage through the birth canal has compressed the thoracic cavity and cleared amniotic fluid from the lungs. The cord remains attached. The infant is placed directly on the mother’s abdomen, chest, or breast, skin to skin. The infant is not dried aggressively. The vernix remains on the skin. A warm blanket may be placed over both mother and infant. The room is quiet.

The infant emits the birth cry, which opens the lungs. The cry subsides. The infant enters a period of quiet alertness, eyes open, and fixes on the mother’s face at the eight-to-twelve-inch distance. This state persists for roughly sixty to ninety minutes and does not recur with the same intensity for weeks. The mother, in the same window, has completed uterine contraction and delivered the placenta, and the endogenous oxytocin surge has produced a state of focused attention on the infant that she will remember, if she experiences it, for the rest of her life.

The cord transfers blood from placenta to infant. The pulmonary circulation opens. Between three and ten minutes, the cord pulsation slows and stops. The umbilical vessels close. The cord blanches. Only now is the cord cut, and it can be cut without a clamp if it has fully closed.

The infant, in the following thirty to sixty minutes, moves through the nine stages Widström documented. The head lifts. The hand-mouth coordination emerges. The infant crawls, sometimes visibly, up the mother’s abdomen. Somewhere between sixty and ninety minutes, the infant self-attaches to the breast. The latch is deep. Colostrum flows. The infant receives the first meal.

The mother’s flora colonizes the vernix. The mother’s oxytocin surge sustains. Body temperature stabilizes. Blood glucose stabilizes. The infant enters the first sleep. The mother enters her own recovery.

This is the first hour when it is not interrupted. Every event described is in the literature. Nothing here is romantic. This is what the biology does when it is left alone.

What to Refuse, and What Requires More

The mother planning a hospital birth in the United States who wants the first hour her physiology can deliver has options. Not all seven interventions can be refused in every hospital, but most can be refused in most.

Delayed cord clamping is available for the asking in most American hospitals in 2026. The written birth plan should specify “delay cord clamping until pulsation ceases, or a minimum of three minutes.” Some hospitals will interpret this as thirty seconds. The plan should specify the minimum. The obstetrician’s agreement should be secured in advance at a prenatal appointment, and documented in the chart. Skin-to-skin contact within the first minute, uninterrupted for the first hour, is available in Baby-Friendly-designated hospitals and increasingly in non-designated hospitals for the asking. The birth plan should specify that weighing, measuring, Apgar assessment, and all non-emergency procedures be deferred to after the first hour. Apgar assessment can be done visually while the infant is on the mother’s chest.

The vitamin K injection, the erythromycin eye ointment, and the day-one hepatitis B vaccine can each be declined in every American state with a signed refusal form. In some states an oral vitamin K protocol is available on request. Delayed bathing, by at least twenty-four hours and preferably until the mother is home, is increasingly available for the asking. Exclusive breastfeeding, with no formula supplementation in the nursery, requires the parents to state the preference explicitly on the birth plan and repeatedly in person, and to keep the infant in the mother’s room rather than the nursery.

The mother who wants the fuller first hour, without the intrusions the American hospital continues to make available on request, has options beyond the hospital. Birthing centers, in states that license them, deliver a substantially undisturbed first hour as their default. Midwife-attended home birth, for the low-risk mother, delivers the first hour without the interventions being present as options at all. The refusal is not required. The interventions are not there to refuse.

The mother who cannot deliver at home, and whose hospital does not offer a birthing-center option, can still preserve most of what the physiology needs. The birth plan matters. The advocate at the birth matters. The prenatal conversation with the obstetrician matters. The seven interventions, one by one, can be reduced or declined. What cannot be done, in the standard American hospital, is arrive without a plan and receive the first hour intact. What the hospital delivers by default is what this essay described.

No cumulative safety study of the seven interventions as a sequence has ever been conducted. None was required, because each intervention was introduced separately, defended separately, and evaluated (when it was evaluated at all) against no comparator except the intervention it replaced. The regulatory capture the reader can name in other domains (pharmaceutical, agricultural, financial) operates here at the level of the individual body, and at the level of the sixty minutes that were once the least medicalized in the human life course.

The infant born in a Kansas farmhouse in 1890 received the first hour by default. The infant born in a Manhattan delivery room in 2026 receives the first hour only if the parents have prepared for months to protect it against interventions the hospital considers routine. The first hour was displaced within roughly a century. It has not disappeared. It is still there, in the physiology, waiting.

How to Explain This to a Six-Year-Old

Imagine a brand new baby, just coming out.

For all the time before hospitals, this is what happened next.

The little tube that connected the baby to the mommy on the inside kept working for a while, like a garden hose finishing a watering. It sent all the rest of the baby’s blood back into the baby’s body. When it was done, the tube stopped on its own. The baby stayed on the mommy’s chest, warm and quiet. In about an hour, the baby crawled up to the mommy’s breast all by itself and started to drink.

That was the first hour. That is what it was.

Now, in most American hospitals, this is what happens instead.

As soon as the baby comes out, a doctor cuts the little tube right away. That means the baby loses about a third of the blood that was supposed to be inside the baby’s body. The blood goes in the trash with the tube.

Then a nurse takes the baby to a table with a bright lamp. She weighs the baby. She measures the baby. She puts a needle in the baby’s leg and gives the baby a shot. She puts sticky medicine in the baby’s eyes so the baby can’t see the mommy’s face clearly. Later, another shot goes in, and that one has a metal called aluminum inside it. After a while, a nurse gives the baby a bath. That washes off a special white coating the baby was born with. The coating was made to keep the baby safe from germs. The bath takes it away.

While all of that is going on, the mommy is on the table by herself. Her body is trying to make a special feeling that helps her fall deeply in love with the baby. But the baby is way over on the warm table, being weighed and measured and stuck with needles. When the baby finally comes back, the baby is wrapped up in a blanket and can’t feel the mommy’s skin very well.

Nobody in the delivery room is trying to be mean. The nurses are doing what they were taught. The doctor is doing what the doctor was taught. But what they were taught to do is not what a baby is made for.

A baby is made for a quiet room, the mommy’s skin, and time. The little tube finishes on its own. The baby finds the mommy’s breast on its own. Everything a baby needs in the first hour is already there. No shots. No goo. No bright lamp. Just the mommy.

It took about a hundred years for hospitals to forget this.

It only takes one baby being born to remember.

References

1. Yao, A.C., Moinian, M., and Lind, J. “Distribution of blood between infant and placenta after birth.” Lancet 2, no. 7626 (1969): 871–873. The three-minute placental transfusion volume in term infants was established in this landmark measurement study and has been replicated in subsequent literature.

2. McDonald, S.J., Middleton, P., Dowswell, T., and Morris, P.S. “Effect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomes.” Cochrane Database of Systematic Reviews 7 (2013): CD004074.

3. World Health Organization. Guideline: Delayed umbilical cord clamping for improved maternal and infant health and nutrition outcomes. Geneva: WHO, 2014.

4. Andersson, O., Hellström-Westas, L., Andersson, D., and Domellöf, M. “Effect of delayed versus early umbilical cord clamping on neonatal outcomes and iron status at 4 months: a randomised controlled trial.” BMJ 343 (2011): d7157.

5. Andersson, O., Lindquist, B., Lindgren, M., Stjernqvist, K., Domellöf, M., and Hellström-Westas, L. “Effect of Delayed Cord Clamping on Neurodevelopment at 4 Years of Age: A Randomized Clinical Trial.” JAMA Pediatrics 169, no. 7 (2015): 631–638.

6. Widström, A.M., Lilja, G., Aaltomaa-Michalias, P., Dahllöf, A., Lintula, M., and Nissen, E. “Newborn behaviour to locate the breast when skin-to-skin: a possible method for enabling early self-regulation.” Acta Paediatrica 100, no. 1 (2011): 79–85. The nine-stage sequence was documented from videotape observation of twenty-eight full-term infants and elaborated further in Widström, A.M., Brimdyr, K., Svensson, K., Cadwell, K., and Nissen, E. “Skin-to-skin contact the first hour after birth, underlying implications and clinical practice.” Acta Paediatrica 108, no. 7 (2019): 1192–1204.

7. Moore, E.R., Bergman, N., Anderson, G.C., and Medley, N. “Early skin-to-skin contact for mothers and their healthy newborn infants.” Cochrane Database of Systematic Reviews 11 (2016): CD003519.

8. Konakion (phytonadione) injectable, product monograph. Hoffmann-La Roche. Formulation includes polysorbate 80, benzyl alcohol (9 mg per 1 mg dose), and propylene glycol. Alternative formulations by Hospira and Amphastar carry comparable excipients.

9. American Academy of Pediatrics, Committee on Nutrition. “Vitamin K compounds and the water-soluble analogues.” Pediatrics 28 (1961): 501–507. The AAP policy adopting routine intramuscular vitamin K prophylaxis at birth dates to this statement.

10. Cornelissen, M., von Kries, R., Loughnan, P., and Schubiger, G. “Prevention of vitamin K deficiency bleeding: efficacy of different multiple oral dose schedules of vitamin K.” European Journal of Pediatrics 156, no. 2 (1997): 126–130. The Dutch, Danish, and Swiss oral protocols are compared in this systematic analysis.

11. Golding, J., Paterson, M., and Kinlen, L.J. “Factors associated with childhood cancer in a national cohort study.” British Journal of Cancer 62, no. 2 (1990): 304–308. Golding, J., Greenwood, R., Birmingham, K., and Mott, M. “Childhood cancer, intramuscular vitamin K, and pethidine given during labour.” British Medical Journal 305, no. 6849 (1992): 341–346. The original findings.

12. FDA. “Benzyl alcohol may be toxic to newborns.” FDA Drug Bulletin 12, no. 2 (1982): 10–11. The gasping-syndrome warning restricting benzyl alcohol use in neonates dates to this bulletin.

13. Unbekoming. “What Is Zeta Potential?” Lies are Unbekoming Substack. The mechanism by which surface-active additives collapse blood-cell surface charge is developed at length in this prior essay.

14. American College of Obstetricians and Gynecologists. “Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy,” and associated guidance on prenatal STI screening. ACOG recommends universal prenatal screening for gonorrhea in all pregnant patients under 25 and for older patients with risk factors, at the first prenatal visit and again in the third trimester when indicated.

15. Recombivax HB (Merck) and Engerix-B (GlaxoSmithKline), pediatric formulation package inserts. Aluminum content per 0.5 mL pediatric dose: 250 micrograms as amorphous aluminum hydroxyphosphate sulfate (Recombivax) or aluminum hydroxide (Engerix-B).

16. Advisory Committee on Immunization Practices. “Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination.” MMWR Recommendations and Reports 40, no. RR-13 (November 22, 1991): 1–25.

17. FDA. “Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition.” 21 CFR 201.323. The FDA-required labeling states that aluminum accumulates at levels associated with central nervous system and bone toxicity in patients with impaired renal function receiving parenteral aluminum greater than 4 to 5 micrograms per kilogram per day. No corresponding regulatory limit exists for aluminum delivered by injectable vaccines in infants.

18. Exley, C. “The toxicity of aluminium in humans.” Morphologie 100, no. 329 (2016): 51–55. Exley, C., Siesjö, P., and Eriksson, H. “The immunobiology of aluminium adjuvants: how do they really work?” Trends in Immunology 31, no. 3 (2010): 103–109.

19. Gherardi, R.K., Eidi, H., Crépeaux, G., Authier, F.J., and Cadusseau, J. “Biopersistence and brain translocation of aluminum adjuvants of vaccines.” Frontiers in Neurology 6 (2015): 4. Gherardi’s macrophagic myofasciitis series traces aluminum from injection site to distant tissue including brain.

20. National Childhood Vaccine Injury Act of 1986, Public Law 99-660. Unbekoming. “The Diagnosis That Ends the Investigation” (on the 1986 NCVIA and the Audrey Edmunds case). Lies are Unbekoming Substack.

21. Tollin, M., Bergsson, G., Kai-Larsen, Y., Lengqvist, J., Sjövall, J., Griffiths, W., Skúladóttir, G.V., Haraldsson, A., Jörnvall, H., Gudmundsson, G.H., and Agerberth, B. “Vernix caseosa as a multi-component defence system based on polypeptides, lipids and their interactions.” Cellular and Molecular Life Sciences 62, no. 19-20 (2005): 2390–2399.

22. World Health Organization. “WHO Recommendations on Newborn Health.” Geneva: WHO, 2018. Delay of the first bath by at least 24 hours after birth is recommended.

23. World Health Organization / UNICEF. “The Ten Steps to Successful Breastfeeding.” Baby-Friendly Hospital Initiative, revised 2018. Step 6: “Give infants no food or drink other than breast-milk, unless medically indicated.”

24. Ballard, O., and Morrow, A.L. “Human milk composition: nutrients and bioactive factors.” Pediatric Clinics of North America 60, no. 1 (2013): 49–74. Colostrum composition, secretory IgA concentration, and oligosaccharide profile are cataloged in this review.

25. Uvnäs-Moberg, K. The Oxytocin Factor: Tapping the Hormone of Calm, Love, and Healing. Cambridge, MA: Da Capo Press, 2003.

26. Odent, M. The Scientification of Love. London: Free Association Books, 1999.

27. Buckley, S.J. Hormonal Physiology of Childbearing: Evidence and Implications for Women, Babies, and Maternity Care. Washington, DC: National Partnership for Women and Families, 2015.

28. Bramson, L., Lee, J.W., Moore, E., Montgomery, S., Neish, C., Bahjri, K., and Melcher, C.L. “Effect of early skin-to-skin mother-infant contact during the first 3 hours following birth on exclusive breastfeeding during the maternity hospital stay.” Journal of Human Lactation 26, no. 2 (2010): 130–137.

29. Bell, A.F., Erickson, E.N., and Carter, C.S. “Beyond labor: the role of natural and synthetic oxytocin in the transition to motherhood.” Journal of Midwifery & Women’s Health 59, no. 1 (2014): 35–42.

30. Dominguez-Bello, M.G., Costello, E.K., Contreras, M., Magris, M., Hidalgo, G., Fierer, N., and Knight, R. “Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns.” Proceedings of the National Academy of Sciences 107, no. 26 (2010): 11971–11975.

Boston Children’s Hospital went from diagnosing almost no eleven-year-olds with central precocious puberty in 2017 through 2019 to diagnosing fifty in a single year. The Children’s Hospital of Philadelphia diagnosed nearly 250 minors with the same condition at age 10 or older between 2017 and 2024, including teenagers aged 14 to 18 — an age at which precocious puberty cannot exist by definition. These findings appear in Wolves in White Coats: How Doctors and Hospitals Pushed and Profited from the Fraud of “Gender Medicine,” a 2026 report commissioned by the U.S. Department of Health and Human Services. The pattern documented is not scattered clinical error. It is the systematic misuse of two diagnostic codes — E34.9 (endocrine disorder, unspecified) and E30.1 (central precocious puberty) — to secure insurance reimbursement for puberty blockers and cross-sex hormones that insurers would not have covered under the actual diagnosis. The report’s own nationwide claims analysis found nearly $50 million billed under the endocrine code and $11 million under the impossible precocious puberty code, for children in the wrong age bands, between 2015 and 2025.

The report was commissioned by HHS and produced by contributors drawn from the Independent Women’s Forum, the Ethics and Public Policy Center, and independent medical practice. Two of the physician contributors carry particular weight for what the document documents. Dr. Eithan Haim, a general surgeon in Texas, anonymously exposed Texas Children’s Hospital’s secret transgender program in May 2023, disclosures that led to the passage of state legislation, a Texas Attorney General investigation, and eventually the $10 million healthcare fraud settlement the report describes. Dr. Quentin Van Meter is a board-certified pediatric endocrinologist with 46 years of continuous clinical experience, trained at Naval Regional Medical Center Oakland and Johns Hopkins. The other contributors include Dr. Aaron Kheriaty, a psychiatrist and bioethicist who has testified before the U.S. and California Senates, and attorneys who have worked on the litigation the report cites. The document’s investigative work rests on primary sources — DOJ court filings, WPATH training slides, published clinic FAQs, whistleblower testimony under oath — not on secondary interpretation.

The document appeared at the moment the federal apparatus for promoting these interventions was being dismantled. The Biden administration had spent four years using executive orders, HHS guidance, CMS rulemaking, DOJ litigation, and EEOC enforcement to expand access to puberty blockers, cross-sex hormones, and surgeries for minors — often over state legislative objection and always without FDA approval of the drugs for these uses. Over 225 hospital systems built pediatric gender clinics during this window. The World Professional Association for Transgender Health, the Endocrine Society, the American Psychological Association, and the American Academy of Pediatrics published guidelines that appeared to represent independent medical consensus. In June 2025 the Supreme Court’s decision in United States v. Skrmetti closed the constitutional route the federal government had used to override state protections. The Texas Children’s Hospital settlement followed in May 2026, the Cleveland Clinic settlement in June, and this report in the second half of the same year. The document was produced when institutional cover was collapsing and the underlying evidence could finally be examined.

The full summary unpacks three findings that together explain how the scheme operated. First: the mechanism by which four ostensibly independent medical societies published converging guidelines that were in fact drafted by an overlapping network — seven of ten Endocrine Society guideline authors were WPATH-affiliated, seven of eight APA task force members were WPATH-affiliated, and the AAP’s 67,000 general members became retroactive “supporters” of a 2018 statement written by a single person and approved by a 13-member board without their input. Second: the specific coaching infrastructure — WPATH training slides, Fenway Health’s public FAQ, the Campaign for Southern Equality’s “Trans in the South” toolkit listing which fabricated diagnoses insurers would accept — that trained clinicians nationally in the coding fraud, published openly until Dr. Haim exposed the toolkit at a Congressional hearing and the page came down. Third: the pattern across eight patient accounts in which children carrying trauma, autism, sexual abuse histories, or documented online grooming were converted into surgical patients within one-hour appointments, and then abandoned by the same institutions when they attempted to reverse course. Layla Jane’s mastectomy at Kaiser San Francisco occurred one month after her thirteenth birthday. She could not sue because her parents had signed an arbitration agreement as part of her health coverage, and the arbitrator ruled the statute of limitations began running when she was 13.

Wolves In White Coats Report

3.53MB ∙ PDF file

Download

Download

Paywall removed for this Summary.

Audio Deep Dive (For all Subscribers)

30 Q&As

Question 1: What does the report mean by “sex-rejecting procedures,” and why does it deliberately reject the term “gender-affirming care”?

Answer: The report uses “sex-rejecting procedures” to describe puberty blockers, cross-sex hormones, and surgeries performed on children who express discomfort with their sex. The chosen terminology is not neutral, and it is not meant to be. “Gender-affirming care” was the industry’s marketing language — a phrase engineered to make interventions sound like compassion and to make refusal sound like harm. The report treats that framing as the euphemism it always was. What is being affirmed is not the child; what is being rejected is the child’s actual body.

The terminology matters because language does the ideological work before the drugs and knives arrive. Calling a mastectomy on a thirteen-year-old girl “top surgery” and framing testosterone injection as “care” reshapes the conversation before evidence enters it. The report’s insistence on precise language — sex-rejecting procedures, chemical and surgical mutilation — restores what the marketing had erased. A healthy adolescent’s breasts are removed. A healthy adolescent’s puberty is chemically halted. These are the events. Naming them accurately is the first act of the accountability the report is trying to establish.

Question 2: How did pediatric gender clinics change the financial calculus of pediatric departments that had historically operated on the thinnest margins in medicine?

Answer: Pediatrics has long been the lowest-paid medical specialty. Pediatric departments in large academic medical centres traditionally generated thinner margins than adult cardiology, oncology, or orthopedics, and wielded correspondingly less internal influence. A typical pediatric encounter treats an ear infection or a rotavirus admission — one visit, one bill, done. Eighty-two percent of pediatric patients between 2008 and 2013 had no chronic conditions at all. That model does not produce revenue at the scale hospital administrators reward.

Gender clinics inverted that equation. They introduced a new category of patient: physiologically healthy children converted, by intervention, into lifelong dependents of the medical system. Once a child is placed on puberty blockers or cross-sex hormones, the Endocrine Society’s own 2017 guidelines call for clinical assessment every three to six months, laboratory monitoring every six to twelve months, and bone density scans every one to two years — for decades. WPATH’s SOC-8 recommends similar cadences continuing through adulthood. Each visit generates a billable encounter, each lab a facility fee, each escalation a surgical revenue line. Pediatrics, endocrinology, plastic surgery, urology, and gynecology all gained continuous revenue where none had existed. In an era of squeezed reimbursements, gender clinics became the growth engine.

Question 3: What is the “captive patient” model, and how does it differ from typical pediatric care?

Answer: A captive patient is one whose entry into treatment forecloses their exit from it. A child arriving at a gender clinic does not receive a one-time intervention; they enter a pipeline. Puberty blockers require ongoing administration. Cross-sex hormones require quarterly assessment and continuous prescription. Surgical procedures require staged operations, revision surgeries for complications, and follow-up care. Complications from earlier procedures — urethral strictures, fistulas, loss of sensation, cosmetic failure — generate additional operating-room time, hospital stays, and further billing. Indirect services embed the patient deeper: fertility preservation, voice therapy, hair removal, mental health counselling for the psychological consequences of the interventions themselves.

The contrast with ordinary pediatric care is stark. A well-child checkup, an ear infection, a broken arm — these are self-limiting events. The child gets better and stops needing the hospital. The captive patient never stops needing the hospital. Insurance reimbursement — private, Medicaid, or Medicare — flows in a predictable, high-margin stream for decades. The model mirrors chronic disease management for diabetes or HIV, with one critical difference: those patients were sick when they arrived. The captive patient walked in physically healthy and was made chronically dependent by the treatment itself.

Question 4: What are the documented lifetime costs of these interventions per patient, and what does the aggregate scale look like across US hospitals?

Answer: Cross-sex hormones alone entail average yearly payer costs ranging from $545 for androgens to $735 for estrogens to $16,385 for GnRH puberty blockers. Lifetime totals for a patient starting as a minor reach $25,000 to $75,000 without any surgery. Compare that with average annual healthcare spending for children under 18 — roughly $3,000. Once surgery is added, individual lifetime spending easily exceeds $100,000 and approaches $170,000. Top surgery averages $12,680 per procedure. Mammoplasty averages $17,426. Vaginoplasty reaches $53,645 across staged procedures. Phalloplasty averages $133,911, before the revisions that complications routinely require.

Scaled across thousands of patients, the aggregate becomes significant. Watchdog analyses tracking billed charges for minors from 2019 onward estimate nearly $120 million in total hospital and clinic billings nationwide, encompassing 5,747 surgical procedures and 8,579 courses of hormones or blockers. Mount Sinai Medical Center in New York billed over $8.2 million; Boston Children’s Hospital, $6.5 million — well over a million per year at each institution across the 2019 to 2023 window. In pediatric departments where margins are traditionally thin, this new patient cohort — young, insured or Medicaid-eligible, and requiring perpetual follow-up — became a strategic growth line that subsidised lower-margin services and elevated the internal power of endocrinology and surgical specialties.

Question 5: What are ICD and CPT codes, and why does the accuracy of coding matter for insurance reimbursement and fraud liability?

Answer: ICD codes document the clinical reason for treatment — the diagnosis. They come from the International Classification of Diseases, currently in its tenth revision, developed collaboratively by the World Health Organization and ten international centres. CPT codes document what the doctor did — the procedure or service. They are promulgated and copyrighted by the American Medical Association. Together, these codes are the common language doctors and insurers use to communicate: the CPT tells the insurer what happened, the ICD tells them why it happened. If the treatment is medically necessary for the diagnosis, the insurer is more likely to reimburse. If not, coverage is denied.

CMS guidelines mandate that doctors code all documented conditions at the highest level of specificity supported by the medical record. HIPAA administrative simplification rules require the use of standardised codes in electronic transactions. When a provider submits false diagnostic codes to secure reimbursement from a federal program like Medicaid or Medicare, they may be liable under the False Claims Act, which carries treble damages plus fines. When they defraud a private insurer, they may be liable under 18 U.S.C. §1347, which criminalises health care fraud regardless of whether the payer is public or private. State false claims statutes add additional exposure. Recent enforcement makes the stakes concrete: Independent Health paid up to $98 million in 2024 for submitting invalid diagnosis codes; Sutter Health paid $90 million in 2021 for unsupported diagnosis codes. The government’s position in announcing the Sutter settlement was direct — providers seeking reimbursement must submit accurate information to ensure proper payment.

Question 6: How is the diagnostic code E34.9 (Endocrine Disorder, Unspecified) being used as a substitute for gender-related diagnoses, and what evidence documents this substitution?

Answer: E34.9 is a diagnostic code for an unspecified endocrine disorder — meant to be used during early workup when the underlying pathology is unknown, before laboratory or imaging tests establish a specific diagnosis. Gender dysphoria is not an endocrine disorder. It produces no hormonal abnormalities. The only endocrine disorders these children have are the ones their doctors create through the interventions themselves. Yet E34.9 is being used, systematically, to describe children with gender dysphoria in order to secure insurance coverage for puberty blockers and cross-sex hormones that would otherwise be denied.

The evidence is unusually clear. A 2016 CMS Office of Minority Health study identified E34.9’s predecessor code as “frequently used by the transgender community to combat the perceived stigma of a GID diagnosis” and named it among the most commonly used non-transgender-specific diagnosis codes. A 2023 University of Iowa study analysed 1,480 patients diagnosed with unspecified endocrine disorder and found only 71 — 4.7% — had an actual endocrine condition. Ninety-six percent were gender-expansive. Leor Sapir’s Manhattan Institute analysis documented a 30% rise in E34.9 diagnoses among minors from 2020 to 2022, a trend not plausibly explained by a genuine surge in endocrine disorders. The report’s own claims analysis found nearly $50 million billed for puberty blockers in patients aged 9 to 17 under E34x codes, with no gender diagnosis and no precocious puberty diagnosis on the claim. Of that, over $40 million was billed specifically under E34.9. The pattern is not incidental. It is architecture.

Question 7: What is central precocious puberty, and why is the E30.1 code appearing on claims for adolescents aged 13 to 17 an indicator of fraud?

Answer: Central precocious puberty is a rare condition with well-defined diagnostic criteria. The traditional threshold for diagnosis is puberty beginning before age 8 in girls or 9 in boys. Treatment with puberty blockers is generally discontinued at age 10 or 11 — the point at which puberty would ordinarily begin. The purpose of the drug in genuine cases is to postpone puberty until the natural age. Puberty occurring within the normal time range is not precocious. It is simply puberty. By definition, no patient over the age of 13 can carry a legitimate diagnosis of central precocious puberty, and no patient of that age should be receiving puberty blockers under that indication.

Yet the claims data shows exactly that pattern at scale. Pennsylvania alone recorded a 2,100% increase in reimbursement for puberty blocker claims using the E30.1 code between 2013 and 2017. The state spent $76 million on puberty blockers for patients 18 and under between 2020 and 2024, with over 1,000 claims for children aged 14 to 18 — children who cannot, by definition, have precocious puberty. The report’s own nationwide analysis found nearly $11 million billed for puberty blockers in patients aged 13 to 17 carrying a precocious puberty diagnosis on the same claim. At the institutional level, Boston Children’s Hospital went from diagnosing almost no 11-year-olds with central precocious puberty in 2017 through 2019 to diagnosing 50 in 2022. The Children’s Hospital of Philadelphia diagnosed almost 250 minors with precocious puberty at age 10 or older between 2017 and 2024, including teenagers aged 14 to 18. A rare condition does not do that. A code being used to launder gender-related prescriptions does.

Question 8: What did the Manhattan Institute analysis, the Pennsylvania data, and the report’s own claims analysis reveal about the scale of miscoded billing?

Answer: Three independent data streams converge on the same conclusion. Leor Sapir’s Manhattan Institute analysis of all-payer claims data documented a 30% rise in E34.9 endocrine disorder diagnoses among minors between 2020 and 2022 — a rise that has no plausible biological explanation. The trend reflects, in Sapir’s words, a greater willingness of gender clinicians to use endocrine disorder codes instead of gender identity codes. He concludes the practice was deliberate, well documented, and pursued with a confidence that neither the medical establishment nor the insurance industry would challenge it. Reporter Meg Brock’s investigation of Pennsylvania Department of Human Services data revealed a 2,100% increase in reimbursement for puberty blocker claims using the precocious puberty code between 2013 and 2017, along with more than 1,900 claims for children aged 10 to 13 and over 1,000 claims for children aged 14 to 18 during the 2020 to 2024 window.

The report’s own nationwide claims analysis, drawn from an all-payer database covering 2015 to 2025, confirms these findings extend well beyond individual states or institutions. Nearly $50 million was billed to public and private insurance for puberty blockers in patients aged 9 to 17 under endocrine disorder codes, with no gender diagnosis and no precocious puberty diagnosis on the claim. Over $40 million of that flowed specifically under E34.9. A separate cohort analysis found nearly $11 million billed for puberty blockers in patients aged 13 to 17 carrying precocious puberty diagnoses — an age at which the diagnosis is medically impossible. Combined with conservative estimates of null-field claims not captured in the source data, tens of millions of dollars have been spent by private and public health insurance based on demonstrably false diagnostic codes. The three data streams tell one story: this is not scattered error. It is a national pattern.

Question 9: What did the DOJ discover at the Children’s Hospital of Philadelphia and Boston Children’s Hospital regarding precocious puberty diagnoses?

Answer: At the Children’s Hospital of Philadelphia, DOJ court filings revealed that between 2017 and 2024, nearly 250 minors received a first-time diagnosis of central precocious puberty at age 10 or older — including numerous teenagers aged 14 to 18. The declaration in support of the government’s investigation stated the finding plainly: this is well beyond the age at which children are typically diagnosed with precocious puberty. The declaration also documented the mechanism: providers using the incorrect diagnosis or billing code — endocrine disorder unspecified instead of gender dysphoria to prescribe cross-sex hormones, or precocious puberty instead of gender dysphoria to prescribe puberty blockers. The government’s investigation into CHOP included allegations of fraudulent billing practices to secure insurance coverage.

At Boston Children’s Hospital, the pattern was even sharper. Government filings noted no clear explanation for why the hospital would go from diagnosing almost no 11-year-olds with central precocious puberty in 2017 through 2019 to diagnosing 50 eleven-year-old patients with it in 2022. The chart included in the declaration shows a single-year spike that has no biological or epidemiological explanation — precocious puberty does not surge that way. What surged was the willingness to apply the code to children who did not have the condition. Both hospitals were subpoenaed by the DOJ as part of a federal investigation into fraudulent billing practices. Boston Children’s is also, notably, a close clinical partner of Fenway Health, which has openly acknowledged using vague diagnosis codes to secure insurance coverage.

Question 10: How did WPATH’s own training presentations coach providers on which codes to use, and what did Dr. Nick Gorton admit about the “linkage of ICD to CPT”?

Answer: The World Professional Association for Transgender Health, the organisation that publishes the standards of care governing this entire field, held a 2021 training presentation titled “Insurance Coverage and Coding Considerations in Gender Affirming Primary Care” delivered by Dr. Madeline Deutsch and Dr. Stephen Rosenthal. The presentation included a slide titled “Other encounter diagnostic codes” recommending E34 for endocrine disorder unspecified and E23/E29 for hypogonadism. A subsequent slide, titled “Care of Transgender/Gender Diverse Adolescents,” listed E34.9 — endocrine disorder, unspecified — as an ICD 9/10 code to use alongside F64.0 for gender dysphoria. The organisation setting the standards for the field was, in the same breath, coaching its members on which alternative codes to submit.

Dr. Nick Gorton, a prominent WPATH member, stated the underlying problem plainly in a lecture titled “Insurance Coverage of Gender Affirming Healthcare: WPATH SOC8 Updates.” His slide read: “Linkage of ICD to CPT can be problematic.” The problem he was referring to was the natural discordance between the procedures providers wanted to perform and the mental health diagnosis codes that would trigger insurance denial. His solution, elaborated in a separate published account, was to enter alternative codes — pelvic pain, for example — to secure coverage for a hysterectomy that would have been rejected under a gender dysphoria code. The admission is significant because it is not an outsider’s characterisation. It is the organisation’s own senior figures documenting, in training materials distributed to clinicians nationally, that the coding was engineered to circumvent insurer scrutiny.

Question 11: What did Fenway Health, QueerDoc, and Planned Parenthood publicly state about their coding practices, and what does this admission reveal about the industry-wide pattern?

Answer: Fenway Health — one of the country’s most prominent gender clinics, a close academic affiliate of Harvard Medical School, and a clinical partner of Boston Children’s Hospital — openly stated on its public FAQ that it can sometimes use a more vague diagnosis code such as hormone disorder, while acknowledging in the same passage that it is not legal to use codes that may be considered clinically inaccurate under the Federal False Claims Act. The organisation went on to state it is working with policymakers and Massachusetts insurers to recognise alternative codes to reduce potential risk to patients. The admission is remarkable: an institution acknowledging that its current coding practice carries fraud exposure and that it is seeking legal cover for the practice rather than abandoning it.

Dr. Crystal Beal’s QueerDoc telemedicine clinic stated on its website that some providers use the code E34.9, endocrine disorder unspecified, and that E34.9 can sometimes be used for labs, prescriptions, and visits. Planned Parenthood of Southeastern Pennsylvania stated it typically uses code E34.9, occasionally F64.9, to meet the needs of insurance companies and patients. Planned Parenthood of Western Pennsylvania acknowledged using the endocrine disorder code while noting the wording of many of these codes was troublesome. QueerDoc was subpoenaed by the DOJ in 2025 for documents relating to whether or how to code or bill for treatment of gender dysphoria using alternative diagnoses or alternative ICD codes. What these admissions reveal is that the miscoding is not the isolated conduct of rogue providers. It is public policy at named institutions, published on official websites, with legal counsel apparently having weighed in on how far the language can go. This is what an industry looks like when fraud has become standard practice.

Question 12: What was the Campaign for Southern Equality’s “Trans in the South” toolkit, and what happened after Dr. Eithan Haim exposed it during Congressional testimony?

Answer: The Campaign for Southern Equality published a resource guide titled “Trans in the South: A Guide to Resources and Services” containing a section called “Insurance Coding Alternatives For Trans Healthcare.” The guide included two tables. The first listed diagnosis codes commonly rejected by insurance — the gender-related F64 codes. The second listed codes commonly accepted by insurance for the same treatments — E34.9 for endocrine disorder to justify hormone replacement, N62 breast hypertrophy to justify mastectomy, N65 deformity of reconstructed breast for further mastectomy or reconstruction, N94.1 dyspareunia for hysterectomy, N92.6 irregular menses for hysterectomy or IUD, N83.2 ovarian cyst for removal of ovaries, R10.2 pelvic pain for hysterectomy or removal of ovaries, N50.819 orchialgia for orchiectomy. The alternative diagnoses were chosen for their diagnostic subjectivity — pain and menstrual complaints rely on patient reporting rather than laboratory testing, making them harder for insurers to challenge.

Dr. Eithan Haim, one of the report’s contributors and the whistleblower who exposed Texas Children’s Hospital’s secret transgender program, presented the toolkit to Texas Representative Brandon Gill during a Congressional hearing in April 2025. His characterisation was direct: this document is a template for how to commit medical fraud. It teaches doctors how to bill insurance companies for interventions without revealing they are being used for gender dysphoria. How do you do a mastectomy without raising red flags? You bill it as breast reduction. His testimony noted that people go to prison for this. In the days following the hearing, the Campaign for Southern Equality webpage displaying the toolkit was taken down. The removal is telling. If the toolkit represented legitimate clinical guidance, there was nothing to hide. Its disappearance after Congressional exposure confirms what its authors understood about what they had published.

Question 13: What did nurse Vanessa Sivadge witness at Texas Children’s Hospital, and what specific fraud mechanisms did she document?

Answer: Vanessa Sivadge worked as a nurse in the gender clinic at Texas Children’s Hospital and went public as a whistleblower in June 2024. Her allegations were specific and severe: TCH was illegally billing Medicaid for transgender procedures despite a 2019 Texas Health and Human Services Commission rule barring Medicaid coverage of sex-change operations, hormones, and blockers. She named two pediatric endocrinologists, Dr. Paul David and Dr. Richard Roberts, the co-medical directors of the Transgender Care Program. The core question her testimony answered was how the hospital had been bypassing the Medicaid exclusion without triggering claims review.

Her testimony to the Texas House Judiciary Subcommittee documented the mechanisms. The hospital misdiagnosed patients to justify the treatments — labelling a biological male with an estrogen deficiency to justify prescribing estrogen, labelling a biological female with a testosterone deficiency to justify prescribing testosterone. The hospital falsified medical records by listing the patient’s preferred gender identity on the record instead of the birth sex, creating a web of confusion that made the fraudulent billing difficult to detect. Omitting the gender-related F64.0 diagnosis from Medicaid claims fraudulently concealed the actual reason for the hormone interventions from claims analysts. The scheme was not a coding shortcut. It was a coordinated system of falsified diagnoses, falsified sex records, and misdirected billing designed specifically to defeat the state’s prohibition. Sivadge’s allegations became the seed from which the Texas Attorney General’s investigation grew — and from which, ultimately, the $10 million TCH settlement emerged.

Question 14: What was the “wean protocol” at Children’s Health Texas, and how was it designed to evade the state’s SB-14 ban?

Answer: Texas SB-14 took effect on September 1, 2023, prohibiting sex-rejecting interventions for minors. The Texas Attorney General’s Office alleged in a February 2025 lawsuit that Children’s Health System of Texas and Dr. Jason Jarin, a pediatric gynecologist at UT Southwestern, developed what they called a “wean protocol” ostensibly to comply with the law while in reality subverting it. The petition alleged Dr. Jarin met repeatedly with hospital leadership under the framing of crafting compliance measures, when the actual work was crafting pretextual protocols to justify continued illegal prescription of cross-sex hormones and puberty blockers to children.

The mechanics were elaborate. The protocol weaned patients over long periods with miniscule interval dose changes designed to maintain the same or similar physiological effect until the patients reached 18 years of age — meaning the drugs continued to work as before, with the paperwork suggesting compliance with a taper. Medical exceptions were determined based on the hormonal reference range for the patient’s opposite sex rather than their actual sex, ensuring that patients would consistently qualify for continued treatment. Broad, pretextual, and medically unsupported exceptions were created for “bone health” and “mental health stability” that ensured patients would never actually have to wean at all. The Attorney General’s Office filed additional healthcare fraud claims in December 2025 alleging that false, misrepresentative, and misleading billing codes constituted billing fraud to secure Medicaid reimbursement for services Texas law and Texas Medicaid explicitly do not allow. The protocol reveals how the fraud adapted when the law changed: the same drugs, the same doses, delivered under new paperwork engineered to survive audit.

Question 15: What did the Texas Children’s Hospital settlement in May 2026 establish, and why is it a landmark in pediatric medicine?

Answer: On May 15, 2026, Texas Attorney General Ken Paxton and the U.S. Department of Justice announced that Texas Children’s Hospital would pay a $10 million fine — the second largest healthcare fraud settlement in the history of pediatric medicine — for billing Texas Medicaid for unallowable and illegal gender-transition interventions, including through the use of false diagnosis codes. The settlement resolved allegations rooted in the whistleblower testimony of Vanessa Sivadge and the investigative work of Dr. Eithan Haim. It stands as the first major financial penalty imposed on a major children’s hospital for the specific pattern of miscoded billing this report documents.

The settlement’s terms extended well beyond the fine. TCH agreed to terminate the employment of five doctors who performed the interventions. The hospital amended its bylaws to trigger automatic relinquishment of privileges for any physician who violates Texas’s prohibition on sex-rejecting procedures — meaning any doctor who resumes the practice loses hospital access without further process. The settlement established the country’s first Detransition Clinic, funded entirely by TCH for its first five years, free of charge to patients. Less than a month later, on June 5, 2026, the Cleveland Clinic Foundation reached a monetary settlement resolving allegations of false billings to public and private payers for sex-rejecting procedures on minors, committing $2 million to provide restorative care for detransitioners regardless of insurance status or ability to pay. The landmark is not simply that a hospital paid. It is that the settlements created, for the first time, funded infrastructure for the people the system harmed — and established that the physicians responsible could lose their careers for continuing.

Question 16: How did the Biden administration use federal civil rights law, executive orders, and agency guidance to promote sex-rejecting procedures across the healthcare system?

Answer: Hours after taking office on January 20, 2021, President Biden issued an executive order declaring it federal policy to prevent and combat discrimination on the basis of gender identity, directing federal agencies to implement the policy through orders, regulations, guidance documents, and enforcement actions. The entire administrative machinery of the federal government was then turned toward expanding sex-rejecting procedures. HHS reinterpreted Section 1557 of the Affordable Care Act — the healthcare nondiscrimination provision — to hold that refusing to provide access to these procedures constituted sex discrimination, opening providers and insurers to federal investigation. The March 2022 guidance document stated that categorically refusing to provide treatment based on gender identity was prohibited discrimination and that restrictions on medically necessary care likely violated Section 1557. CMS approved Colorado’s essential health benefits benchmark plan requiring insurance coverage of the full range of interventions, with Administrator Chiquita Brooks-LaSure calling Colorado a model for other states to follow.

The reach extended to nearly every federal agency. HHS’s Office of Population Affairs issued guidance endorsing puberty blockers, cross-sex hormones, and top and bottom surgeries starting in early adolescence — despite FDA never having approved any of these drugs for these purposes. The DOJ sent a letter to state attorneys general reminding them of federal protections for youth seeking the procedures, and filed statements of interest in lawsuits challenging state prohibitions. The EEOC took the position that excluding coverage from employee health plans constituted both sex and disability discrimination. The DOJ argued in prison litigation that denying access to the procedures was cruel and unusual punishment under the Eighth Amendment. Secretary of State Anthony Blinken called denial of these procedures “violence.” OPM directed federal employee health carriers to cover the interventions. The Department of Defense provided taxpayer-funded coverage for military service members. HHS’s April 2024 HIPAA rule was designed, in the agency’s own acknowledgement, to make it more difficult for law enforcement to investigate whether reproductive health care was unlawful. The apparatus was not incidental. It was coordinated, aggressive, and coextensive with the reach of federal authority.

Question 17: What did the NIH-funded Olson-Kennedy study reveal, and why was some of its data suppressed from publication?

Answer: The National Institutes of Health paid nearly $10 million for a study on puberty blockers and cross-sex hormones for youth, led by Dr. Johanna Olson-Kennedy. The study’s puberty blocker data was intentionally suppressed by the researcher. The reason was not scientific. She told The New York Times in October 2024 that she had withheld the findings out of concern that they would support state laws prohibiting sex-rejecting procedures for minors. The data, in other words, was unfavourable to the interventions — and that unfavourability was itself the reason for suppression. The House Committee on Oversight and Government Reform launched an investigation into the suppression of taxpayer-funded research.

The study data that was published on cross-sex hormones fared no better under scrutiny. The lead author declared the results provided a strong scientific basis that gender-affirming care is crucial for the psychological well-being of patients. The methodological reality contradicted the announcement. The study’s hypothesis was retroactively changed after inconsistent findings emerged. The study failed to report findings for six of the eight variables in the original preregistered hypothesis. The study contained multiple confounding variables, including participant use of psychotherapy that the analysis did not adequately control for. Most gravely, two of the 315 study participants died by suicide after starting cross-sex hormones — a finding that would, in any other therapeutic context, prompt immediate re-evaluation of the treatment itself. Here it was folded into a positive conclusion. Ten million taxpayer dollars purchased research that was either suppressed for reaching the wrong conclusions or restructured to reach the right ones. The scientific record has been shaped accordingly.

Question 18: What was the Supreme Court’s decision in United States v. Skrmetti, and how has the Trump administration reversed the Biden-era framework?

Answer: In June 2025, the Supreme Court rejected the constitutional challenge that the Biden Department of Justice had brought against state laws prohibiting sex-rejecting procedures for minors. The Biden DOJ had argued that Tennessee’s SB-1 and similar state laws violated the Equal Protection Clause of the Fourteenth Amendment. The Court’s decision in Skrmetti closed the constitutional avenue by which the federal government had sought to override state protections for children. The ruling removed the legal ceiling that had constrained states from acting and left the field of policy to legislatures rather than to litigation.

The Trump administration’s reversals across the executive branch were coordinated and comprehensive. Attorney General Pam Bondi filed a letter reversing the government’s position in Skrmetti. HHS rescinded the May 2021 Section 1557 notification and the March 2022 guidance, and issued a clarification rejecting the theory that gender dysphoria not resulting from physical impairment qualifies as a protected disability. CMS finalised a rule prohibiting essential health benefit status for the procedures, sent a letter to state Medicaid directors noting the procedures lack reliable evidence of long-term benefits and are known to cause long-term irreparable harm, and proposed rules limiting federal Medicaid, Medicare, and CHIP funding. CMS Administrator Mehmet Oz requested an urgent review of hospital quality standards. The FTC hosted a workshop on the dangers of the procedures and launched a public inquiry into consumer harm. HHS commissioned an independent peer-reviewed umbrella review that found the procedures carry risk of significant harms. HHS opened a whistleblower portal. The FBI solicited tips. Bondi’s memo “Preventing the Mutilation of American Children” directed DOJ to investigate suspected cases of female genital mutilation and False Claims Act violations. OPM removed federal employee coverage. The Department of Defense reversed its coverage policy. The Department of Veterans Affairs rescinded its directive on cross-sex hormone therapy. The apparatus that had been aimed at expansion was, within months, aimed at accountability.

Question 19: What is WPATH, and how did its guidelines evolve from Harry Benjamin’s cautious 1949 approach to endorsing hormones and surgeries for children at the onset of puberty?

Answer: The organisation now known as the World Professional Association for Transgender Health was founded as the Harry Benjamin International Gender Dysphoria Association, named after the New York internist who became involved in these interventions in 1949 when sexologist Alfred Kinsey referred a patient — a male raised as a girl who wished to rid himself of all physical signs of maleness. Benjamin’s approach was cautious. He believed hormone treatment might be reasonable but recognised no one knew the long-term implications for the health and well-being of patients so treated. He urged patients to proceed slowly and to change the body only as a last resort. His cautious approach was codified in the earliest standards of care published by his association in 1979, which provided that hormonal and surgical treatments should be administered only to adults.

The subsequent trajectory was one of continuous loosening. WPATH first endorsed the Dutch Protocol in 1998, permitting puberty blockers at the onset of puberty, cross-sex hormones for those 16 or older, and surgery only for adults. In 2012 the guidelines relaxed further to permit cross-sex hormones for children under 16. Version 8 in 2022 endorsed puberty blockers and cross-sex hormones at the onset of puberty and allowed children to receive many surgical procedures previously reserved for adults. Under-oath testimony established that WPATH’s official position is that castration may be a medically necessary procedure even for a physically healthy man with no recognised mental health conditions who presents as a eunuch seeking castration. The 2022 revision was, on its own authors’ admission in emails later uncovered, hoped to land in such a way as to have serious effects in the law and policy settings. WPATH removed age limits for adolescent surgeries under pressure from the Biden administration on the theory that age listings would result in devastating legislation for trans care. The organisation setting global clinical standards was — as an Eleventh Circuit judge put it — an organisation whose lodestar is ideology, not science.

Question 20: How did the Endocrine Society, American Psychological Association, and American Academy of Pediatrics come to publish guidelines that mirror WPATH’s positions?

Answer: The mechanism was overlapping authorship. The Endocrine Society published revised guidelines for the treatment of gender-dysphoric persons in 2017. The guidelines identified ten authors, at least seven of whom appear to have been affiliated with WPATH, and one of whom is listed as an author on WPATH’s 2022 guidelines. The Endocrine Society’s guidelines foreshadowed WPATH’s relaxations, suggesting suppression of puberty for adolescents meeting diagnostic criteria for gender incongruence and stating there may be compelling reasons to initiate sex hormone treatment before age 16 in some adolescents — even though the guidelines conceded there are minimal published studies of these treatments administered before ages 13.5 to 14. The American Psychological Association’s 2015 Guidelines for Psychological Practice with Transgender and Gender Nonconforming People was assembled by an eight-member task force, at least seven of whom were WPATH members or otherwise affiliated with the organisation. The guidelines’ stated purpose was assisting psychologists in trans-affirmative practice.

The American Academy of Pediatrics followed a distinct but equally troubling path. In 2016 the AAP partnered with the Human Rights Campaign to create a guide for families with transgender children. Jason Rafferty then modified this guideline to craft the 2018 Policy Statement, which mirrored the 2009 Endocrine Society guidelines but explicitly labelled any kind of mental health evaluation or treatment as unethical. The statement was approved by the AAP’s 13-member Board of Directors without any input from the organisation’s 67,000 general members. Those 67,000 pediatricians were retroactively made supporters of a position they had never seen. AAP membership only became aware of the content after publication. The prominent LGBT-advocate psychologist James Cantor immediately took the position statement to task, pointing out its countless flaws. In 2023 the AAP Board unanimously reaffirmed the 2018 statement — again, without waiting for its own systematic review of the evidence, which still has not been completed. In each of these organisations, the mechanism was the same: a small ideologically committed group produced the language, and the institutional imprimatur was applied on top.

Question 21: What role did online platforms like Roblox, Minecraft, and Discord play in the exposure of children to gender ideology, based on the first-hand accounts?

Answer: The pattern across the parent and detransitioner accounts is unmistakable. Children were introduced to gender ideology not through their families, their schools, or their doctors — but through the chat features of games marketed as safe creative play. Lily Burns believed she was protecting her children by providing only non-smart phones and permitting creation-focused video games like Roblox and Minecraft. She did not know about the chat features. It was through those chats that her oldest son met a transgender-identifying adult and was first exposed to the ideology. Christy Davidson’s son Thomas encountered the concept at age 12 while playing Minecraft. He chose a pink-and-blue bandana for his character. Other players began praising him for being transgender and introduced him to gender identity concepts. The conversation moved from the game to the messaging app Discord, where the exposure deepened into what Davidson later discovered were inappropriate exchanges.

Luke Healy’s account is the most explicit. He first encountered gender ideology online at age 10. What began with ordinary childhood interests — anime, fantasy, internet fandoms — progressed to online communities where adults and older peers discussed sex, pornography, and transgender identity with children. In his own words, some of those adults actively groomed him. By 13 he believed he was a girl in the wrong body. The pattern reveals what parental controls could not catch: the vector was not content posted for children to consume, it was contact with adults inside spaces designed for children. Sydney Aviles’s early exposure came through a news clip about transgender individuals using opposite-sex bathrooms, which planted a seed that grew through online searching. Clementine Breen searched the internet with questions like “Why do I hate being a girl?” and the search results led her to gender ideology. Across the accounts, the internet was not merely where the children encountered the ideology. It was where the ideology reached them, groomed them, and — in Healy’s word for it — recruited them.

Question 22: How were school counsellors and clinics coordinating to socially transition children without parental knowledge?

Answer: The accounts document a consistent pattern in which schools functioned as the first medical intake. Layla Jane pretended to be a boy at school in the sixth grade, and the school did not inform her parents. School officials coordinated meetings with Pride Center adults on campus without parental knowledge. By the time Jane told her parents she believed she was a boy, she had already been living a double life for months, with the school as the infrastructure that maintained the concealment. Clementine Breen confided in a school guidance counsellor at age 12. Within months the counsellor had coordinated meetings at school to socially transition her, including explaining transgenderism to her classmates. Her parents were only pulled in after the social transition was already underway.

Luke Healy’s account describes a similar dynamic. When he told his parents he believed he was a girl, they were alarmed and sought help through Kaiser Permanente. The people who actually engaged the question of what might have caused his distress were his parents. The institutional figures — counsellors and medical providers — treated the new identity as settled and moved quickly to affirm it. What emerges across the accounts is a coordinated pipeline in which schools acted as the recruitment and social-transition layer, referring children to LGBTQ community centres and gender clinics that then delivered the medical intervention. Parents were kept out of the process at the school stage and, once they arrived at the clinic stage, were presented with a settled diagnosis and a treatment plan already in motion. The clinics did not treat parents as partners in their child’s care. They treated parents as obstacles to be managed.

Question 23: What was the “live son or dead daughter” framing that providers presented to parents, and how did it function as a pressure mechanism?

Answer: The framing was direct and it was used deliberately. Layla Jane’s parents were told that failing to allow their daughter to undergo sex-rejection interventions could mean losing their child. The choice presented to them was starkly binary: a live son or a dead daughter. Trusting the doctors and desperate to protect their child, they consented. Christy Davidson’s family encountered the same script. The social worker at Phoenix Children’s gender support program told them that hormones were necessary — without them, Thomas would commit suicide. The Kaiser Permanente psychologist who diagnosed Lily Burns’s son with gender dysphoria after just three appointments recommended cross-sex hormones and cited the WPATH standards of care. Sydney Aviles’s practitioners at Lurie Children’s Chicago told her the side effects should not deter her from starting testosterone.

The mechanism is coercive by design. Parents arrive at a clinic with a distressed child. They are told, by people wearing white coats, that the alternative to compliance is their child’s death. No parent is equipped to challenge that framing in the moment. The specialist speaks with the weight of medicine behind them. The evidence for the underlying claim — that these interventions prevent suicide — is precisely the evidence the HHS review found to be missing. But that finding came later. In the room, the parent has minutes to decide and no counterweight to the professional certainty being deployed against them. The framing works because it converts a treatment decision into an immediate life-or-death emergency, foreclosing any deliberation that might arrive at a different answer. It works also because the people using it know what they are doing. Under-oath emails from WPATH authors reveal they hoped their guidelines would land with serious effects in litigation. The suicide framing was part of the same rhetorical strategy — a claim engineered less to describe reality than to produce parental consent under duress.

Question 24: What happened to Layla Jane, and what does her case reveal about forced arbitration and statute of limitations barriers to accountability?

Answer: Layla Jane was 11 when she began experiencing discomfort with her body. She had entered puberty early, was being bullied, and struggled with undiagnosed autism, severe anxiety, and depression. She had experienced suicidal ideation since elementary school. Instead of receiving comprehensive mental health treatment, she found her way to online transgender content and Caitlyn Jenner coverage. Kaiser Permanente quickly diagnosed her with gender dysphoria without a full diagnostic workup for her longstanding mental health conditions. At 12 she was prescribed Lupron. In June 2017 she began testosterone. In September 2017, one month after her 13th birthday, she underwent a double mastectomy at Kaiser San Francisco. Her parents were told the choice was a live son or a dead daughter. At 17 she began questioning her transition. She tapered herself off testosterone without medical supervision. No provider followed up when she stopped picking up prescriptions.

Shortly after turning 18, Jane filed a medical malpractice claim against Kaiser. Her case was dismissed on procedural grounds that reveal how the legal system has been engineered to protect the providers. Because her parents had signed a Kaiser Permanente arbitration agreement on her behalf as part of her health coverage, she was barred from a jury trial — a public forum in which evidence would be examined and testimony taken under cross-examination. An arbitrator instead ruled that the statute of limitations began running when she was 13, the year of her surgery. She would have needed to sue by age 16. She did not detransition until nearly 18. No doctor faced cross-examination. No public record was created. Jane now lives with chronic joint pain, urinary dysfunction, nerve damage, and the permanent alterations to her voice and body. She advocates for extended statutes of limitations for minors and reform of forced arbitration agreements. Her case shows that the legal system built around these interventions ensures the harm outlives every deadline for accountability.

Question 25: What did Clementine Breen experience after her double mastectomy at age 14, and how did her providers respond when she began to detransition?

Answer: Breen was 12 when she encountered gender dysphoria online. She had been sexually abused at age seven but had not processed the trauma. As puberty approached she felt intense anxiety about her changing body and began searching the internet with questions like “why do I hate being a girl?” The search results led her to gender ideology. She confided in a school guidance counsellor, and her parents were contacted immediately. Within months the counsellor had coordinated her social transition at school. At Children’s Hospital Los Angeles her first appointment was approximately one hour long. Clinicians told her parents she was 100 percent trans and at high risk of suicide if not affirmed. She was 12. She was placed on Lupron shortly thereafter, began testosterone at 13, and underwent a double mastectomy at 14. No comprehensive evaluation of her childhood sexual abuse was conducted before medicalisation.

Following her mastectomy her testosterone dose was more than doubled from 30 mg to 70 mg weekly to stabilise her mental health. Within months she experienced severe insomnia, obsessive exercise, disordered eating, escalating anger, and a psychotic episode. She began self-harming for the first time in her life. Her healthcare providers did not attribute these symptoms to testosterone. She was prescribed multiple psychiatric medications simultaneously — Zoloft, Seroquel, Guanfacine, Hydroxyzine. When she later entered Dialectical Behavioural Therapy for trauma and began confronting her sexual abuse, she realised her identity distress had been intertwined with the unaddressed abuse. At 18 she stopped testosterone. Her psychosis resolved. Her first menstrual cycle occurred at nearly 19, and she was emotionally overwhelmed and unprepared. When she began stating plainly that she was a woman and regretted the interventions, her providers became evasive and eventually ceased responding to her emails and calls. She now experiences irregular menstrual cycles, severe cramps, chest pain during menstruation, and vaginal atrophy requiring topical estrogen. An OB-GYN told her there is no established care plan for patients with her medical history. Her lawsuit was limited by California’s statute of limitations. Her message to medical professionals: if I can’t give you a reason why I’m doing something, you shouldn’t be doing it.

Question 26: What documented physical harms did the detransitioners describe, and why does the medical system have no protocol for treating them?

Answer: The catalogue is long and consistent. Sydney Aviles developed sub-clinical hypothyroidism requiring lifelong levothyroxine, elevated red blood cell and hematocrit counts, and vasovagal syncope that caused seizures during blood draws — leaving her unable to safely undergo the therapeutic phlebotomy that would have managed the hormone side effects. Layla Jane’s abnormal liver labs at age 14 were never attributed to the testosterone she was injecting weekly. She now lives with severe joint instability, back pain from no strenuous activity, hips and knees that crack painfully, urinary dysfunction, chronic nerve pain from her mastectomy — electric shocks, numbness, phantom itching beneath grafted skin — genital atrophy, and permanent voice changes. Clementine Breen has irregular untrackable menstrual cycles, severe cramps, chest pain during menstruation, vaginal atrophy requiring topical estrogen. Soren Aldaco required manual expression of post-operative hematoma with Q-Tips and had three cups of blood drained from her chest post-mastectomy. Luke Healy developed gynecomastia from estrogen. Rose Marie has a permanently deep voice, fatigue, weakness, limb tingling, difficulty using the bathroom, and irregular menstrual cycles. Across all accounts, retained mammary tissue after mastectomy still carries breast cancer risk, and lost fertility and inability to breastfeed are permanent.

The medical system has no protocol for treating any of it. The reason is structural. The interventions were built on the premise that transition was the endpoint. No one designed a reversal pathway because the ideological framework did not permit reversal to exist. Detransitioners across the accounts describe the same experience: being told they are in uncharted territory, having their providers cease communication once they announce detransition, finding no doctor who knows what to do. Breen was told by an OB-GYN there is no established care plan for patients with her medical history. Rose Marie found no medical help after stopping testosterone. The absence is not a knowledge gap awaiting research. It is the predictable consequence of a treatment paradigm that treated its casualties as impossibilities. The Texas Children’s Hospital settlement’s establishment of the country’s first Detransition Clinic in May 2026 is significant precisely because it acknowledges what the system had denied for a decade — that these patients exist, that they need care, and that the institutions responsible for their harm bear responsibility for their treatment.

Question 27: What patterns emerged across the eight patient accounts regarding underlying trauma, autism, mental health conditions, and the failure to address them?

Answer: The pattern is present in every account and absent from every clinical response. Sydney Aviles had experienced sexual assault and her parents’ divorce, entered puberty at 9 with severe PMDD symptoms, and struggled with mental health. Rose Marie was in and out of foster care and homeless at 16 when she encountered the LGBTQ centre that referred her for hormones. Clementine Breen was sexually abused at age 7 and never processed the trauma before the abuse was diagnosed a decade later. Layla Jane had undiagnosed autism, severe anxiety, depression, and suicidal ideation since elementary school. Christy Davidson’s son Thomas had autism and a rare chromosomal disorder. Luke Healy was groomed online from age 10 by adults who discussed sex and pornography with him. Soren Aldaco entered the medical system through online communities that framed sex rejection as the appropriate response to her adolescent distress. Lily Burns’s son was groomed through Minecraft chat by a transgender-identifying adult. The children arriving at these clinics were carrying trauma, neurodevelopmental conditions, mental health diagnoses, or grooming histories that would, in any competent clinical assessment, have been the primary focus of care.

They were not the focus of care. The response was uniform across the institutions: diagnose gender dysphoria after a brief evaluation, prescribe puberty blockers or hormones, refer for surgery. Clementine Breen was told she was 100 percent trans in a one-hour appointment. Sydney Aviles received a referral to Lurie Children’s after her therapist accepted her transgender identity without question. Layla Jane received minimal mental health diagnoses in her records — social anxiety, later mood disorder not otherwise specified — before irreversible surgery. Luke Healy noted the only people who seriously asked what might have caused his distress were his parents. The clinical failure is not that these children were misdiagnosed. It is that no genuine diagnosis was attempted. The transgender identity was accepted as self-evident and the underlying conditions — trauma, autism, depression, grooming — were either ignored or interpreted as evidence supporting the diagnosis rather than as candidate explanations for the distress. A generation of children was medicalised for conditions they did not have while the conditions they did have went untreated.

Question 28: How did the report use claims data methodology to identify institutions involved in these practices, and what are the limitations of that analysis?

Answer: The report drew on a nationwide all-payer medical claims database covering 2015 through 2025, limited to minor patients. Patient age was estimated from birth year alone with July 1 assigned as a default birthdate, meaning all age values are approximate. Three cohorts were constructed. Cohort A identified claims for puberty blockers carrying an endocrine disorder diagnosis on the same claim, with no gender-related diagnosis and no central precocious puberty diagnosis, in patients aged 9 to 17 — a combination that isolates prescriptions justified only by the vague endocrine code. Cohort B identified claims for puberty blockers carrying a central precocious puberty diagnosis in patients aged 13 to 17, the age band at which precocious puberty cannot exist by definition. Cohort C examined cross-sex hormone prescriptions in states with prohibitions in force, restricted to minors, with the hormone direction crossing the recorded sex. Each cohort was summarised by payer channel and by the specific codes billed, and organisations were identified by National Provider Identifier where at least one qualifying claim was submitted.

The limitations are stated with care. Reported claim charges reflect billed amounts captured in the source data. Some claims — value-based care arrangements, for example — may record charges as null, meaning the totals are conservative under-representations of actual charges. All results are treated as directional signals rather than findings and require verification against underlying records. Rows billed under an individual provider NPI with no organisation name are excluded. The list of organisations shows which appear, not how many patients each had. The state used for the cross-sex hormone cohort is where the visit happened, not where the patient lives; visits whose location could not be determined are excluded. Anti-androgens and similar supporting medications were excluded because they have no directional test. Only paid, dispensed prescriptions were included. The cross-sex determination rested only on the relationship between the prescription and the recorded sex, independent of coding practice elsewhere in the record. The methodology is transparent about what it cannot prove — the data flags patterns worth investigation, not conclusive findings of wrongdoing. What the data does establish is that the patterns are national, not confined to the institutions already the subject of legal action, and that tens of millions of dollars have been billed to public and private insurance under codes that cannot bear scrutiny.

Question 29: What recommendations does the report make for policymakers, regulators, and law enforcement to address the fraud?

Answer: The report’s recommendations sit on the demonstration that the tools for enforcement already exist and have already been used successfully against other forms of healthcare fraud. Government actors — Congress, state legislators, and executive branch officials at both state and federal levels — have the tools needed to investigate and prosecute this activity. The recent cases confirm the framework: the $98 million Independent Health settlement and the $90 million Sutter Health settlement demonstrate that the federal government has vigorously enforced the False Claims Act against providers submitting unsupported or invalid diagnosis codes. The $10 million Texas Children’s Hospital settlement and the Cleveland Clinic resolution show the same framework applies to sex-rejecting procedures. What has been missing is not legal authority. What has been missing is the willingness to apply it.

The specific recommendations follow from that framework. State Medicaid programs should conduct periodic reviews of claims associated with the ICD codes documented in the report — particularly E34.9 and E30.1 — to ensure providers are not submitting false claims and are in alignment with federal and state laws. States should ensure that managed care organisations have similar internal controls. When suspicious coding or billing is identified, states should follow federal regulations regarding referrals to their Medicaid Fraud Control Units, state Attorneys General offices, or U.S. Attorney’s Offices. Section 1902(a)(61) of the Medicaid Act requires that state Medicaid plans provide for the operation of a Medicaid Fraud Control Unit unless the state demonstrates it is not cost-effective. Sections 1903(a)(6), 1903(b)(3), and 1903(q) govern federal matching funds and set standards for effective performance including investigation and prosecution of provider fraud. States must comply to receive federal financial participation. The report also identifies a role for the private bar: attorneys can pursue judgments by identifying false billing practices and filing suit under the False Claims Act, which allows private parties to bring qui tam actions on behalf of the government and share in the recovery. The infrastructure to prosecute this fraud is not hypothetical. It is statutory, funded, and demonstrably effective. The report’s recommendation is to use it.

Question 30: What does the report mean when it concludes that the exposed fraud is “only the tip of the iceberg”?

Answer: The phrase does specific work. It signals that everything documented in the report — the nearly $50 million in miscoded endocrine claims, the $11 million in impossible precocious puberty claims, the CHOP and BCH patterns, the Texas Children’s Hospital scheme, the Cleveland Clinic settlement, the WPATH training materials, the Fenway and QueerDoc and Planned Parenthood admissions, the eight harrowing patient accounts — represents what became visible when the federal government began to look. The visible portion is substantial. It also, by the nature of the enforcement mechanisms that produced it, cannot be the whole. Only interventions billed through insurance appear in the claims data. Cash pay or care billed outside insurance channels is not captured. Only institutions with National Provider Identifiers submitting qualifying claims appear in the rosters. Only patterns matching the specific cohort definitions surfaced in the analysis. Every methodological choice was conservative. The scale beneath the visible is unknown, and every indicator suggests it is larger than what has been documented.

The framing also carries a diagnostic point about what the report is describing. What the fraud reveals is not the failure of a small number of bad actors within an otherwise sound system. It is the standard operating procedure of a system in which the professional societies coach the coding, the clinics publish the coding on their websites, the advocacy organisations distribute the toolkits, the federal government under one administration promoted the underlying interventions, the insurance companies paid the claims, and the medical schools produced generations of practitioners trained to see all of this as care. The visible fraud is the portion that generated documentation. The invisible portion is everything that happened within the same architecture, at the same institutions, using the same techniques, that did not generate documentation — or whose documentation has not yet been examined. Given that combination of financial incentives, ideological capture, and regulatory failure, the report’s authors conclude the exposed fraud is only the tip of the iceberg. The judgement is not rhetorical. It is what the visible evidence, extrapolated by the mechanisms that produced it, requires.

Analogy

Imagine a small town where the local pediatric clinic has always operated at the edge of solvency. Children get ear infections, break their arms, and stop needing the clinic. One day the clinic discovers a new category of patient: healthy children who, if a certain diagnosis is applied to them, will require monthly visits, quarterly labs, staged surgeries, and lifetime medication — for decades. The insurance company will pay for all of it, provided the paperwork lists a physical condition rather than the actual reason.

The clinic learns to write the paperwork correctly. When the child does not have the physical condition, the clinic writes it anyway — endocrine disorder, unspecified, will do. When the child is fourteen, the clinic writes down that the child has a condition that ends at age eleven — precocious puberty. The professional association publishes training slides showing which codes work. The advocacy groups publish toolkits listing which alternative diagnoses insurance will accept without asking questions. The Harvard-affiliated clinic across town publishes a FAQ acknowledging the practice may not be legal but explaining they are working on that. The federal government, for four years, tells the clinic this is civil rights work and threatens investigation of anyone who refuses to participate.

The children in this town are not sick. They arrive troubled — some autistic, some sexually abused, some groomed by adults online, some in foster care, some simply girls uncomfortable with puberty. The clinic tells their parents that if they refuse the drugs and the surgeries, their child will die by suicide. The parents, terrified and trusting the white coats, sign the forms. The children have their breasts removed at thirteen. Their puberty is chemically halted. Their voices deepen. Their fertility ends. Some, years later, realise what happened and try to reverse course. The clinic stops answering their emails. There is no protocol for them. They are told they are in uncharted territory.

The paperwork is the fraud. The children are the harm. The billions of dollars are the reason. The report’s task is to walk into that clinic with the documents, the whistleblowers, the settlements, and the patients’ own testimony — and show that every part of the machinery worked exactly as it was designed to.

The One-Minute Elevator Explanation

American hospitals discovered that healthy children diagnosed with gender dysphoria could be converted into lifelong medical dependents worth up to $170,000 each in billable revenue. Over 225 hospital systems built pediatric gender clinics. The problem was that insurance would not always pay for these interventions under the actual diagnosis, so providers systematically submitted false diagnostic codes — labelling gender dysphoria as endocrine disorder unspecified, or fabricating central precocious puberty diagnoses for fourteen-year-olds, which is medically impossible. Boston Children’s Hospital went from diagnosing almost no eleven-year-olds with precocious puberty to diagnosing fifty in a single year. The Children’s Hospital of Philadelphia diagnosed 250 minors with the condition at age 10 or older, including teenagers. The World Professional Association for Transgender Health, the Endocrine Society, and the American Academy of Pediatrics — all interlocked by shared authorship — set the standards that made the pipeline possible. The Biden administration used every federal agency to promote the interventions and threaten anyone who refused. Whistleblowers exposed the scheme. Texas Children’s Hospital paid $10 million and funded the country’s first Detransition Clinic. The Supreme Court closed the constitutional route the federal government had used to override state protections. The patients — girls without breasts, women who cannot menstruate normally, young men with gynecomastia and no protocol for their care — remain. The report documents the fraud, the harm, the ideology that enabled both, and concludes that what has been exposed is only the tip of the iceberg. [Elevator dings]

Threads to follow: the Cass Review in the United Kingdom, which independently reached similar conclusions about the evidence base; the SEGM (Society for Evidence-Based Gender Medicine) publications documenting the international reversal in Europe; and Leor Sapir’s ongoing work at the Manhattan Institute on insurance fraud in transgender medicine.

12-Point Summary

1. The captive patient model transformed pediatric medicine’s economics. Pediatrics had long been the lowest-paid, thinnest-margin specialty in medicine, treating acute conditions that resolved and stopped generating revenue. Gender clinics inverted that structure by converting physically healthy children into lifelong medical dependents. Once a child was placed on puberty blockers or cross-sex hormones, the Endocrine Society’s own guidelines called for quarterly clinical assessment, biannual lab monitoring, and periodic bone density scans continuing through adulthood. Individual lifetime costs reached $75,000 without surgery and $170,000 with surgery. Aggregate billing across US hospitals reached nearly $120 million for minors between 2019 and 2023, with Mount Sinai New York billing $8.2 million and Boston Children’s Hospital $6.5 million during that window. What had been a low-margin specialty became a strategic growth line. Endocrinology and surgical departments gained volume, prestige, and internal power. Hospital administrators gained a reliable revenue stream. The pediatric child was the raw material of the transformation.

2. Two diagnostic codes carry the fraud. The scheme rests on the systematic misuse of E34.9 (Endocrine Disorder, Unspecified) as a substitute for the gender-related F64 codes, and E30.1 (Central Precocious Puberty) as a substitute for gender dysphoria to justify puberty blockers in adolescents. Gender dysphoria is not an endocrine disorder. Central precocious puberty by definition cannot exist in children over 13. A 2023 University of Iowa study found 96% of patients coded with unspecified endocrine disorder were gender-expansive. Pennsylvania recorded a 2,100% increase in reimbursement for puberty blocker claims using the precocious puberty code between 2013 and 2017. The report’s own nationwide analysis found nearly $50 million billed under endocrine codes and $11 million billed under precocious puberty codes for children in the wrong age band. CMS guidelines mandate coding at the highest level of specificity supported by the record. The pattern documented is the mass violation of that rule at industrial scale.

3. The professional associations coached the fraud. WPATH’s 2021 training presentation, delivered by Drs. Deutsch and Rosenthal, included slides recommending E34.9 for adolescents alongside the gender dysphoria code — teaching clinicians which alternative codes to submit. Dr. Nick Gorton, a prominent WPATH member, stated the underlying purpose plainly in a slide: linkage of ICD to CPT can be problematic. Fenway Health, Harvard-affiliated, publicly acknowledged using vague codes while conceding this may not be legal under the False Claims Act. QueerDoc and Planned Parenthood of Southeastern and Western Pennsylvania published the same guidance on their websites. The Campaign for Southern Equality’s Trans in the South toolkit listed which fabricated diagnoses insurers accepted — pelvic pain for hysterectomy, breast hypertrophy for mastectomy, orchialgia for orchiectomy. When Dr. Eithan Haim exposed the toolkit during Congressional testimony, the page came down. The coaching was industry-wide, publicly posted, and organised.

4. Whistleblowers made the scheme visible. Vanessa Sivadge, a nurse at Texas Children’s Hospital’s gender clinic, went public in June 2024 with allegations that the hospital was illegally billing Medicaid for transgender procedures despite Texas’s 2019 exclusion. Her testimony documented specific mechanisms: labelling biological males with estrogen deficiency, biological females with testosterone deficiency, falsifying preferred gender identity on the medical record instead of birth sex, omitting the gender-related diagnosis from claims to conceal the actual purpose. Dr. Eithan Haim, an author of this report, had anonymously exposed TCH’s secret transgender program in May 2023, spurring the passage of state legislation banning the interventions. His disclosures led to the Texas Attorney General’s investigation and, ultimately, to the $10 million settlement. Whistleblowers, not regulators, made the pattern legible.

5. The Texas Children’s Hospital settlement established a new template. On May 15, 2026, Texas Children’s Hospital agreed to pay $10 million — the second largest healthcare fraud settlement in pediatric medicine history — for billing Medicaid using false diagnosis codes for illegal gender-transition interventions. The settlement went beyond the fine. TCH agreed to terminate five doctors, amend its bylaws to automatically revoke privileges for any physician violating the state ban, and fund the country’s first Detransition Clinic free of charge to patients for five years. On June 5, 2026, the Cleveland Clinic Foundation reached a similar settlement committing $2 million to restorative care for detransitioners. The settlements created, for the first time, funded infrastructure for the patients the system had harmed — and established that continuing the practice cost hospitals their doctors and their money.

6. The Biden administration used the federal government as a promotion apparatus. Hours after inauguration, executive order 13988 declared it federal policy to combat discrimination on the basis of gender identity. HHS reinterpreted Section 1557 of the Affordable Care Act to hold that refusing sex-rejecting procedures constituted sex discrimination. CMS approved Colorado’s essential health benefits plan mandating coverage. HHS’s Office of Population Affairs endorsed puberty blockers, hormones, and surgery for adolescents despite no FDA approval. DOJ threatened state attorneys general and filed statements of interest in litigation. EEOC treated exclusion from employer plans as sex and disability discrimination. Secretary of State Blinken called denial of the procedures “violence.” OPM, DOD, and VA extended taxpayer-funded coverage. The HIPAA reproductive health privacy rule was designed to obstruct law enforcement investigation. The apparatus was coordinated, aggressive, and coextensive with federal reach.

7. The suppressed Olson-Kennedy study reveals how the science was manufactured. The NIH spent nearly $10 million on a study of puberty blockers and cross-sex hormones for youth. The puberty blocker data was intentionally withheld from publication by the lead researcher, who told The New York Times in October 2024 she suppressed the findings out of concern they would support state laws restricting the interventions. The hormone data that was published had its hypothesis retroactively changed, failed to report six of eight preregistered variables, and recorded two suicides among 315 participants — a finding that in any other therapeutic context would prompt reevaluation. The lead author instead declared the results provided strong scientific basis for the interventions. Ten million taxpayer dollars purchased research either suppressed for reaching the wrong conclusions or restructured to reach the right ones. The published scientific record has been shaped by that selection.

8. Professional society capture explains why guidelines mirror across organisations. The Endocrine Society’s 2017 guidelines identified ten authors, at least seven affiliated with WPATH, with one appearing as an author on WPATH’s 2022 guidelines. The American Psychological Association’s 2015 guidelines had an eight-member task force, at least seven WPATH-affiliated. The American Academy of Pediatrics’ 2018 policy statement was drafted by Jason Rafferty and approved by a 13-member board without input from the AAP’s 67,000 general members — who were then retroactively counted as supporters. In 2023 the AAP board unanimously reaffirmed the position before completing its own systematic review, which remains uncompleted. The mechanism was the same across every organisation: a small ideologically committed group produced the language, and the institutional imprimatur was applied on top. The consensus was not scientific. It was overlapping authorship.

9. Online platforms functioned as the recruitment vector. Roblox, Minecraft, and Discord — games and chat services marketed as safe creative play — repeatedly appear as the site of first exposure in the parent and detransitioner accounts. Christy Davidson’s son Thomas was praised for being transgender at age 12 in Minecraft chat after choosing a pink-and-blue bandana for his character. Lily Burns’s son met a transgender-identifying adult through Minecraft chat features she did not know existed. Luke Healy was groomed by adults from age 10 in online communities that discussed sex, pornography, and transgender identity with children. The exposure was not passive content consumption. It was direct contact with adults inside spaces designed to gather children, delivering ideological framing at the developmental moment children are most vulnerable to identity suggestion.

10. Schools coordinated with clinics to bypass parents. The accounts document a consistent institutional pipeline. Layla Jane’s school in sixth grade did not inform her parents that she was pretending to be a boy at school, coordinating meetings with Pride Center adults on campus without parental knowledge. Clementine Breen’s school guidance counsellor coordinated her social transition, including classroom explanations to peers, before her parents were fully informed. The clinic then received the child with a settled diagnosis already in place. Parents arrived to find the intake work completed. When they raised concerns, they were framed as obstacles — Lily Burns’s family psychologist called her a gatekeeper. The pipeline required parents to be managed, not partnered with. The children arrived at the surgical decision through a process their parents had not been included in.

11. The “live son or dead daughter” framing coerced parental consent. Across the accounts, the pressure mechanism was identical. Layla Jane’s parents were told the choice was between a live son and a dead daughter. Christy Davidson was told her son would commit suicide without hormones. Clementine Breen’s parents were told at her first appointment that she was 100 percent trans and at high risk of suicide if not affirmed. The evidence base for the suicide claim is precisely what the HHS umbrella review found to be missing. In the room, none of that mattered. Parents faced a specialist wearing a white coat, invoking their child’s death, with minutes to decide. The framing was engineered to foreclose deliberation and convert a treatment decision into an emergency. The consent it produced was consent under duress by any standard other than the medical one.

12. The exposed fraud is the tip of the iceberg. Only interventions billed through insurance appear in the claims data. Only institutions with National Provider Identifiers submitting qualifying claims appear in the rosters. Every methodological choice was conservative — null-charge fields were treated as absent, restrictive cohort definitions excluded borderline cases. What the report documents is what became visible when the federal government began looking. What the report cannot document is everything within the same architecture, at the same institutions, using the same techniques, that did not generate documentation or whose documentation has not been examined. Given the combination of financial incentives, ideological capture, and regulatory failure that produced the visible pattern, the invisible portion must be larger. The report concludes with the phrase because the evidence requires it — not as rhetoric but as inference. What has been exposed is the beginning of the accountability, not its end.

The Golden Nugget

The most profound and least-known element buried in this report is not the fraud itself. It is the mechanism the professional societies used to manufacture medical consensus — and the specific admission, made under oath by a WPATH author, that guidelines were engineered for legal effect rather than clinical accuracy.

The mechanism is this: seven of the ten authors of the 2017 Endocrine Society guidelines were WPATH-affiliated. Seven of the eight members of the 2015 American Psychological Association task force were WPATH-affiliated. The 2018 American Academy of Pediatrics policy statement was written by a single person, Jason Rafferty, and approved by a 13-member board — with the AAP’s 67,000 general members having no input and becoming aware of the content only after publication. The Endocrine Society, APA, AAP, and WPATH did not independently reach the same conclusions. They were the same conclusions, drafted by an overlapping group of people, and stamped by four separate organisational logos. What the public and legislators saw as a convergent medical consensus was a single ideological network wearing four different institutional coats.

The under-oath admission makes the design explicit. Emails uncovered in litigation showed WPATH authors hoping their guidelines would land in such a way as to have serious effects in the law and policy settings. One author testified it is ethically justifiable to advocate for language changes to strengthen litigants’ positions in court. The Biden administration pressed WPATH to remove age limits for adolescent surgeries on the theory that specific age listings would result in devastating legislation for trans care. The guidelines were not clinical documents that happened to have legal implications. They were legal documents drafted in clinical language, produced by people who understood exactly what they were doing and why.

The implication reaches beyond this scandal. If four peer medical societies can publish overlapping guidelines drafted by a small ideological network and have those guidelines received as scientific consensus, the mechanism can be — and almost certainly has been — used elsewhere. The gender medicine case is legible now because the harm to children forced the question open. The same architecture, using the same overlapping authorship, is likely producing “consensus” positions across other domains of medicine that have not yet been examined. The golden nugget is not that the gender medicine consensus was manufactured. It is that the manufacturing method exists as a general capability of professional societies, and that no institutional immune system currently detects it.

The document that starts the whole catastrophe is a merchant’s delivery order. A fragment of burned parchment found in the town of Provins, listing thirty-six sous for wagons of hay, six new lengths of cloth with seal for rue des Blancs-Manteaux, and six bunches of six Crusaders’ roses at twenty deniers each for six locations in the town on the feast of Saint John, including three bunches for the whores’ street because the prostitutes wanted little hats of roses for the feast day too. That is the entire secret. A retired colonel misreads it as a Templar plan for world domination, three editors at a Milan publishing house take his misreading and build a coherent seven-century conspiracy on top of it, and the readers who receive that conspiracy believe it so completely that they hang one of the editors from the wire of Foucault’s pendulum in a Paris museum on the night of Saint John’s Eve. This is the mechanism Foucault’s Pendulum (1988) puts under a microscope. The mechanism is not that credulous people invent patterns where none exist. The mechanism is that fabricated grand conspiracies serve as cover for the ordinary coordination of power. Invent a seven-century Templar-Rosicrucian-Merovingian synthesis and hand it to the credulous, and three things follow. You satisfy the appetite for hidden meaning, which lets people stop looking at what is actually in front of them. You produce the crank profile the establishment needs to discredit anyone asking real questions. You build a decoy elaborate enough that the actual mechanisms of power operate unremarked while everyone chases the map.

Umberto Eco, born in Alessandria in 1932, was professor of semiotics at the University of Bologna for most of his working life. His scholarly range covered Thomas Aquinas, James Joyce, medieval aesthetics, and the semiotics of popular culture including Superman comics, and his 1980 novel The Name of the Rose had already established him as one of the few academic semioticians whose fiction was read by the general public. He wrote Foucault’s Pendulum from inside the field that studies how signs generate meaning and how readers project meaning onto signs that carry none. The novel is a semiotician’s clinical case study in the form of a thriller. Eco knew exactly what he was doing when he built a three-hundred-page trap for the reader who cannot stop looking for the hidden pattern, and he built the trap with the expertise of a man who had spent his career watching the same trap catch academics, theologians, and advertising executives.

The book appeared in 1988, at the point when the political radicalism of the 1968 generation had largely dissolved into a market for the occult. The novel documents this shift directly in its Milan scenes. The old customers of Pilade’s Bar who once peddled the works of Che are back a decade later selling herbals, Buddhism, and astrology. Transcendental meditation schools and macrobiotic restaurants have opened in the storefronts where the revolutionary bookshops used to be. The Red Brigades and the Moro kidnapping recede, and in their place a whole publishing ecosystem grows up around Rosicrucians, neo-Templars, Rennes-le-Château enthusiasts, Grail hunters, and disciples of Guénon and Papus. Baigent, Leigh, and Lincoln’s Holy Blood, Holy Grail had appeared in 1982 and was selling in the hundreds of thousands. Eco writes into a market saturated with the exact material his editors will parody, and he writes for a readership that in many cases had already bought several volumes of that material without irony.

Three men build the trap they walk into. Casaubon is the narrator, a young Templar scholar. His two colleagues at Garamond Press in Milan are Jacopo Belbo, a melancholy Piedmontese editor with a childhood memory he never quite recovers from, and Diotallevi, an orphan who has convinced himself he must have been Jewish and spends his hours on the Kabbalah. All three meet Colonel Ardenti when he arrives at the office with the Provins parchment and his decoding of it. Ardenti vanishes the same night after a visit from a man calling himself Rakosky. Years later, the same publisher launches a vanity-press line aimed at occultists, and the three editors begin reading Rosicrucian, neo-Templar, Luciferian, and Kabbalist manuscripts by the dozen. As a game, they combine every occult tradition of the last seven centuries into a single coherent conspiracy and call it the Plan. It absorbs the Templars, the Rosicrucians, the Freemasons, the Illuminati of Bavaria, the Grail, the Comte de Saint-Germain, the Protocols of the Elders of Zion, and eventually the spark plugs of a car. Everything fits, because they wrote it to fit. Then their consultant Aglié, an elegant elderly Italian who claims to have known the eighteenth century personally, takes it seriously and passes it to his network. Diotallevi dies of cancer and tells Belbo on his deathbed that his cells have learned to anagrammatize the Torah of his body in the same way the three of them anagrammatized the Torah of history. Belbo is summoned to Paris, refuses to hand over a map he does not have, and is hanged from the wire of the pendulum in the Conservatoire des Arts et Métiers on the night of Saint John’s Eve. Casaubon flees to a country house in the Piedmontese hills and writes the account the reader is holding.

Foucault’s Pendulum came to my attention when James Corbett covered it recently on The Corbett Report, in the monthly Film, Literature and the New World Order series, with Tom Oliver Regenauer as the guest who proposed it. The mainstream reading of the book, that it is a diagnosis of why silly people believe in conspiracies, is the shallow one and probably a deliberate misreading. Eco is not telling you there is no coordination behind the visible order of things. He is telling you that the elaborate synthetic conspiracies the credulous construct are decoys, and that decoys are useful to the people running the actual show. Aglié is real. The Tres is real. Colonel Ardenti really vanishes in the opening chapters, before the three editors invent anything. Inspector De Angelis really has a bomb placed under his wife’s car. Belbo really dies. The novel stands in the small canon of works that diagnose the psychology of belief without offering the reader an exit. Dostoevsky’s Demons is one antecedent, Borges another, and Eco’s book belongs on the same shelf. The full summary unpacks the three rules that govern every conspiracy ever assembled (analogy, coherence as proof, prior belief as authority); Diotallevi’s deathbed argument that the linguistic term metathesis and the oncological term metastasis come from the same Greek root, and that his cancer is his body doing to itself what the three editors did to history; and the revelation that Aglié, the elegant consultant who has cultivated the editors for years, is the same figure who took the original parchment from Colonel Ardenti in the opening pages, meaning the Plan the editors thought they were inventing was already in motion before they began. In the closing pages Casaubon sits at a country house in the Piedmontese hills, watches the vineyards on the Bricco’s slopes, and bites into a peach. Where ammonoids once fed, diamonds. Where diamonds once grew, vineyards. That is the Kingdom, and there is nothing hidden behind it, and Casaubon is at peace with that. He is also certain that They are on their way up the road. The novel does not correct him.

Audio Deep Dive (for Paid Subscribers)

Read more

Two molecules. Both cheap. Both simple. Both used for decades. One has been approved for a single condition. The other has been officially demonized. Neither has killed anyone.

In June I wrote about twelve remedies they can’t patent. The essay described a pattern: the cheaper a substance is, the more versatile it is, the more the evidence stacks up, the harder the door gets pushed shut. Two of those twelve now have their own books.

The DMSO Book: The Suppressed Science of Medicine’s Most Versatile Compound

Buy on Lulu → · 219 pages · USD $19.99

100,000 studies. Zero deaths. One FDA approval. Dimethyl sulfoxide has been studied for over sixty years, used by millions, and killed no one — and the FDA has approved it for exactly one condition. The DMSO Book compiles nearly 330 questions and answers across six major sources: A Midwestern Doctor’s combination-therapy series, Morton Walker’s foundational 1993 text, Amandha Dawn Vollmer’s practical guide, Archie Scott’s clinician handbook, klimer’s first-person survivor account, and A Midwestern Doctor’s work on DMSO and cancer. It covers chronic pain, burns, strokes, autoimmune conditions, antibiotic-resistant infections, eye diseases, and cancer. It documents preparation, dosage, and combination protocols with antibiotics, chemotherapy, magnesium, ivermectin, anaesthetics, and antifungals. It traces the history — Zaytsev’s 1866 synthesis, Herschler’s discovery at Crown Zellerbach, Jacob’s clinical breakthrough at Oregon Health Sciences — and the FDA’s decades-long suppression of the research.

The compound wasn’t dangerous. It was too versatile to be allowed.

For the person managing chronic pain who has been offered nothing but escalating prescriptions. For the household that wants a single reference to keep on the shelf next to the first-aid kit.

Chlorine Dioxide: The Forbidden Remedy

Buy on Lulu → · 201 pages · USD $19.99

Chlorine dioxide is not bleach. It is a molecule that works with the body rather than against disease — at a voltage of 0.95 volts, within the electrical range of human tissue, delivering oxygen precisely where it is needed and breaking down into salt and oxygen when its work is done. It has been used in water purification for decades. Its oxidative properties are not disputed even by the agencies that warn against its therapeutic use. What is suppressed is the possibility that a substance this simple, this inexpensive, and this widely available could address conditions that generate billions in pharmaceutical revenue.

The book brings together five independent voices who arrived at overlapping conclusions through separate pathways: Dr. Andreas Kalcker, biophysicist and world authority on chlorine dioxide research; Kerri Rivera, whose autism recovery protocol has restored speech and behaviour in nonverbal children; Xuewu Liu, whose intratumoral injection work is showing significant promise in cancer; Curious Outlier, whose Universal Antidote documentary has reached millions; and Jim Humble, who discovered the Master Mineral Solution in the Bolivian jungle in 1996. Their protocols are documented in full. Their limitations are stated honestly. Their evidence — clinical observation supported by studies involving thousands of patients, validated by the daily practice of over 5,000 doctors in the COMUSAV network across sixty countries — is presented so the reader can evaluate it themselves.

For the parent of a nonverbal child who has been told there is nothing left to try. For anyone who has watched a family member exhaust the conventional options and wants to know what the record actually shows.

A note of thanks

The first five books have been out for a matter of weeks, and something I did not expect has already happened: a meaningful number of you are buying the shelf. Two books, three, the full set, sometimes more than one copy of the same title to give away. I see every order. Each one is a real person deciding to put money and space on a shelf behind this work. Thank you. I know what it costs to buy books you have, in effect, already read online — and I know what it means that you are doing it anyway.

The shelf

Seven books now. More coming.

The first five took on specialisms trained not to see the thing they treat — motherhood, vaccination, dentistry, veterinary medicine, psychiatry. These two take on something different: not a profession, but a category of substance. Cheap. Simple. Versatile. Too useful to be allowed a fair hearing.

The books are printed to order and shipped worldwide from Lulu. The full shelf is at lulu.com/spotlight/unbekoming.

— Unbekoming

The surgeon who left a sponge inside Mrs. Harris sat her and her husband down in his consultation room, put the x-ray on the view box, and told them plainly that he had left it behind, that he was sorry, that it should not have happened, that it would come out the following week, and that there would be no charge from himself or the hospital. There was no anger, no threat, no accusation. The Harrises continued as clinic patients for another twenty-four years without a lawyer. That specific arithmetic — honest disclosure of medical error, offered inside a genuine doctor-patient relationship, producing a quarter century of continued care rather than a settlement — sits at the centre of Reflections of a Country Doctor (1996). Barry Ladd’s memoir of thirty years in general practice is not primarily a book about medicine. It is a book about what medicine was structurally capable of when the underlying contract between doctor and patient was still intact, and what disappears when that contract is dismantled.

Ladd trained at the State University of New York College of Medicine at Syracuse, interned at Fitzsimmons Army Hospital in Denver, and served as a United States Air Force flight surgeon in Japan before entering private practice in 1963 in a small farming community forty miles south of Chicago. He stayed thirty years, delivering fifteen hundred babies, handling one hundred and eighty thousand office visits, and taking care of four generations in the same families. He retired at sixty in 1993, tired physically and emotionally, having spent the last two weeks of his career in a Chicago courtroom defending a malpractice suit he won. He is not a paradigm dissenter. He is an ordinary, competent family physician of his generation writing as a first-person witness to a transformation that occurred beneath him while he practiced. His authority in the book is entirely observational, and the observations are specific.

The book appeared in 1996, three years into Ladd’s retirement and two years after the failure of the Clinton health reform. By that point managed care had reorganised American medicine around network economics, and Health Maintenance Organizations and Preferred Provider Organizations were forcing patients to switch from longstanding family physicians onto contracted panels selected by employers and insurers. Medicare had capped Ladd’s office-visit reimbursement at twenty dollars against his fee of thirty-two. Defensive medicine, driven by the collapse of the malpractice environment that had allowed the surgeon’s honest apology to Mrs. Harris, had produced what Ladd calls a mind-boggling volume of unnecessary testing. New family practice residents, in his account, “knew a lot but didn’t do much” — they treated the simple and routine and referred everything else, positioning themselves to be replaced by nurse practitioners and physician assistants who would be equally effective and considerably cheaper. Ladd wrote at the point where the old model was recent enough to be remembered directly and the new model was consolidated enough to be described.

The book sits inside a small archive of insider accounts of American medicine written by practitioners at the moment the industrialisation of their work became visible to them — witnesses from within the profession to the shape of what was replacing it. The full summary unpacks three specific findings: the total 1964 cost of eighteen months of home-based congestive heart failure treatment for Julia at the house by the Des Plaines River (less than one hundred dollars, including her death in her own bed with her husband’s arms around her); the covert testicular-artery ligation his mentor suggested as a solution to the retarded farm boy whose father wanted him castrated to protect his fifteen-year-old sister, and Ladd’s refusal to perform it; and the sperm sample that revealed John Wright, “Father of the Year,” had never fathered his three children — his wife had used his brother, mechanically and without passion, three times, because she could not bear to put her husband through the discovery of his own sterility. On his first day in practice, arriving at a house call for a chest pain, Ladd reached into his black bag for the morphine and never got to use it: the patient pitched forward onto the floor, his glasses flew off, and one lens popped out of the frame and spun crazily on the boards.

Audio Deep Dive (for Paid Subscribers)

Read more

Author’s Note

The August 10, 2026 executive order on childhood vaccines is presented as reform. Read carefully, it is two documents at once. The first document names concerns that critics of the schedule have documented for decades. The second document preserves every product on the schedule intact. Both documents were signed at the same time by the same pen.

This essay is a companion to the IACC Strategic Plan analysis. Where that document could not name the cause, this one names some of the causes and preserves them.

The Sentence in Section 2(b)

Section 2(b) of the August 10, 2026 executive order states that the combined measles, mumps, rubella vaccine should be administered as three separate single-disease shots “once such products are domestically available,” and “to the maximum extent feasible, all childhood immunizations should be administered at separate medical visits.”¹

This single sentence contains the structure of the entire document.

The first half is a concession critics of the schedule have been documenting for decades. The combined MMR carries injury patterns the separate shots do not. The density of injections in the current pediatric schedule exceeds what the body can process without damage. Both claims have been treated as fringe in mainstream discussion. Both are now written into a presidential directive.

The second half is a preservation mechanism. “Once such products are domestically available” places the split MMR behind a supply condition that does not currently exist. “To the maximum extent feasible” places injection spacing behind a standard that the current pediatric visit already meets by fitting multiple injections into a single appointment. The concession names the harm. The conditional language keeps the harm in place.

First Pair: The Aluminum Admission

Section 3(c) directs the HHS Task Force on Safer Childhood Vaccines to “develop additional alternative adjuvants to aluminum and conduct comparative safety and efficacy studies.”¹

Alternative adjuvants would not need to be developed if the existing adjuvant were safe. Comparative safety studies would not be needed if the safety of the current adjuvant were established. The word “alternative” presumes something to replace, and the word “comparative” presumes something to compare against. What the executive order now concedes was documented in the peer-reviewed biomedical literature more than a decade before it was signed.

In 2013, a research group at the Université Paris-Est demonstrated that aluminum adjuvant injected into a mouse reached the brain one year after injection. Macrophages at the injection site engulfed the aluminum particles and carried them through the lymphatic and blood circulation. The blood-brain barrier did not block the passage because the aluminum was inside the cells that cross it. The researchers described the delivery as a Trojan horse passage into the brain. Their conclusion, in the peer-reviewed biomedical literature, was that continuously escalating doses of this material in the population might become “insidiously unsafe,” particularly in infants whose blood-brain barrier is still forming.²

A 2017 follow-up study from the same group inverted the standard toxicology assumption. Low repeated doses of aluminum adjuvant were more neurotoxic than large single doses. Higher doses formed inflammatory nodules at the injection site that walled the aluminum off locally. Lower doses did not form nodules and reached the brain unimpeded. The current pediatric schedule administers small aluminum doses repeatedly across dozens of injections. That is the regime the 2017 study identified as most likely to move aluminum into the brain.² The peer-reviewed conclusion was that the classical rule that “the dose makes the poison” does not describe how this material behaves.

In 2017 Christopher Exley of Keele University in England examined brain tissue from five people who had died with autism. Aluminum content was elevated in every case. More striking than the elevation was the location. The aluminum sat inside cells of the same type that carry aluminum from vaccine injection sites through the body. Exley concluded that the aluminum in these brains had reached them via the same pathway the earlier studies had mapped: injection site, macrophage, blood-brain barrier, brain tissue.²

Thomas Cowan compiles this literature in Vaccines, Autoimmunity, and the Changing Nature of Childhood Illness, together with the parallel work of Christopher Shaw, Lucija Tomljenovic, and Guillemette Crépeaux.²

The executive order does not remove a single aluminum-containing product from the schedule. It does not require a comparative safety study before continued administration. It directs plans “within 90 days,” which is planning, not action. The current products remain recommended. The children who receive them between now and whenever an alternative is developed, tested, approved, manufactured, and distributed will receive the material that a French research group had warned about, in peer-reviewed print, thirteen years earlier.

The admission is real. The preservation is complete.

The First Pair above operates within the establishment’s own framing of aluminum as the substance to worry about. That framing is narrower than the physical evidence supports.

Second Pair: The MMR Split

Section 2(b) directs that the MMR be administered as three separate shots “once such products are domestically available.” Section 3(a) directs the task force to “offer options to administer core childhood vaccines, starting with MMR, as single vaccines rather than combination products/doses, including by working with the private sector and other countries as appropriate, while guaranteeing continued availability of combination vaccines.”¹

The final clause carries the preservation. Combination products are guaranteed to remain available. The separate-shot alternatives are directed to be developed. The combined MMR remains the product that will be administered until the split products exist domestically and are chosen by the parent, the pediatrician, and the insurer.

Three components delivered in a single injection carry a load different from three separate shots. Parental reports of regression, the clustering of onset following the combined shot rather than the separate components, and decades of critical writing all point to the combination itself as the site of injury. Andrew Wakefield’s 1998 paper in The Lancet documented twelve children with regressive developmental disorder; parents linked the onset of behavioural symptoms to the combined MMR immunization in eight of the twelve cases. Wakefield’s own recommendation at the time was that parents have the option of separate vaccines rather than the combined shot.³

Merck is the sole US manufacturer of the licensed MMR product and does not offer measles, mumps, or rubella as separate shots for the US market. The company has faced a False Claims Act suit filed by two of its former virologists alleging manipulation of the mumps component efficacy data.⁴ The domestic availability condition, in practical terms, places the split MMR behind whatever Merck chooses to do next, or behind whatever competitor emerges from the task force process, or behind whatever the private sector and other countries produce for export to the United States.

Japan discontinued the combined MMR in 1993 after concerns about aseptic meningitis from the mumps component of the vaccine. Since then, Japanese public health authorities have administered the mumps vaccine separately from a combined measles-and-rubella shot.³ The executive order that claims to align US recommendations with “best practices from peer, developed countries” makes no reference to Japan’s precedent. Thirty-three years after Japan restructured its own MMR delivery, the separated products the executive order directs the task force to develop remain unavailable in the United States.

The physical measurements of the reform are straightforward. Each 0.5 mL dose of the combined MMR contains, per Merck’s own package insert, 14.5 mg of sorbitol, 14.5 mg of hydrolyzed gelatin, 1.9 mg of sucrose, up to 0.3 mg of recombinant human albumin, fetal bovine serum, and approximately 25 mcg of neomycin, in a base of sodium phosphate buffer.¹⁴ Merck’s historical single-antigen products (Attenuvax, Mumpsvax, Meruvax II) carried the identical excipient loading per 0.5 mL dose. Under the reformed schedule, a child would receive three 0.5 mL injections in place of one. The total volume of injected material triples. So does the mass of every excipient the vials contain: 43.5 mg of sorbitol, 43.5 mg of hydrolyzed gelatin, 75 mcg of neomycin, and three separate exposures to fetal bovine serum.

The admission that the MMR should be split is significant. Every year that passes before the split products are available is a year in which the combined MMR is the recommended product. The executive order does not restrict the combined MMR during that period. It preserves it explicitly.

Third Pair: The Spacing

The second clause of Section 2(b) states that “to the maximum extent feasible, all childhood immunizations should be administered at separate medical visits.”¹

Neil Miller’s Review of Critical Vaccine Studies compiles the published literature on the cumulative burden of the current schedule.⁵ The number of injections administered in the first eighteen months of life has multiplied several times over the past four decades. The volume of adverse events reported to VAERS has moved in the same direction. The studies compiled include comparisons showing that simultaneous administration of multiple injections carries adverse event rates the same injections administered separately do not.

The mechanism is not obscure. Charles Richet’s Nobel Prize work on injection-induced sensitization, awarded in 1913, established that foreign proteins introduced by injection produce a body-wide response of increasing intensity with each subsequent exposure.⁶ Introducing foreign material through the skin bypasses the digestive and mucosal routes through which the body normally processes such material. The response is what the body does to defend the terrain when material enters through a route it is not designed to handle. Multiplying the number of simultaneous introductions multiplies the burden.

“To the maximum extent feasible” is the phrase that governs this admission. Feasibility is defined nowhere in the document. In current pediatric practice, it is feasible to administer six injections at a single well-child visit: the visit takes ten minutes, the parent is present, the pediatrician is billing, and the insurer is reimbursing on the schedule. Nothing in current feasibility requires separation. The executive order does not redefine feasibility. It appeals to it.

The admission is significant. It concedes that same-visit administration carries risk that separated administration does not. The preservation follows: nothing in the order requires the redefinition of feasibility that would give the preference operational force.

The Vials

The aluminum admission focuses attention on a declared ingredient. It says nothing about what is in the vial that no one declared.

In 2017, Antonietta Gatti and Stefano Montanari, materials scientists at the Italian National Council of Research, published a peer-reviewed examination of forty-four vaccines obtained from pharmacies in Italy and France.¹³ They used a Field Emission Gun Environmental Scanning Electron Microscope with X-ray spectroscopy to identify the elemental composition of every particle they found in a twenty-microliter drop of each. The manufacturers included Sanofi, GlaxoSmithKline, Pfizer, Novartis, and Merck.

Forty-three of the forty-four vaccines contained particulate contamination that appeared on no package insert. The elemental catalog included lead, tungsten, stainless steel, bismuth, gold, silver, platinum, cerium, zirconium, hafnium, antimony, strontium, barium, copper, tin, and zinc, in various alloy combinations. None of these materials had a declared role in any of the vaccines’ formulations.

The particle counts vary. Anti-tetanus products returned the lowest counts, in single digits per twenty-microliter drop. The childhood vaccines returned the highest. Varilrix, the chickenpox vaccine, returned 2,723 particles per twenty microliters. Infanrix hexa, the six-in-one combination given to infants, returned 1,821. Cervarix returned 1,569. Gardasil returned between 304 and 454, depending on the batch. A standard injection is half a milliliter, or twenty-five drops of the size Gatti and Montanari examined.

The forty-fourth vaccine was Feligen CRP by Virbac. It contained none of the heavy metals or industrial alloys cataloged in the human samples. Feligen is for cats. The veterinary production line examined by the same instruments at the same resolution produced a clean vial. The human production lines did not.

The instruments Gatti and Montanari used are standard equipment in materials science, semiconductor manufacturing, forensic analysis, and environmental toxicology. Any contract laboratory with the relevant instruments could replicate the protocol in an afternoon. The pharmaceutical manufacturers named in the paper already own instruments of this class for other purposes. The examination has never been part of pharmaceutical quality control for injectable products.

What pharmaceutical quality control actually examines is different. Sterility testing checks for viable microorganisms. Endotoxin testing checks for bacterial cell wall fragments. Potency assays confirm the declared active ingredient. Visible particulate inspection involves a trained human holding the vial to a light. Visible inspection cannot resolve particles below approximately fifty microns. Most of what Gatti and Montanari documented falls below that threshold.

The executive order does not require the examination the Gatti and Montanari paper demonstrated. It does not name the contamination the paper documented. It directs research into alternative adjuvants to aluminum. It does not direct research into what else is in the vial.

The paper was published nine years ago in the International Journal of Vaccines and Vaccination. The findings have not been refuted. No follow-up examination has been commissioned by any of the manufacturers named. No regulatory framework requiring the testing has been proposed by the FDA, the European Medicines Agency, or any national medicines agency. Administrative action has been taken against the authors by Italian authorities. The instruments still exist, the samples remain on the pharmacy shelf, and the examination has not been repeated by anyone the industry or the regulators have authorized to speak.

The “gold standard” schedule the executive order establishes does not require the manufacturers to know, or disclose, what is actually in the vials they produce. The debate about aluminum adjuvants presupposes that aluminum is the substance to worry about. Aluminum is a declared ingredient. What Gatti and Montanari documented is what is in the vial that no one declared.

Liability

The National Childhood Vaccine Injury Act of 1986 removed civil liability from vaccine manufacturers for injuries caused by federally recommended childhood vaccines. Injured parties can no longer sue in state court for defective design. Product liability was replaced by a specialized federal compensation program funded by an excise tax on doses, adjudicated without juries, with capped damages, tight filing deadlines, and burden-of-proof rules that shift against petitioners.

The Supreme Court affirmed the structure in Bruesewitz v. Wyeth (2011), holding that childhood vaccines are “unavoidably unsafe” products for which design-defect claims in state court are preempted.¹²

The result is a market in which the manufacturer captures every dollar of revenue from every dose sold under the schedule and bears no cost for the injuries the doses cause. The number of routine childhood vaccines approximately tripled after 1986. This is the predicted behavior of firms operating in the incentive structure Congress created. Product liability is the mechanism through which the ordinary market prices harm: plaintiffs sue, insurers price the risk, manufacturers redesign or withdraw the product. Without that mechanism, no signal returns to the manufacturer indicating a product should be improved or withdrawn. Harm accumulates on the consumer side of the transaction indefinitely.

The executive order does not touch the 1986 Act. It reclassifies products within the schedule, directs alternative adjuvants to be developed, and permits some conditional splitting and spacing. Every product it discusses remains liability-free. Every alternative adjuvant the task force develops, if adopted, will be liability-free the moment it enters the schedule. The task force itself, revived by the order after nearly three decades of dormancy, operates within a statutory framework in which the manufacturers of the products it reviews face no financial consequence for the injuries those products cause.

The $50 million Gardasil settlement documented above is a rare exception. Merck paid because the Gardasil plaintiffs found routes around the 1986 Act’s preemption, primarily through state-court design-defect claims that survived early motions. Merck’s own description of the settlement as “not material” is the market speaking: this is what liability costs when the shield holds against most claims and fails against only a few. A functional liability system would return that number to something material.

This is the structural layer under everything the essay has documented. The aluminum adjuvants Gherardi warned about remain on the schedule because no market signal against them exists. The combined MMR remains the recommended product because Merck bears no cost for the injuries the combination causes. HPV, hepatitis B at birth, and the ever-lengthening schedule stay in place because reclassification within the schedule preserves the liability shield around every product it touches. Section 4’s exemption fight matters, and the podium admissions at the signing were real, but neither reaches the mechanism that generates the harm. That mechanism is the 1986 Act.

What Has No Counter-Admission

The three categories in Section 2(a) retain every currently recommended childhood vaccine product.¹

The first category, immunizations recommended for all children, includes measles, mumps, rubella, diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type B, pneumococcal disease, human papillomavirus, and varicella.

The HPV vaccine is on this list. It is aimed at adolescent sexual behavior, not at any childhood exposure, which places a vaccine addressing future sexual activity in the same tier as those addressing the traditional childhood conditions. Mary Holland and her co-authors compiled the injury signal, the litigation record, and the regulatory history of this product in The HPV Vaccine on Trial.⁷ In June 2026, weeks before the executive order was signed, Merck agreed to pay approximately $50 million to settle more than 200 lawsuits brought by plaintiffs who alleged Gardasil caused injuries including postural orthostatic tachycardia syndrome and other reproductive and cardiovascular conditions. Merck denied liability while describing the settlement as “not material” to the company.¹⁰ None of that record appears in the executive order. The HPV vaccine moves through the document as an established consensus product.

The second category, recommended for high-risk groups, includes hepatitis B. In current US practice, hepatitis B is administered at birth to every infant, regardless of maternal status. The executive order does not restrict this. It places hepatitis B in the high-risk category, which describes what the product was originally designed for (intravenous drug users, sex workers, healthcare workers) rather than what it is currently administered to (every newborn on the first day of life). The gap between the category label and the practice is not closed. The birth dose is not addressed.

The third category, shared clinical decision-making, includes COVID-19 and influenza. This is the softest category. It permits the products to remain recommended without requiring them.

The categorization overlaps with itself. Hepatitis A and hepatitis B each appear in both category (ii) and category (iii). The meningococcal products appear in both. A product placed under “shared clinical decision-making” is at the same time placed under “high-risk groups.” The classification is provisional rather than analytical; it tells the reader what tier each product occupies while placing multiple products in multiple tiers at once.

The schedule contains every product it did the day before the executive order was signed. No product has been removed, no age of administration changed, no dose reduced. What defenders will describe as a reduction from seventeen routine vaccines to eleven is a reclassification of six vaccines into the other two categories, not an elimination of any product. The reforms specified in Sections 2(b) and 3 concern the manner of administration, the components of manufacture, and the future development of alternatives. The list of what is administered stands.

The Conditional Language

Reading the sections together, the pattern is a system rather than a scatter of phrases.

“Once such products are domestically available.” “To the maximum extent feasible.” “As appropriate.” “Consistent with applicable law.” “Within 90 days, present plans.” “Take appropriate steps.” “To the fullest extent allowable by law.” “Subject to the availability of appropriations.”¹

None of these phrases, taken alone, is unusual for a federal document. Read together, they compose the mechanism by which the admissions coexist with the preservation. Every concession is conditional, every directive prospective, every action contingent on further process the order initiates but does not complete. The task force will present plans, alternative adjuvants remain to be developed, and states will be advised to consider updates to their own laws. The reform is not enacted by the order. It is scheduled by the order for consideration at a later time under conditions the order does not create.

The word most frequently absent from the document is “shall,” used without qualification. When “shall” appears, it is generally followed by a qualifier. Shall take appropriate measures. Shall, within 90 days, present plans. Shall be implemented consistent with applicable law and subject to the availability of appropriations.

An executive order that removes products from the schedule requires no such qualifiers. An executive order that adjusts recommendations without removing products requires all of them.

The conditional language and the liability shield are not competing explanations. They operate at different depths. The conditional language is the drafting technique available to a White House whose task could be accomplished by drafting. What made that possible was the liability shield. A market operating under normal liability rules would already have removed the products the order preserves.

Section 4

Section 4 contains the one non-conditional directive in the document.

The Attorney General is directed to “take appropriate measures to further meritorious legal actions challenging State laws that conflict with States’ constitutional and Federal statutory obligations related to parental authority, religious freedom, disability accommodations, and equal protection under the law, including, to the extent applicable under Federal law, States’ obligations to provide religious and medical exemptions from childhood and adolescent immunization requirements.”¹

If enforced, this provision changes the ground for parental choice. State laws restricting religious and medical exemptions have been the primary mechanism by which the pediatric schedule has been made effectively mandatory for school enrollment. California’s SB 277, New York’s repeal of religious exemptions, and Maine’s LD 798 narrowed or eliminated non-medical exemption access across the past decade. Some states have gone further still. California’s AB 144, signed in September 2025, freezes the state’s baseline vaccine recommendations at the pre-January 2025 federal ACIP schedule and authorizes California officials to update independent of any subsequent federal changes. California, Oregon, Washington, and Hawaii coordinate through the West Coast Health Alliance, which draws its recommendations from professional medical societies rather than from the CDC.¹¹ Federal legal action against those laws, if pursued with the resources of the Department of Justice and sustained across administrations, would need to overcome both the narrowed exemptions and the insulation statutes designed to preserve pre-order schedules.

The provision may also function as political cover. It gives the executive order a piece of visible, dramatic action that can absorb press attention while the schedule itself continues undisturbed. The exemption fight is legible to the public in a way that the aluminum adjuvant development timeline is not. A DOJ suit against a state exemption law generates coverage; the continued administration of the current MMR does not. An administration that wanted to appear to be reforming the schedule while leaving the schedule intact would design an order that looked exactly like this one.

Both readings are available in the document as written. The order directs the action. The action has not yet occurred. Enforcement will be determined by the priorities of the Attorney General, the resources allocated, the cases selected, the standing of the plaintiffs, and the response of the federal courts. None of these are specified in the order. The provision that is materially significant is also the provision whose meaning will be determined by events not yet in evidence.

The document does not tell us which reading is correct. It presents both.

The Signing

The executive order was signed in the Oval Office on August 10, 2026. What was said from the podium during the signing ceremony is public record.⁹

President Trump described the volume of vaccines pushed into a small child in one visit as excessive, comparable to a soda bottle’s worth of material. He said the combined MMR components “can be explosive” when given together, though safe when administered separately. Hepatitis B, in his view, should wait until adolescence rather than being given at birth. The administration’s goal, he said, was to return the autism rate to something like its level thirty years earlier.

Robert F. Kennedy Jr., the Secretary of Health and Human Services, cited the autism prevalence figures directly: one in thirty-one children nationally, one in nineteen in California, one in twelve and a half boys. In 1970, the baseline was less than one in ten thousand. “Genes don’t cause epidemics,” Kennedy said. Something in the environment did. He then named what HHS was studying: aluminum adjuvants, the timing of the hepatitis B vaccine, vaccinated-versus-unvaccinated health outcomes, and conditions ranging from allergies to autism to what medicine labels autoimmune disease. The Secretary of Health and Human Services stood in the Oval Office and named the categories that critical writers have been naming for decades.

Stephen Miller, deputy chief of staff, told the room that giving children shot after shot at population scale produces “vaccine injuries.” He asked why Japan gives measles, mumps, and rubella as separate shots while the United States packages them together.

Jay Bhattacharya, director of the NIH, addressed the genetic-predisposition frame directly. Genetic vulnerability could contribute, he said, but could not by itself account for the scale of the rise. Environmental factors had to be involved.

Every product on the schedule remained recommended in the document they signed.

The scale of what was admitted from the podium is itself the finding. The President of the United States acknowledged, at the signing of a federal directive, that the childhood vaccine schedule has produced an autism rate several hundred times higher than the rate a generation earlier. He accepted, as a policy goal, reversing it. In any other industry, the head of state admitting an industry-caused epidemic on this scale would trigger cascading legal liability, regulatory dissolution, and product withdrawal. In this industry, the admission produced a task force, a directive to develop alternatives, and reclassification of six products from one category to two. The admission was safe to make because the products admitted to be causing the epidemic have been legislatively shielded from the lawsuits the admission would otherwise trigger.

The Beating

The essay to this point has treated the reforms as the executive order presents them: as concessions worth analyzing. Measured on their own physical terms, the reforms do not reduce the harms they claim to address. The MMR case shows the reforms tripling every measurable quantity of the injection they claim to make safer.

Laura Hayes, in her November 2018 talk “Why Is This Legal?”,⁸ proposed the analogy that reveals what the safer-schedule concessions actually amount to. A parent beating their child seven times a week is convinced to reduce the beatings to three times a week. This sounds safer in theory, but any of the beatings could still be fatal or cause permanent injury. As Hayes put it, there is no “safe schedule for beating a child.”

The August 10, 2026 executive order does not propose reducing the beatings. It admits that the beatings are harmful. It proposes to space some of them out to separate visits, once conditions permit, to the maximum extent feasible. In the case of the MMR, the document goes further. The combined injection is admitted to be harmful. The proposed reform is to replace it with three separate injections. A child who currently receives one 0.5 mL MMR shot would, under the reformed schedule, receive three 0.5 mL shots. The reform triples the number of times the child is held down and injected. It also triples the volume of material injected, the mass of every excipient the vials contain, and, per the contamination Gatti and Montanari documented, the exposure to whatever undeclared industrial debris is in the production line. The admission of harm from the combination is answered by tripling every measurable quantity of the beating.

The document admits the harm. It does not stop the beating. In the MMR case, the reform multiplies it.

References

¹ Executive Order, “Delivering Gold Standard Childhood Vaccine Recommendations for Americans,” The White House, August 10, 2026.

² Thomas Cowan, MD, Vaccines, Autoimmunity, and the Changing Nature of Childhood Illness, Chelsea Green Publishing, 2018. Chapters on aluminum adjuvants, macrophage transport, and the Gherardi/Crépeaux work on macrophagic myofasciitis and aluminum biopersistence.

³ John Leake and Peter A. McCullough, MD, MPH, Vaccines, Skyhorse Publishing, 2025. Chapters on the Wakefield case, the 1998 Lancet paper, and Japan’s 1993 discontinuation of the combined MMR.

⁴ United States ex rel. Krahling and Wlochowski v. Merck & Co., Case No. 10-cv-4374, US District Court for the Eastern District of Pennsylvania. False Claims Act suit filed August 2010 by two former Merck virologists alleging manipulation of mumps component efficacy testing; amended complaint filed 2012; a district court ruled in Merck’s favor in July 2023.

⁵ Neil Z. Miller, Miller’s Review of Critical Vaccine Studies: 400 Important Scientific Papers Summarized for Parents and Researchers, New Atlantean Press, 2016. Sections on cumulative injection burden and simultaneous administration.

⁶ Charles Richet, “Anaphylaxis,” Nobel Lecture, December 11, 1913. Documented mechanism of injection-induced sensitization.

⁷ Mary Holland, Kim Mack Rosenberg, Eileen Iorio, The HPV Vaccine on Trial: Seeking Justice for a Generation Betrayed, Skyhorse Publishing, 2018.

⁸ Laura Hayes, “Why Is This Legal?” presentation delivered November 2, 2018, Your Health Freedom symposium, Utah. Republished October 8, 2025.

⁹ President Trump signing remarks and press conference on Executive Order “Delivering Gold Standard Childhood Vaccine Recommendations for Americans,” The White House, August 10, 2026. All quotations in this section are drawn from the official transcript.

¹⁰ “Merck to Settle Bulk of Gardasil Suits for About $50 Million,” Bloomberg, June 4, 2026. Settlement of approximately 200 cases alleging Gardasil caused injuries including postural orthostatic tachycardia syndrome and premature ovarian insufficiency; Merck denied liability and characterized the settlement as “not material.”

¹¹ California Assembly Bill 144, signed by Governor Newsom on September 17, 2025. Establishes the California Department of Public Health as the state authority for vaccine recommendations, using the pre-January 2025 federal ACIP schedule as the baseline. West Coast Health Alliance formed September 3, 2025 by California, Oregon, Washington, and Hawaii.

¹² Bruesewitz v. Wyeth LLC, 562 U.S. 223 (2011). Supreme Court decision holding that the National Childhood Vaccine Injury Act of 1986 preempts all design-defect claims against vaccine manufacturers by plaintiffs seeking compensation for injury or death caused by a vaccine’s side effects.

¹³ Antonietta M. Gatti and Stefano Montanari, “New Quality-Control Investigations on Vaccines: Micro- and Nanocontamination,” International Journal of Vaccines and Vaccination 4(1):7-14, 2017. Electron microscopy and X-ray spectroscopy examination of forty-four vaccines from Sanofi, GlaxoSmithKline, Pfizer, Novartis, and Merck; documented undeclared particulate contamination in forty-three of forty-four samples.

¹⁴ M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live) Package Insert, Merck Sharp & Dohme LLC. Composition of Attenuvax (Measles Virus Vaccine Live), Mumpsvax (Mumps Virus Vaccine Live), and Meruvax II (Rubella Virus Vaccine Live) confirmed via Merck package inserts and CDC vaccine excipient tables.

Additional Sources

Executive Order 14407, “Realigning United States Core Childhood Vaccine Recommendations With Best Practices From Peer, Developed Countries,” May 29, 2026.

Presidential Memorandum, “Aligning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries,” December 5, 2025.

Romain K. Gherardi and F.J. Authier, “Macrophagic myofasciitis: characterization and pathophysiology,” Lupus 21(2):184-189, 2012.

G. Crépeaux et al., “Non-linear dose-response of aluminium hydroxide adjuvant particles: Selective low dose neurotoxicity,” Toxicology 375:48-57, 2017.

Christopher A. Shaw and Lucija Tomljenovic, “Aluminum in the central nervous system: toxicity in humans and animals, vaccine adjuvants, and autoimmunity,” Immunologic Research 56(2):304-316, 2013.

California SB 277 (2015). New York PBH § 2164 amendment (2019). Maine LD 798 (2019). State-level statutes narrowing religious and personal-belief exemptions.